Plenary Session:

J. N. Poynter, G. Rennert, J. D. Bonner, H. S. Rennert, J. K. Greenson, and S. B. Gruber

HMG CoA reductase inhibitors and the risk of colorectal cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 1. [Abstract]  

R. Stupp, W. P. Mason, M. J. Van Den Bent, M. Weller, B. Fisher, M. Taphoorn, A. A. Brandes, G. Cairncross, D. Lacombe, and R. O. Mirimanoff

Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group
J Clin Oncol (Meeting Abstracts) 2004 22: 2. [Abstract]  

D. P. Petrylak, C. Tangen, M. Hussain, P. N. Lara, J. Jones, M. E. Talpin, P. Burch, G. Greene, E. Small, and E. D. Crawford

SWOG 99–16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone(M)/prednisone(p) in men with androgen-independent prostate cancer (AIPCA)
J Clin Oncol (Meeting Abstracts) 2004 22: 3. [Abstract]  

M. A. Eisenberger, R. De Wit, W. Berry, I. Bodrogi, A. Pluzanska, K. Chi, S. Oudard, T. Christine, N. James, and I. Tannock

A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC)
J Clin Oncol (Meeting Abstracts) 2004 22: 4. [Abstract]  

J. A. Sloan, H. McLeod, D. Sargent, X. Zhao, C. Fuchs, R. Ramanathan, S. Williamson, B. Findlay, R. Morton, and R. M. Goldberg

Preliminary evidence of relationship between genetic markers and oncology patient quality of life (QOL)
J Clin Oncol (Meeting Abstracts) 2004 22: 5. [Abstract]  

Breast Cancer:

M. Yoshimoto, M. Makita, S. Nishimura, K. Tada, F. Kasumi, F. Akiyama, Y. Hoshikawa, Y. Miki, M. Matsuura, and T. Noda

Prediction of the therapeutic response to paclitaxel by gene expression profiling in neoadjuvant chemotherapy for breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 500. [Abstract]  

L. Gianni, M. Zambetti, K. Clark, J. Baker, M. Cronin, G. Mariani, J. Rodriguez, M. L. Carcangiu, P. Valagussa, and S. Shak

Gene expression profiles of paraffin-embedded core biopsy tissue predict response to chemotherapy in patients with locally advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 501. [Abstract]  

J. Hannemann, H. M. Oosterkamp, C. A. J. Bosch, C. Loo, A. Witteveen, A. Velds, E. J. T. H. Rutgers, S. Rodenhuis, and M. Van de Vijver

Changes in gene expression profiling due to primary chemotherapy in patients with locally advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 502. [Abstract]  

L. Pusztai, J. Wang, K. Coombes, S. Hoersch, M. Ayers, J. Ross, K. Hess, G. Hortobagyi, W. Symmans, and J. Stec

Cross platform comparison of multigene predictors of response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer generated by cDNA arrays and Affymetrix GeneChips
J Clin Oncol (Meeting Abstracts) 2004 22: 503. [Abstract]  

M. D. Schnall, J. Blume, D. Bluemke, S. Smazal, G. Deangelis, S. Harms, C. Kuhl, N. Hylton, and C. Gatsonis

MRI detection of multi focal breast carcinoma: Report from the International Breast MRI Consortium
J Clin Oncol (Meeting Abstracts) 2004 22: 504. [Abstract]  

S. B. Holmberg, D. Crivellari, D. Zahrieh, J. F. Forbes, P. Rey, D. M. Dent, P. Schaefer, J. Bernhard, I. Campbell, and C.-M. M. Rudenstam

A randomized trial comparing axillary clearance versus no axillary clearance in older patients ( 60 years) with breast cancer: First results of International Breast Cancer Study Group Trial 10–93
J Clin Oncol (Meeting Abstracts) 2004 22: 505. [Abstract]  

R. E. Mansel, A. Goyal, L. Fallowfield, and R. G. Newcombe

Sentinel node biopsy in breast cancer: The first results of the randomized multicenter ALMANAC Trial
J Clin Oncol (Meeting Abstracts) 2004 22: 506. [Abstract]  

B. Lloveras, M. Monzo, R. Colomer, A. Llombart, M. Ramos, J. I. Mayordomo, D. Fuster, and E. Alba

Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 507. [Abstract]  

V. Stearns, D. F. Hayes, Y. Jin, L. Ullmer, A. Nguyen, A. M. Storniolo, D. Flockhart, and Z. Desta

The effect of CYP 2D6 genotype and CYP2D6 inhibitors on tamoxife
J Clin Oncol (Meeting Abstracts) 2004 22: 508. [Abstract]  

D. F. Hayes, M. Cristofanilli, G. T. Budd, M. Ellis, A. Stopeck, J. Matera, M. C. Miller, G. V. Doyle, W. J. Allard, and L. W. Terstappen

Monitoring circulating tumor cell (CTC) levels to predict rapid progression in metastatic breast cancer (MBC): A prospective, multi-institutional tria
J Clin Oncol (Meeting Abstracts) 2004 22: 509. [Abstract]  

K. S. Albain, S. Nag, G. Calderillo-Ruiz, J. P. Jordaan, A. Llombart, A. Pluzanska, M. Pawlicki, A. S. Melemed, J. O'Shaughnessy, and J. M. Reyes

Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall surviva
J Clin Oncol (Meeting Abstracts) 2004 22: 510. [Abstract]  

G. Comella, D'Aiuto, P. Comella, R. Thomas, I. Capasso, P. Silvestro, A. Russo, A. Petrillo, L. Lapenta, and G. Frasci

Comparison of weekly cisplatin-epirubicin-paclitaxel (PET) with triweekly epirubicin-paclitaxel (ET) in locally advanced breast cancer (LABC). SICOG 9908 phase III tria
J Clin Oncol (Meeting Abstracts) 2004 22: 511. [Abstract]  

A. D. Seidman, D. Berry, C. Cirrincione, L. Harris, L. Dressler, H. Muss, L. Norton, E. Winer, and C. Hudis

CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC
J Clin Oncol (Meeting Abstracts) 2004 22: 512. [Abstract]  

V. J. Möbus, M. Untch, A. du Bois, H.-J. Lueck, C. Thomssen, W. Kuhn, C. Kurbacher, U. Nitz, R. Kreienberg, and C. Jackisch

Dose-dense sequential chemotherapy with epirubicin(E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients ( 4 +LN). First results of an AGO-trial
J Clin Oncol (Meeting Abstracts) 2004 22: 513. [Abstract]  

R. Paridaens, P. Therasse, L. Dirix, L. Beex, M. Piccart, D. Cameron, T. Cufer, K. Roozendaal, M. Nooij, and M.-R. Mattiacci

First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast Group
J Clin Oncol (Meeting Abstracts) 2004 22: 515. [Abstract]  

L. Asmar, J. Cantrell, S. J. Vukelja, J. E. Pippen, J. O'Shaughnessy, J. L. Blum, R. J. Brooks, S. Mull, H. Guo, and S. Jones

A planned comparison of menopausal symptoms during the first year in 1,000 patients receiving either exemestane or tamoxifen in a double-blind adjuvant hormonal study
J Clin Oncol (Meeting Abstracts) 2004 22: 516. [Abstract]  

T. Whelan, P. Goss, J. Ingle, J. Pater, L. Shepherd, M. Palmer, D. Tu, N. Robert, S. Martino, and H. Muss

Assessment of quality of life (QOL) in MA.17, a randomized placebo-controlled trial of letrozole in postmenopausal women following five years of tamoxifen
J Clin Oncol (Meeting Abstracts) 2004 22: 517. [Abstract]  

P. E. Lonning, J. Geisler, L. E. Krag, L. Ottestad, Y. Bremnes, A. I. Hagen, E. Schlichting, A. Polli, J. Paolini, and G. Massimini

Effect of exemestane on bone: A randomized placebo controlled study in postmenopausal women with early breast cancer at low risk
J Clin Oncol (Meeting Abstracts) 2004 22: 518. [Abstract]  

V. F. Semiglazov, V. Semiglazov, V. Ivanov, A. Bozhok, E. Ziltsova, R. Paltuev, G. Dashian, A. Kletzel, E. Topuzov, and L. Berstein

The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in postmenopausal women with ER- positive breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 519. [Abstract]  

A. U. Buzdar, K. Hunt, T. Smith, D. Francis, M. Ewer, D. Booser, E. Singletary, T. Buchholz, A. Sahin, and G. N. Hortobagyi

Significantly higher pathological complete remission (PCR) rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline-containing chemotherapy (CT): Initial results of a randomized trial in operable breast cancer (BC) with HER/2 positive disease
J Clin Oncol (Meeting Abstracts) 2004 22: 520. [Abstract]  

T. R. J. Evans, A. Yellowlees, E. Foster, H. Earl, D. A. Cameron, A. W. Hutcheon, R. E. Coleman, J. Crown, R. C. Leonard, and J. L. Mansi

Phase III randomised trial of doxorubicin (A) and docetaxel (D) versus A and cyclophosphamide (C) as primary medical therapy (PMT) in women with breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 521. [Abstract]  

I. A. Olivotto, C. Bajdik, P. M. Ravdin, B. Norris, A. J. Coldman, C. Speers, S. Chia, and K. Gelmon

An independent population-based validation of the adjuvant decision-aid for stage I-II breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 522. [Abstract]  

N. Harbeck, R. E. Kates, M. P. Look, and J. A. Foekens

Pooled analysis (n=8,377) evaluates predictive impact of uPA and PAI-1 for response to adjuvant therapy in breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 523. [Abstract]  

J. Ragaz, K. Miller, S. Badve, Y. Dayachko, S. Dunn, T. Nielsen, A. Brodie, D. Huntsman, C. Bajdik, and G. Sledge

Adverse association of expressed vascular endothelial growth factor (VEGF) with long-term outcome of stage I-III breast cancer (BrCa), with co-expression data of VEGF and Her2, Cox2, uPA and ER. Results from the British Columbia Tissue Microarray Project
J Clin Oncol (Meeting Abstracts) 2004 22: 524. [Abstract]  

S. Maier, I. Nimmrich, A. Marx, S. Eppenberger-Castori, F. Jaenicke, A. Paradiso, F. Spyratos, J. Foekens, M. Schmitt, and N. Harbeck

DNA methylation profile predicts risk of recurrence in tamoxifen-treated, node-negative breast cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 525. [Abstract]  

T. Saarto, L. Vehmanen, C. Blomqvist, and I. Elomaa

Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 527. [Abstract]  

T. Powles, A. Paterson, E. McCloskey, M. Kurkilahti, and J. Kanis

Oral clodronate for adjuvant treatment of operable breast cancer: Results of a randomized, double-blind, placebo-controlled multicenter trial
J Clin Oncol (Meeting Abstracts) 2004 22: 528. [Abstract]  

A. Jaschke, G. Bastert, E. F. Solomayer, S. Costa, F. Schuetz, and I. J. Diel

Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow - a longtime follow-up
J Clin Oncol (Meeting Abstracts) 2004 22: 529. [Abstract]  

I. Kokufu, N. Kohno, S. Takao, M. Yamamoto, M. Miyashita, S. Kohno, and F. Kimura

Adjuvant pamidronate (PMT) therapy for the prevention of bone metastasis in breast cancer (BC) patients (pts) with four or more positive nodes
J Clin Oncol (Meeting Abstracts) 2004 22: 530. [Abstract]  

J. Geisler, P. E. Lonning, L. E. Krag, L. Ottestad, Y. Bremnes, A. I. Hagen, E. Schlichting, E. S. Ofjord, A. Polli, and G. Massimini

Estrogens and bone metabolism in postmenopausal women with early breast cancer at low risk treated with exemestane: a randomized placebo-controlled study
J Clin Oncol (Meeting Abstracts) 2004 22: 531. [Abstract]  

M. Colleoni, S. Gelber, R. Snyder, S. B. Holmberg, M. Fey, B. Thuerlimann, J. Lindtner, M. Byrne, C. Mendiola, and A. S. Coates

Randomized comparison of adjuvant tamoxifen (Tam) versus no hormonal treatment for premenopausal women with node-positive (N+), early stage breast cancer: first results of International Breast Cancer Study Group Trial 13–93
J Clin Oncol (Meeting Abstracts) 2004 22: 532. [Abstract]  

D. Wallwiener, K. Possinger, P. Schmid, V. Tarutinov, L. Suchina, H. Hillger, E. Kienle, L. Maubach, S. Kahlert, and M. Untch

A phase III trial comparing adjuvant treatment with leuprorelin acetate 3M-Depot for 24 months with CMF chemotherapy in ER/PR + node + pre-perimenopausal breast cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 533. [Abstract]  

G. Von Minckwitz, E. Graf, M. Geberth, W. Eiermann, W. Jonat, B. Conrad, K. Brunnert, B. Gerber, H. H. Zippel, and M. Kaufmann

Goserelin versus CMF as adjuvant therapy for node-negative, hormone receptor-positive breast cancer in premenopausal patients. The GABG IV-A-93 trial
J Clin Oncol (Meeting Abstracts) 2004 22: 534. [Abstract]  

J. R. Yarnold, J. M. Bliss, H. Earl, D. George, D. Lawrence, S. H. Mortazavi, T. J. Perren, V. Raina, and D. Spooner

Ovarian ablation (OA) in pre-menopausal women with early breast cancer prescribed 5 years tamoxifen (T) or T plus chemotherapy (CT)–results from the UK NCRI Adjuvant Breast Cancer (ABC) international trial of 2,144 patients
J Clin Oncol (Meeting Abstracts) 2004 22: 535. [Abstract]  

J. Robertson, E. Gutteridge, K. L. Cheung, S. Pinder, and A. Wakeling

Oestrogen receptor expression in human breast cancer during long-term fulvestrant treatment
J Clin Oncol (Meeting Abstracts) 2004 22: 536. [Abstract]  

M. Dowsett and I. E. Smith

Molecular effects of anastrozole (A) and tamoxifen (T) alone and combined (C) in the IMPACT trial of neoadjuvant treatment of primary breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 537. [Abstract]  

M. Tubiana-Hulin and F. Spyratos

Response to neo-adjuvant exemestane in post-menopausal breast cancer patients: correlation with biological factors measured by real-time quantitative RT-PCR (QRT-PCR)
J Clin Oncol (Meeting Abstracts) 2004 22: 538. [Abstract]  

A. Franco, N. Col, and R. T. Chlebowski

Discordance in estrogen (ER) and progestin receptor (PR) status between primary metastatic breast cancer: a meta-analysis
J Clin Oncol (Meeting Abstracts) 2004 22: 539. [Abstract]  

R. Leonard, N. Bundred, A. Buzdar, P. Canney, D. Rea, A. Stewart, and M. Verrill

Trilostane, an effective signal transduction inhibitor for advanced ER+ve and ER-ve post-menopausal breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 540. [Abstract]  

S. Massarweh, C. K. Osborne, M. Dipietro, A. E. Wakeling, and R. Schiff

Tamoxifen's agonist effect on breast cancer growth is mediated by activation of EGFR/HER-2 with preservation of its antagonist effect on ER-dependent gene expression
J Clin Oncol (Meeting Abstracts) 2004 22: 541. [Abstract]  

P. Fumoleau, M. Campone, D. Vorobiof, M. Casado, P. Ruff, S. Khoo Kei, H. Cortes-Funes, S. Khalfallah, I. Caroff, and C. Colin

Phase II study of i.v. vinflunine as second line in patients with metastatic breast cancer after anthracycline-taxane failure
J Clin Oncol (Meeting Abstracts) 2004 22: 542. [Abstract]  

J. L. Blum, M. A. Savin, G. Edelman, J. E. Pippen, N. Robert, J. Sandbach, S. Carrasco, and J. A. O'Shaughnessy

Long term disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel
J Clin Oncol (Meeting Abstracts) 2004 22: 543. [Abstract]  

J. Baselga, P. Fumoleau, M. Gil, R. Colomer, H. Roche, H. Cortes-Funes, H. Burstein, P. Kaufman, S. Kong, and L. Moore

Phase II, 3-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results
J Clin Oncol (Meeting Abstracts) 2004 22: 544. [Abstract]  

J. A. Low, S. B. Wedam, A. Brufsky, A. Berman, E. Croarkin, R. Parks, S. M. Steinberg, N. Mannan, T. Fojo, and S. M. Swain

A phase 2 trial of BMS-247550 (ixabepilone), an epothilone B analog, given daily x 5 in breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 545. [Abstract]  

J. Brown, J. Von Roenn, R. O'Regan, R. Bergan, S. Badve, A. Rademaker, S. Feehan, J. Petersen, M. Patton, and W. Gradishar

A phase II study of the proteasome inhibitor PS-341 in patients (pts) with metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2004 22: 546. [Abstract]  

H. J. Burstein, B. Overmoyer, R. Gelman, P. Silverman, J. Savoie, K. Clarke, L. Dumadag, J. Younger, and E. P. Winer

Rebeccamycin analog for refractory breast cancer: a randomized phase II trial
J Clin Oncol (Meeting Abstracts) 2004 22: 547. [Abstract]  

F. A. Tager and P. S. McKinley

Cognitive functioning before chemotherapy treatment in women with breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 548. [Abstract]  

M. Ruzich, B. Ryan, C. Owen, A. Delahunty, and R. Stuart-Harris

A prospective evaluation of cognitive function in patients with early breast cancer receiving adjuvant chemotherapy
J Clin Oncol (Meeting Abstracts) 2004 22: 549. [Abstract]  

L. Gladieff, P. Fumoleau, P. Kerbrat, J. Bonneterre, F. Mayer, M. Namer, A. Monnier, M.-J. Goudier, E. Luporsi, and H. Roche

Which are the interactions between baseline body mass index (BMI), toxicity of chemotherapy (CT), and efficacy of adjuvant treatments? 9-year follow-up results of French Adjuvant Study Group (FASG) trials
J Clin Oncol (Meeting Abstracts) 2004 22: 550. [Abstract]  

H. Simon, A. Monnier, M. Namer, H. Roche, P. Fumoleau, P. Kerbrat, J. Bonneterre, P. Clavere, and E. Luporsi

Prognostic factors of contralateral breast cancer (CBC) in 3,653 early breast cancer (EBC) patients (pts): 9-year follow-up results of French Adjuvant Study Group (FASG) trials
J Clin Oncol (Meeting Abstracts) 2004 22: 551. [Abstract]  

A. Tinker, C. Speers, J. Barnett, I. Olivotto, and S. Chia

Impact of reduced dose intensity of adjuvant anthracycline based chemotherapy in a population based cohort of stage I-II breast cancers
J Clin Oncol (Meeting Abstracts) 2004 22: 552. [Abstract]  

G. G. Steger, E. Kubista, H. Hausmaninger, M. Gnant, C. Tausch, A. Lang, H. Samonigg, A. Galid, and R. Jakesz

6 vs. 3 cycles of epirubicin/docetaxel + G-CSF in operable breast cancer: results of ABCSG-14
J Clin Oncol (Meeting Abstracts) 2004 22: 553. [Abstract]  

F. Icli, H. Akbulut, D. Dincol, H. Onur, A. Demirkazik, R. Cam, F. Cay, S. Demirci, A. Uner, and S. Erekul

Addition of 2 cycles of EP (Etoposide + Cisplatin) to the 4 cycles of adjuvant AC (doxorubicin + cyclophosphamide) improves the survival in node positive patients with breast cancer after 10 years
J Clin Oncol (Meeting Abstracts) 2004 22: 554. [Abstract]  

T. A. Buchholz, W. A. Woodward, S. L. Tucker, E. A. Strom, K. K. Hunt, A. U. Buzdar, G. H. Perkins, N. R. Schechter, and G. N. Hortobagyi

Defining the competing risk of local-regional and distant recurrence in 1,256 patients treated with mastectomy and doxorubicin-based adjuvant chemotherapy
J Clin Oncol (Meeting Abstracts) 2004 22: 555. [Abstract]  

S. J. Katz, P. M. Lantz, N. K. Janz, A. Fagerlin, B. Salem, I. Lakhani, and M. Morrow

Shared decision-making and surgical treatment for breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 556. [Abstract]  

M. Morrow, P. Lantz, N. Janz, A. Fagerlin, M. Mujahid, and S. Katz

Patterns and correlates of breast reconstruction: results of a population based study
J Clin Oncol (Meeting Abstracts) 2004 22: 557. [Abstract]  

M. Schaapveld, R. Otter, E. G. E. De Vries, W. T. A. Van der Graaf, J. De Vries, and P. H. B. Willemse

The number of histologically examined axillary lymph nodes can improve the prediction of individual prognosis of primary breast cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 558. [Abstract]  

G. Zavagno, G. L. De Salvo, G. Scalco, F. Bozza, R. Marconato, L. Barutta, C. Racano, D. Casara, and M. Lise

Sentinella-GIVOM, a randomized clinical trial (RCT) on sentinel node biopsy (SNB) versus axillary lymph node dissection (ALND) in breast cancer (BC): results of first interim analysis
J Clin Oncol (Meeting Abstracts) 2004 22: 559. [Abstract]  

B. Taback, N. Hansen, K. Conway, and A. Giuliano

Recurrence patterns following a negative sentinel lymph node biopsy in patients with early-stage breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 560. [Abstract]  

Y. Xing, M. Ding, D. Cox, M. I. Ross, K. K. Hunt, and J. N. Cormier

Meta-analysis of sentinel lymph node biopsy following preoperative chemotherapy in patients with operable breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 561. [Abstract]  

C. Peters-Engl, P. Konstantiniuk, C. Tausch, A. Haid, B. Hoffmann, M. Jagoutz-Herzlinger, F. Kugler, S. Redtenbacher, S. Roka, and P. Schrenk

The impact of preoperative breast biopsy on the risk of sentinel lymph node metastases: analysis of 2502 cases from the Austrian Sentinel Node Biopsy Study Group
J Clin Oncol (Meeting Abstracts) 2004 22: 562. [Abstract]  

C. Correa, W.-T. Hwang, V. A. Ferrari, H. I. Litt, L. J. Solin, and E. E. Harris

Late myocardial perfusion defects in left versus right-sided radiotherapy (RT) for breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 563. [Abstract]  

R. R. Kuske, K. Winter, D. W. Arthur, J. Bolton, R. A. Rabinovitch, J. R. White, W. F. Hanson, and R. M. Wilenzick

A phase II trial of brachytherapy alone following lumpectomy for stage I or II breast cancer: initial outcomes of RTOG 9517
J Clin Oncol (Meeting Abstracts) 2004 22: 565. [Abstract]  

L. G. Dressler, G. Broadwater, D. Berry, C. Cirrincione, D. Cowan, L. Harris, D. Moore, H. Muss, D. Hayes, and M. Ellis

A comparison of two HER2 FISH methods to measure HER2 amplification and predict clinical outcome
J Clin Oncol (Meeting Abstracts) 2004 22: 566. [Abstract]  

E. A. Perez, V. J. Suman, N. E. Davidson, S. Martino, P. A. Kaufman, W. L. Lingle, P. J. Flynn, J. N. Ingle, D. Visscher, and R. B. Jenkins

HER2 testing by local, central, and reference laboratories in the NCCTG N9831 Intergroup Adjuvant Trial
J Clin Oncol (Meeting Abstracts) 2004 22: 567. [Abstract]  

D. V. Miller, R. B. Jenkins, W. L. Lingle, N. E. Davidson, P. A. Kaufman, S. Martino, S. R. Dakhil, and E. A. Perez

Focal HER2/neu amplified clones partially account for discordance between immunohistochemistry and fluorescence in-situ hybridization results: data from NCCTG N9831 Intergroup Adjuvant Trial
J Clin Oncol (Meeting Abstracts) 2004 22: 568. [Abstract]  

G. H. Raab, B. Hoegel, J. Biebl, and W. Eiermann

Chromogen in situ hybridisation (CISH) for HER2 assessment is highly concordant with FISH in core cut biopsies of primary T2 breast cancers
J Clin Oncol (Meeting Abstracts) 2004 22: 569. [Abstract]  

B. Leyland-Jones, M. Marty, J. Baselga, U. Gatzemeier, C. Barton, and S. Lennon

Effects of trastuzumab (H) and chemotherapy on circulating HER2 extracellular domain (ECD) in patients with metastatic breast cancer (MBC) and non-small cell lung cancer (NSCLC)
J Clin Oncol (Meeting Abstracts) 2004 22: 570. [Abstract]  

L. Del Mastro, P. Bruzzi, M. Venturini, G. Cavazzini, A. Contu, L. Gallo, F. Testore, B. Castagneto, A. Lavarello, and R. Rosso

HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy (CT) in early breast cancer (BC) patients
J Clin Oncol (Meeting Abstracts) 2004 22: 571. [Abstract]  

V. Valero, E. Gill, V. Paton, H.-Y. Chang, A. U. Buzdar, G. Park, G. Hortobagyi, and M. Ewer

Normal cardiac biopsy results following co-administration of doxorubicin (A), Cyclophosphamide (C) and trastuzumab (H) to women with HER2 positive metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 572. [Abstract]  

N. J. Robert, B. Leyland-Jones, L. Asmar, R. J. Belt, D. Ilegbodu, D. M. Loesch, R. N. Raju, M. Cobleigh, K. S. Albain, and D. J. Slamom

Randomized phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: An update including survival
J Clin Oncol (Meeting Abstracts) 2004 22: 573. [Abstract]  

M.-C. Gast, J. Bonfrer, E. Rutgers, J. Schellens, and J. Beijnen

New discriminatory serum protein profiles in breast cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 574. [Abstract]  

V. Bramwell, G. Doig, A. Tuck, S. Wilson, K. Tonkin, T. Vandenberg, and A. Chambers

Osteopontin (OPN): A novel tumor marker of potential utility in metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 575. [Abstract]  

P. Wulfing, J. Tio, C. Kersting, B. Sonntag, H. Buerger, C. Wulfing, U. Euler, W. Boecker, A. H. Tulusan, and L. Kiesel

Use of endothelin-A-receptor expression to predict poor response to primary chemotherapy in locally advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 576. [Abstract]  

X. Yang, A. R. Tan, D. Nguyen, S. Lipkowitz, and S. M. Swain

Gene expression profile changes following erlotinib treatment in patients with metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 577. [Abstract]  

S. B. Wedam, J. A. Low, X. Yang, C. Chow, A. Berman, R. Eulate, D. Danforth, S. M. Hewitt, S. M. Steinberg, and S. M. Swain

A pilot study to evaluate response and angiogenesis after treatment with bevacizumab in patients with inflammatory breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 578. [Abstract]  

W. Janni, B. Rack, C. Schindlbeck, B. Strobl, D. Rjosk, S. Braun, H. Sommer, K. Pantel, B. Gerber, and K. Friese

Association of persistence of isolated tumor cells (ITC) in bone marrow (BM) of breast cancer patients with risk for relapse
J Clin Oncol (Meeting Abstracts) 2004 22: 579. [Abstract]  

A. Llombart-Cussac, G. Moreno-Bueno, A. Ruiz, J. Albanell, J. I. Mayordomo, V. Carñana, V. Guillem, R. Diaz-Uriarte, J. Palacios, and I. Garcia-Ribas

Gene expression profiling (GEP) for the prediction of response to neoadjuvant paclitaxel and gemcitabine in breast cancer (BC). Preliminary results from a Phase II trial
J Clin Oncol (Meeting Abstracts) 2004 22: 580. [Abstract]  

D. McKillop, G. Raab, H. Eidtmann, A. Furnival, A. Riva, J. Forbes, J. Mackey, M. P. Spence, M. Koehler, and D. Slamon

Intratumoral and plasma concentrations of gefitinib in breast cancer patients: Preliminary results from a presurgical investigatory study (BCIRG 103)
J Clin Oncol (Meeting Abstracts) 2004 22: 581. [Abstract]  

M.-L. W. Ah-See, A. Makris, N. J. Taylor, R. J. Burcombe, M. Harrison, J. J. Stirling, P. I. Richman, M. O. Leach, and A. R. Padhani

Does vascular imaging with MRI predict response to neoadjuvant chemotherapy in primary breast cancer?
J Clin Oncol (Meeting Abstracts) 2004 22: 582. [Abstract]  

T. Delozier, C. Ségura, C. Levy, C. Delcambre, D. Allouache, O. Switsers, J.-M. Ollivier, B. Vié, F. Joly, and J.-Y. Génot

Reducing dose density in adjuvant chemotherapy (C) is detrimental in early breast cancer (EBC). A review of 872 adjuvant treatments in Centre François Baclesse
J Clin Oncol (Meeting Abstracts) 2004 22: 583. [Abstract]  

B. Gerber, W. Janni, A. Krause, H. Müller, T. Reimer, J. Makovitzky, G. Kundt, and K. Friese

Prevention of repeated benign endometrial pathology in postmenopausal women with breast cancer and tamoxifen-induced endometrial pathology: A randomized trial comparing anastrozole and tamoxifen
J Clin Oncol (Meeting Abstracts) 2004 22: 584. [Abstract]  

G. N. Hortobagyi, S.-W. Kau, A. U. Buzdar, R. L. Theriault, D. J. Booser, K. Gwyn, and V. Valero

What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis?
J Clin Oncol (Meeting Abstracts) 2004 22: 585. [Abstract]  

H. Inaji, Y. Park, K. Okamura, S. Mitsuyama, T. Saito, J. Koh, S. Kyono, K. Higaki, H. Koyama, and T. Suzuki

A randomized controlled study comparing CMF plus TAM with UFT plus TAM as postoperative adjuvant therapy in women with node-positive breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 586. [Abstract]  

H. Sommer, W. J. Janni, B. Rack, D. Steinfeld, W. Simon, D. Augustin, M. Heinrigs, F. V. Bismarck, N. Harbeck, and M. Kiechle

The ADEBAR-trial: Effect of participation in a randomized phase III study (evaluating the role of adjuvant docetaxel in high-risk breast cancer patients) on treatment strategies and individual patient care in recruiting centers
J Clin Oncol (Meeting Abstracts) 2004 22: 587. [Abstract]  

M. Kaufmann, E. Graf, W. Jonat, W. Eiermann, H. H. Zippel, M. Geberth, B. Conrad, G. Gademann, and K. D. Schulz

Goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with breast cancer. GABG trial IV-B-93
J Clin Oncol (Meeting Abstracts) 2004 22: 588. [Abstract]  

S. Kuemmel, J. Krocker, A. Kohls, M. Budner, G.-P. Breitbach, K. Ruhland, U. Köhler, B. Reischauer, J.-U. Blohmer, and D. Elling

A phase III randomised trial comparing the tolerability of dose-dense chemotherapy in older to that in younger breast cancer patients with four or more positive lymph nodes
J Clin Oncol (Meeting Abstracts) 2004 22: 589. [Abstract]  

G. Y. Locker

An economic evaluation of anastrozole versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer (EBC) from a US healthcare perspective
J Clin Oncol (Meeting Abstracts) 2004 22: 590. [Abstract]  

N. Love, P. Ravdin, G. Hortobagyi, G. Grana, M. F. Paley, and L. Poltorack

Influence of prior therapy on breast cancer survivors' preferences for adjuvant systemic therapy in hypothetical scenarios
J Clin Oncol (Meeting Abstracts) 2004 22: 591. [Abstract]  

M. E. Marty, R. C. Coombes, C. Peckitt, F. R. Pérez López, A. Tres, F. Morvan, N. Tubiana-Mathieu, M. Espié, and J. M. Bliss

Prospective meta-analysis of randomised trials of cyclophosphamide, methotrexate & fluorouracil (CMF) vs fluorouracil, epirubicin & cyclophosphamide (FEC) chemotherapy in early breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 592. [Abstract]  

C. McNeil, F. Collinson, K. Smith, R. Dunleavey, J. Boyages, and R. Kefford

Delay in conventional breast cancer treatment associated with alternative therapy usage
J Clin Oncol (Meeting Abstracts) 2004 22: 593. [Abstract]  

K. Pollow, W. Schoenegg, H. Koelbl, R. Kreienberg, A. Dubois, D. Elling, K.-J. Winzer, U. Koehler, and G. Hoffmann

Safety and tolerability of adjuvant exemestane plus goserelin with or without tibolone in receptor-positive, node-negative primary breast cancer in premenopausal women: The final results of the randomized multicenter ADAGIO pilot study
J Clin Oncol (Meeting Abstracts) 2004 22: 594. [Abstract]  

D. W. Rea, L. Hiller, H. M. Earl, J. A. Dunn, S. Bathers, D. Spooner, R. J. Grieve, R. K. Agrawal, and C. J. Poole

Tolerability and efficacy of classical CMF (cCMF) using oral cyclophosphamide (OC) vs intravenous cyclophosphamide (IVC) in early stage breast cancer: A non-randomised comparison of patients (pts) treated in the National Epirubicin Adjuvant Trial (NEAT)
J Clin Oncol (Meeting Abstracts) 2004 22: 595. [Abstract]  

A. Rodriguez-Lescure, M. Martin, A. Ruiz, E. Alba, L. Calvo, M. Ruiz-Borrego, B. Munarriz, J. M. Lopez-Vega, and C. A. Rodriguez

Multicenter, randomized phase III study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles (cy) of FEC vs 4 cy of FEC followed by 8 weekly paclitaxel (T) administrations: Safety analysis of GEICAM 9906 trial
J Clin Oncol (Meeting Abstracts) 2004 22: 596. [Abstract]  

R. Sainsbury, G. Locker, and J. Cuzick

The use of adjuvant chemotherapy in the ATAC trial: Nationality correlates with the use of chemotherapy
J Clin Oncol (Meeting Abstracts) 2004 22: 597. [Abstract]  

J. M. Sun, W. Han, D. W. Kim, T. Y. Kim, I. A. E. Park, D. Y. Noh, D. S. Heo, Y. J. Bang, K. J. Choe, and N. K. Kim

Clinical relevance of HER-2 expression in node-negative breast cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 598. [Abstract]  

P. Bougnoux, M. Combe, M.-J. Goudier, T. Facchini, and V. Lotz

Phase II randomized trial of docetaxel (D) monotherapy vs epirubicin plus docetaxel (ED) as neoadjuvant treatment of operable breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2004 22: 599. [Abstract]  

Y. Eralp, T. L. Smith, S.-W. Kau, V. Valero, A. Buzdar, G. N. Hortobagyi, and B. Arun

Body mass index (BMI) is a predictor for response to neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger
J Clin Oncol (Meeting Abstracts) 2004 22: 600. [Abstract]  

G. Frasci, G. D'Aiuto, P. Comella, R. Thomas, M. Rinaldo, M. Di Bonito, R. Rubulotta, S. Bonagura, M. Licenziato, and G. Comella

Two-month cisplatin-epirubicin-paclitaxel (PET) weekly administration for the treatment of large operable breast cancer. SICOG 0105 phase II study
J Clin Oncol (Meeting Abstracts) 2004 22: 601. [Abstract]  

M. F. D. Gaui, R. Salgado, C. G. Ferreira, and N. Spector

Second-line neoadjuvant chemotherapy (NEO) with cisplatin (C), 5 fluorouracil (5FU) and radiotherapy (XRT) for locally advanced breast (LABC) refractory to anthracyclines: Evaluation after a long-term follow up
J Clin Oncol (Meeting Abstracts) 2004 22: 602. [Abstract]  

M. J. Gil Gil, A. Barnadas, L. Cirera, I. Tusquets, M. Muñoz, A. Arcusa, L. Prieto, A. Moreno, J. Graupera, and M. Margeli

Primary hormonal therapy with exemestane in patients with breast tumors >3 cm in diameter: Results of a Spanish multicenter phase II trial
J Clin Oncol (Meeting Abstracts) 2004 22: 603. [Abstract]  

B. T. J. Hennessy, H. Kuerer, A. Sahin, A. U. Buzdar, S. W. Kau, S. E. Singletary, G. N. Hortobagyi, and V. Valero

Long-term outcome of patients with complete eradication of cytologically proven axillary node metastases after primary chemotherapy: The University of Texas M. D. Anderson Cancer Center experience
J Clin Oncol (Meeting Abstracts) 2004 22: 604. [Abstract]  

M. T. Ionta, A. Scanu, F. Atzori, D. Vacca, A. Contu, A. Farris, V. Lorusso, S. Palmeri, L. Minerba, and B. Massidda

Unexpectedly high survival rate in very poor prognosis stage III B breast cancer patients receiving cisplatin-based primary chemotherapy. A multicenter Italian study
J Clin Oncol (Meeting Abstracts) 2004 22: 605. [Abstract]  

J. L. Jones, E. Rhei, M. A. Gadd, M. Howard-Mcnatt, K. S. Hughes, B.-A. Lesnikoski, R. L. Christian, J. T. Rabban, C. Kaelin, and B. L. Smith

Predictive value of sentinel lymph node biopsy prior to neoadjuvant chemotherapy in clinically node negative breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 606. [Abstract]  

H. G. Lee, J. J. Lee, K.-H. Jung, Y. Kwon, E. H. Shin, K.-W. Chung, K. H. Shin, E.-A. Kim, E. S. Lee, and J. Ro

Phase III randomized trial of primary chemotherapy with doxorubicin/cyclophosphamide (AC) vs docetaxel/capecitabine (TX) for stage II/III breast cancer (BC): Interim analysis
J Clin Oncol (Meeting Abstracts) 2004 22: 607. [Abstract]  

P. Sanchez-Rovira, B. Duenas, M. Cidraque, R. Duenas, A. Jaen, A. Sanchez, E. Martinez, B. Medina, E. Carrasco, and A. Lozano

Dose-dense and sequential combination of epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab as neoadjuvant chemotherapy in stage II and III breast cancer. A phase II and pharmacogenomic study
J Clin Oncol (Meeting Abstracts) 2004 22: 608. [Abstract]  

N. Sato, M. Sano, M. Hino, M. Kimura, M. Fujimori, K.-I. Ito, K. Maeno, H. Nakagomi, and K. Negishi

Neoadjuvant paclitaxel for operable breast cancer: Multicenter phase II trial with clinical outcomes, analysis of mutation of the class I ß-tubulin gene
J Clin Oncol (Meeting Abstracts) 2004 22: 609. [Abstract]  

R. S. Davidson, M. Chaudhry, R. Localio, M. D. Schnall, and S. M. Domchek

Predicting the extent of invasive disease by MRI to enhance the use of minimally invasive techniques in the management of early stage breast carcinoma
J Clin Oncol (Meeting Abstracts) 2004 22: 610. [Abstract]  

I. Germain, A. Fortin, A. Dagnault, T. T. Vu, and M. Larochelle

The value of the number of nodes removed (or the ratio of involved nodes) as a prognostic factor in breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 611. [Abstract]  

C. G. Hargon, G. Burton, B. Li, F. Ampil, and D. Lillian

6FDG PET scan evaluation of suspicious breast lesions developing after breast conservation therapy for breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 612. [Abstract]  

T. K. Helmberger, V. Heinemann, C. Vick, A. Wallnöfer, A. Gotz, and M. F. Reiser

Percutaneous radiofrequency ablation (RFA) of hepatic metastases in patients with metastatic breast cancer: An interim analysis
J Clin Oncol (Meeting Abstracts) 2004 22: 613. [Abstract]  

F. Nakhlis, S. Hurwitz, K. A. Mayzel, E. Levin, M. M. Duggan, and M. J. Lawler

Preoperative breast MRI: Who should get it?
J Clin Oncol (Meeting Abstracts) 2004 22: 614. [Abstract]  

J. Shen, K. K. Hunt, N. Q. Mirza, S. Krishnamurthy, S. E. Singletary, H. M. Kuerer, F. Meric-Bernstam, B. Feig, M. I. Ross, and G. V. Babiera

Intramammary lymph node metastases are an independent predictor in breast cancer outcomes
J Clin Oncol (Meeting Abstracts) 2004 22: 615. [Abstract]  

R. H. I. Andtbacka, G. Babiera, E. Singletary, K. K. Hunt, F. Meric-Bernstam, B. Feig, F. Ames, M. Ross, Y. Dejesus, and H. M. Kuerer

The incidence, prophylaxis and treatment of venous thromboembolism in patients undergoing breast cancer surgery
J Clin Oncol (Meeting Abstracts) 2004 22: 616. [Abstract]  

E. G. C. Brain, T. Bachelot, D. Serin, Y. Graïc, J. C. Eymard, J. M. Extra, M. Combe, C. Nogues, and J. Rouëssé

Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high-risk node negative (pN0) and limited node positive (pN+3) breast cancer (BC) patients (pts): First analysis of toxicity
J Clin Oncol (Meeting Abstracts) 2004 22: 617. [Abstract]  

F. Efficace, P. Therasse, M. Piccart, C. Coens, K. Van Steen, M. Welnicka-Jaskiewicz, T. Cufer, M. Lichinitser, L. Shepherd, and A. Bottomley

Predicting survival with health-related quality of life scores in locally advanced breast cancer: Results from an international randomized controlled trial
J Clin Oncol (Meeting Abstracts) 2004 22: 618. [Abstract]  

T. D. Szucs, R. Leonard, R. Pettengell, R. Paridaens, C. Jackisch, M. Constenla, A. Bosly, and M. Schwenkglenks

Dose-limiting effects of neutropenic events in six European audits of adjuvant breast cancer chemotherapy
J Clin Oncol (Meeting Abstracts) 2004 22: 619. [Abstract]  

M. Martin, A. Lluch, M. A. Seguí, A. Antón, A. Ruiz, M. Ramos, A. Rodríguez-Lescure, and E. Adrover

Prophylactic growth factor (GF) support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-negative breast cancer (BC): An interim safety analysis of the GEICAM 9805 study
J Clin Oncol (Meeting Abstracts) 2004 22: 620. [Abstract]  

C. Moinpour, J. Wu, G. Donaldson, A. Liepa, A. Melemed, J. Oshaughnessy, E. Rappold, and K. Albain

Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): Quality of life (QoL) and pain palliation results from the global phase III study
J Clin Oncol (Meeting Abstracts) 2004 22: 621. [Abstract]  

J. E. Mortimer, B. Burke, S. Fisher, and Y. Podbilewicz-Schuller

Changes in sexual function over time in women receiving adjuvant therapy for early stage breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 622. [Abstract]  

C. L. Shapiro, K. M. Carpenter, and B. L. Andersen

Sexual behavior (SB) and relationship satisfaction after first distant recurrence (REC) in metastatic breast cancer (MBC): Preliminary results from prospective trials
J Clin Oncol (Meeting Abstracts) 2004 22: 623. [Abstract]  

K. D. Voduc, S. Tyldesley, and S. Chia

Risk of radiation pneumonitis in breast cancer patients treated with adjuvant taxanes and radiation
J Clin Oncol (Meeting Abstracts) 2004 22: 624. [Abstract]  

X. Yu, S. Zhou, D. Kahn, D. R. Hollis, R. G. Prosnitz, P. H. Hardenbergh, M. A. Blazing, T. Wong, S. Borges-Neto, and L. B. Marks

Persistence of radiation (RT)-induced cardiac perfusion defects 3–5 years post RT
J Clin Oncol (Meeting Abstracts) 2004 22: 625. [Abstract]  

R. Bartsch, U. Pluschnig, C. Wenzel, D. Hussian, G. J. Locker, R. Mader, C. C. Zielinski, and G. G. Steger

Oral vinorelbine in the treatment of advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 626. [Abstract]  

J.-U. Blohmer, M. Hauschild, J. Hilfrich, A. Kleine-Tebbe, S. Kuemmel, and W. Lichtenegger

Safety and efficacy of first-line epirubicin–docetaxel (ED) versus epirubicin–cyclophosphamide (EC): A multicenter randomized phase III trial in metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2004 22: 627. [Abstract]  

D. A. Cameron, E. Winer, S. Campos, and J.-P. Guastalla

A comparative study of exemestane versus anastrozole in post-menopausal breast cancer subjects with visceral disease
J Clin Oncol (Meeting Abstracts) 2004 22: 628. [Abstract]  

P. Carlini, E. Bria, D. Giannarelli, G. Ferretti, P. Papaldo, A. Fabi, E. Ruggeri, M. Milella, E. Terzoli, and F. Cognetti

New aromatase inhibitors (AIs) as 2^nd-line endocrine therapy (ET) in metastatic breast cancer (MBC): A comprehensive review of 5832 women from 14 phase III trials
J Clin Oncol (Meeting Abstracts) 2004 22: 629. [Abstract]  

S. K. Chia, M. Clemons, L. A. Martin, A. Rodgers, K. Gelmon, and L. Panasci

A multi-centre phase II trial of pegylated liposomal doxorubicin and trastuzumab in HER-2 over-expressing metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2004 22: 630. [Abstract]  

J. P. Crown, S. Leyvraz, M. Verrill, V. Guillem, A. Efremidis, J. Garcia-Conde Bru, R. Welch, A. Montes, R. Leonard, and J. Baselga

Effect of tandem high-dose chemotherapy (HDC) on long-term complete remissions (LTCR) in metastatic breast cancer (MBC), compared to conventional dose (CDC) in patients (pts) who were not selected on the basis of response to prior C: Mature results of the IBDIS-I
J Clin Oncol (Meeting Abstracts) 2004 22: 631. [Abstract]  

A. A. Epenetos, R. Ceriani, J. Peterson, P. Cagnoni, Y. Nieto, and R. Jones

Phoenix- A humanised ⁹⁰Y-conjugated monoclonal antibody for the treatment of relapsed breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 632. [Abstract]  

K. A. Gelmon, T. Whelan, J. Latreille, I. Olivotto, C. Sawka, K. Pritchard, S. Bondy, R. Cosby, R. Roberts, and M. Levine

Patterns of trastuzumab (T) use in three Canadian provinces
J Clin Oncol (Meeting Abstracts) 2004 22: 633. [Abstract]  

A. Gennari, P. Conte, C. Orlandini, V. Guarneri, R. Rosso, and P. Bruzzi

Changes in survival and time to progression in metastatic breast cancer (MBC) patients enrolled into clinical trials from 1983 to 2001
J Clin Oncol (Meeting Abstracts) 2004 22: 634. [Abstract]  

W. Gradishar, S. Wolinsky, T. Vishalpura, B. Nightengale, and T. Bramley

Cost-effectiveness of nanoparticle albumin-bound (nab) paclitaxel (ABX) vs Cremophor-based paclitaxel (CP) in the treatment of metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2004 22: 635. [Abstract]  

V. Guillem Porta, M. Martin, M. Gil Gil, P. Kellokumpu-Lehtinen, F. Majois, J. Gasmi, D. Aubert, and O. Bourrillon

Evaluation of vinorelbine (N) and trastuzumab (H) as first-line therapy for patients (pts) with HER2- positive metastatic breast cancer (HER2+ MBC): Impact on clinical response and cardiac function
J Clin Oncol (Meeting Abstracts) 2004 22: 636. [Abstract]  

E. Heidemann, G. V. Minckwitz, N. Holländer, R. Souchon, M. Clemens, M. Mahlke, B. Eggeling, A. Marseille, G. Krekeler, and M. Kaufmann

Mitoxantrone plus docetaxel vs single agent mitoxantrone in metastatic breast cancer (MBC): Results of a multicenter randomized trial
J Clin Oncol (Meeting Abstracts) 2004 22: 637. [Abstract]  

C. X. Ma, P. Steen, K. M. Rowland, R. D. Niedringhaus, J. W. Kugler, J. N. Ingle, E. A. Perez, and A. A. Adjei

A phase II study of a combination of pemetrexed (Pem) and gemcitabine (Gem) in patients with metastatic breast cancer (MBC): An NCCTG study
J Clin Oncol (Meeting Abstracts) 2004 22: 639. [Abstract]  

L. Maiorino, G. Frasci, D'Aiuto, P. Comella, R. Thomas, D'Aniello, P. Silvestro, A. Russo, L. Lapenta, and G. Comella

Weekly cisplatin-epirubicin-paclitaxel (PET) vs. triweekly epirubicin-paclitaxel (ET) in metastatic breast cancer (MBC). Interim analysis of the SICOG 9908 phase III trial
J Clin Oncol (Meeting Abstracts) 2004 22: 640. [Abstract]  

P. Schmid, W. Schippinger, T. Nitsch, G. Huebner, R. Kreienberg, W. Schultze, H. Hausmaninger, M. Wischnewsky, H. Samonigg, and K. Possinger

Up front tandem high-dose chemotherapy (HD) compared to standard chemotherapy with doxorubicin and paclitaxel (AT) in metastatic breast cancer (MBC): Final results of a randomized trial
J Clin Oncol (Meeting Abstracts) 2004 22: 641. [Abstract]  

D. Slamon, C. H. Yeon, T. Pienkowski, D. Northfelt, W. Eiermann, R. Patel, J. Crown, A. Riva, S. Blitz, and M. Pegram

Survival analysis from two open-label non-randomized phase II trials of trastuzumab (H) combined with docetaxel (T) and platinums (C, cisplatin or carboplatin) (TCH) in women with HER2+ advanced breast cancer (ABC)
J Clin Oncol (Meeting Abstracts) 2004 22: 642. [Abstract]  

D. A. Yardley, F. A. Greco, L. L. Porter, H. A. Burris, C. Phelps, C. Webb, L. Schlabach, L. M. Fichtel, and J. D. Hainsworth

First line treatment with weekly docetaxel, vinorelbine, and trastuzumab in HER2 overexpressing metastatic breast cancer (HER2+ MBC): A Minnie Pearl Cancer Research Network phase II trial
J Clin Oncol (Meeting Abstracts) 2004 22: 643. [Abstract]  

P. F. Lebowitz, J. Eng-Wong, F. Balis, B. Widemann, N. Jayaprakash, S. Gantz, C. Chow, M. Merino, and J. Zujewski

A phase I trial of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in hormone-receptor positive metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 644. [Abstract]  

S. J. Stanway, A. Purohit, L. Woo, S. Sufi, N. Dobbs, M. Elliott, B. Potter, M. Reed, and R. C. Coombes

First phase I trial of a steroid sulfatase inhibitor in breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 645. [Abstract]  

G. F. Tidmarsh, I. O. Kudajbergenova, S. N. Navrusov, and V. V. Stepula

An open label phase II trial of glufosfamide: A ß-D-glucose-linked isophosphoramide mustard given as 1-hour infusion in patients with advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 646. [Abstract]  

S. Barker, H. R. Glover, S. D. M. Malouitre, J. R. Puddefoot, and G. P. Vinson

Divergent effects of tamoxifen and trilostane in activating protein–1 gene transcription and progesterone receptor expression in breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 647. [Abstract]  

E. Gutteridge, J. M. Gee, R. I. Nicholson, and J. F. R. Robertson

Biological markers associated with response to gefitinib (ZD1839) in patients with breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 648. [Abstract]  

G. Hudelist, W. Koestler, J. Attems, K. Czerwenka, R. Mueller, M. Manavi, G. Steger, E. Kubista, C. J. Zielinski, and C. F. Singer

Active Her-2/neu signal transduction in breast cancer –relevance of a ligand-independent activation mechanism and impact on the efficacy of trastuzumab-based treatment
J Clin Oncol (Meeting Abstracts) 2004 22: 649. [Abstract]  

L. E. Krag, J. Geisler, P. E. Lonning, L. Ottestad, T. Risberg, A. I. Hagen, E. A. Lien, A. Polli, J. Paolini, and G. Massimini

Lipid and coagulation profile in postmenopausal women with early breast cancer at low risk treated with exemestane: A randomized, placebo-controlled study
J Clin Oncol (Meeting Abstracts) 2004 22: 650. [Abstract]  

M. Kusama, H. Kaise, D. Ota, S. Nakayama, T. Miisaka, A. Tsuchida, T. Aoki, Y. Hakamada, and M. Arima

Evaluation of sensitivity to 5-FU on the basis of TS and DPD activity in micro tissue specimens
J Clin Oncol (Meeting Abstracts) 2004 22: 651. [Abstract]  

S. Landt, H. Bühler, N. Vorsteher, K. Evers, B. Duvnjak, H. Adam, N. Bangemann, J. U. Blohmer, and G. Schaller

Myocardial expression of HER2 and HER4 in anthracycline-pretreated breast cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 652. [Abstract]  

S. E. Rivkin, A. M. Gown, J. A. Malmgren, R. J. Tickman, M. Atwood, and D. Iriarte

Vascular endothelial growth factor expression and survival in node positive breast cancer patients treated with adjuvant therapy
J Clin Oncol (Meeting Abstracts) 2004 22: 653. [Abstract]  

R. Wieder and V. Joseph

All trans-retinoic acid modulates survival signaling in dormant breast cancer cells
J Clin Oncol (Meeting Abstracts) 2004 22: 654. [Abstract]  

J. Zidan, I. Dashkovski, A. Hadary, W. Basher, and C. Cozacov

Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease
J Clin Oncol (Meeting Abstracts) 2004 22: 655. [Abstract]  

P. J. Barrett-Lee, J. M. Bliss, A. M. Brunt, K. Dehshiri, A. N. Harnett, L. Johnson, D. Lawrence, A. Robinson, and K. Weerasekera

Polychemotherapy (CT) in pre- and post-menopausal women with early breast cancer prescribed 5 years tamoxifen (T) –results from the UK NCRI Adjuvant Breast Cancer (ABC) international trial in 1991 patients
J Clin Oncol (Meeting Abstracts) 2004 22: 656. [Abstract]  

B. Bermejo, A. Lluch, I. Benet, J. M. Sastre, J. V. Ferrer, T. Garcia, L. Chumbes, P. Martinez, and J. Garcia-Conde

Persistence of occult metastatic cells in bone marrow after adjuvant systemic therapy predicts relapse in localized breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 657. [Abstract]  

M. Bhattacharyya, S. Vinnicombe, D. Ryan, R. Al-Mufti, R. Carpenter, and C. Gallagher

Use of magnetic resonance imaging to plan breast conserving surgery following neoadjuvant chemotherapy for early breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 658. [Abstract]  

E. Bria, C. Nisticò, F. Cuppone, D. Giannarelli, and E. Terzoli

Impact of taxanes in association with anthracyclines in 1^st line chemotherapy for metastatic breast cancer (MBC): Comprehensive review of 2805 patients in 7 phase III trials
J Clin Oncol (Meeting Abstracts) 2004 22: 659. [Abstract]  

S. Delaloge, M. Tubiana-Hulin, A. Wardley, L. Del Mastro, A. Santoro, A. Zambelli, A. Bonetti, C. Boni, F. Habib, and S. Brienza

A multistep randomized phase II/III trial comparing oxaliplatin (OXA)+5 fluorouracil (FU) to vinorelbine (VIN)+FU (FUN) after taxane (T)/anthracycline (A) failure in advanced/metastatic breast cancer (MBC) patients (pts): Final results
J Clin Oncol (Meeting Abstracts) 2004 22: 660. [Abstract]  

T. N. Fehm, S. Becker, G. Pergola-Becker, S. Duerr-Stoerzer, E. Solomayer, and D. Wallwiener

Prediction of tumor cell dissemination in primary breast cancer by tumor biological and clinicopathological factors
J Clin Oncol (Meeting Abstracts) 2004 22: 661. [Abstract]  

S. Fracchioli, R. Bellino, R. Arisio, K. Mingrone, A. Durando, G. Giardina, D. Katsaros, M. Massobrio, M. Porpiglia, and R. Vicelli

Ductal carcinoma in situ (DCIS): USC/Van Nuys Prognostic Index (VNPI) and the impact of micropapillary histotype
J Clin Oncol (Meeting Abstracts) 2004 22: 662. [Abstract]  

A. M. Gonzalez-Angulo, S. W. Kau, K. Broglio, A. U. Buzdar, R. L. Theriault, V. Valero, N. Sneige, D. Frye, G. N. Hortobagyi, and M. Cristofanilli

Invasive lobular carcinoma (ILC) "classic type": Distinct clinical features
J Clin Oncol (Meeting Abstracts) 2004 22: 663. [Abstract]  

J. J. Griggs, M. E. S. Sorbero, K. Sattelberg, and A. W. Dick

Does detection and treatment of ductal carcinoma in situ prevent invasive cancer?
J Clin Oncol (Meeting Abstracts) 2004 22: 664. [Abstract]  

E. Grunfeld, M. Levine, J. Julian, K. Pritchard, D. Coyle, D. Mirsky, S. Verma, S. Dent, C. Sawka, and D. Ginsburg

A randomized controlled trial (RCT) of routine follow-up for early stage breast cancer: A comparison of primary care versus specialist care
J Clin Oncol (Meeting Abstracts) 2004 22: 665. [Abstract]  

A. N. Harnett, J. M. Bliss, L. Johnson, D. Lawrence, V. Raina, and A. Robinson

Thromboembolic events (TEE) in UK NCRI Adjuvant Breast Cancer (ABC) international trial –retrospective and prospective audits
J Clin Oncol (Meeting Abstracts) 2004 22: 666. [Abstract]  

D. Hicks, M. Skacel, E. Downs-Kelly, M. Cheang, J. Pettay, T. Nielsen, D. Huntsman, R. Powell, J. Hainfeld, and T. Grogan

Invasive breast cancer clinical outcome is predicted by a novel bright-field assay for the simultaneous detection of HER2 gene amplification and protein expression (SILVERFISH)
J Clin Oncol (Meeting Abstracts) 2004 22: 667. [Abstract]  

N. Kohno, K. Aogi, H. Minami, S. Nakamura, T. Asaga, Y. Iino, T. Watanabe, C. Goessl, Y. Ohashi, and S. Takashima

A randomized, double-blind, placebo-controlled phase III trial of zoledronic acid in the prevention of skeletal complications in Japanese women with bone metastases from breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 668. [Abstract]  

H. Kourea, A. K. Koutras, V. Zolota, I. Grimani, E. Tzorakoeleptherakis, D. Koukouras, G. Fountzilas, H. Gogas, K. Kyriakou, and H. P. Kalofonos

Expression of cell cycle-related proteins p27kip1, p21waf1 and p53 in node-negative invasive ductal carcinoma of the breast
J Clin Oncol (Meeting Abstracts) 2004 22: 669. [Abstract]  

D. Luftner, H. Dilk, P. Henschke, R. Geppert, M. Dietel, H. Stein, K. Wernecke, K. Possinger, and B. Heine

Results of a 10-year retrospective search in two university institutes of pathology: Concordance of HER-2/neu expression of primary breast carcinomas and their metachronous distant metastases
J Clin Oncol (Meeting Abstracts) 2004 22: 670. [Abstract]  

G. H. Perkins, M. C. Green, L. P. Middleton, S. H. Giordano, S. M. Garcia, E. A. Strom, N. R. Schechter, P. Allen, T. A. Buchholz, and G. N. Hortobagyi

Medullary breast carcinoma: Outcomes and prognosis with the utilization of chemotherapy
J Clin Oncol (Meeting Abstracts) 2004 22: 671. [Abstract]  

J. Y. Petit, G. Curigliano, F. Bertolini, G. Peruzzotti, S. Gandini, S. Zurrida, S. Martella, R. Ghisini, F. De Braud, and A. Goldhirsch

Systemic effects of surgery: Quantitative analysis of circulating basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-ß) in patients with breast cancer who underwent limited or extended surgery
J Clin Oncol (Meeting Abstracts) 2004 22: 672. [Abstract]  

R. G. Prosnitz, X. Yu, S. Zhou, D. Kahn, D. R. Hollis, P. H. Hardenbergh, S. Borges-Neto, T. Wong, M. A. Blazing, and L. B. Marks

Impact of patient-specific factors in the development of radiation (RT)-associated cardiac perfusion defects
J Clin Oncol (Meeting Abstracts) 2004 22: 673. [Abstract]  

J. C. Reddy, S. Rai, G. Lieberman, and P. Klein

Patient benefit from trastuzumab plus a taxane regardless of estrogen receptor (ER) status or prior adjuvant therapy for HER2+ metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2004 22: 674. [Abstract]  

I. E. Smith and M. Dowsett

Assessment of lipids and bone-derived resorption products during neoadjuvant therapy with anastrozole (A), v tamoxifen (T), v combination (C) in the IMPACT trial
J Clin Oncol (Meeting Abstracts) 2004 22: 675. [Abstract]  

J. A. Sparano, U. Hopkins, S. Moulder, and L. Vahdat

A phase I trial of the farnesyl transferase inhibitor tipifarnib plus doxorubicin-cyclophosphamide in patients with metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 676. [Abstract]  

C. L. Vogel, J. R. Mackey, and M. Martin

The role of growth factor support following neutropenic events in early stage breast cancer (BC) patients treated with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC): A sub-analysis of BCIRG 001
J Clin Oncol (Meeting Abstracts) 2004 22: 677. [Abstract]  

Z. Vujaskovic, E. Jones, E. Rosen, Z. Rabbani, S. Kim, V. Liotcheva, M. Dewhirst, T. Samulski, L. Prosnitz, and K. Blackwell

High degree of correlation between in vivo tumor oxygenation measurements and carbonic anhydrase IX tissue staining in operable human breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 678. [Abstract]  

H. Yaziji, T. S. Barry, L. C. Goldstein, H. H. Hwang, A. W. Hing, and A. M. Gown

Discrepancies between immunohistochemistry and fluorescence in situ hybridization for HER-2 testing in breast cancer: The role of a quality assurance program on a cohort of 3564 patients
J Clin Oncol (Meeting Abstracts) 2004 22: 679. [Abstract]  

C. H. Yeon, D. Slamon, R. Patel, A. Cartmell, B. Leyland-Jones, P. Klein, W. Eiermann, J. Wolter, G. Lieberman, and M. Pegram

Clinical benefit of trastuzumab (H) among patients with HER2-positive metastatic breast cancer (MBC) not achieving objective responses when treated with H plus chemotherapy (CT)
J Clin Oncol (Meeting Abstracts) 2004 22: 680. [Abstract]  

H. Zhao, T. Ray, P. Robinson, C. Miyamoto, and M. P. Achary

A novel DNA marker associated with breast metastasis
J Clin Oncol (Meeting Abstracts) 2004 22: 681. [Abstract]  

R. Altaha, E. Crowell, B. Ducatman, G. Higa, and J. Abraham

Risk of brain metastases in HER2/neu-positive breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 682. [Abstract]  

B. E. Ellerin, J. Seidenfeld, and S. C. Formenti

A systematic review of post-lumpectomy radiation therapy regimens
J Clin Oncol (Meeting Abstracts) 2004 22: 683. [Abstract]  

P. Koralewski, M. Blasinska Morawiec, A. Tekiela, E. Chmielowska, M. Campone, J. Bonneterre, B. Longerey, and S. Lafaye de Micheaux

Phase I study of vinorelbine (VRL) alternating i.v. and oral in combination with docetaxel (DTX) as 1st line chemotherapy (CT) of metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2004 22: 684. [Abstract]  

A. Z. Bluming

Hormone replacement therapy (HRT) in women with previously treated primary breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 685. [Abstract]  

V. Raina, M. Bhutani, R. Bedi, A. Sharma, S. Deo, N. K. Shukla, B. K. Mohanti, and G. Rath

Analysis of early breast cancer (EBC) cases at IRCH, AIIMS, New Delhi
J Clin Oncol (Meeting Abstracts) 2004 22: 686. [Abstract]  

D. M. Mintzer, A. L. Davis, and M. Klitus

Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: The effect of taxanes
J Clin Oncol (Meeting Abstracts) 2004 22: 687. [Abstract]  

P. F. Escobar, R. Patrick, L. Rybicki, S. Grundfest-Broniatowski, J. Kim, and J. Crowe

Clinical predictors of residual breast disease after primary induction chemotherapy
J Clin Oncol (Meeting Abstracts) 2004 22: 688. [Abstract]  

M. L. Quan, R. Delgado, and K. Van Zee

Atypical vascular lesions including angiosarcoma after breast conservation
J Clin Oncol (Meeting Abstracts) 2004 22: 689. [Abstract]  

S. Wang, P. Fan, and X. Liu

Study on micrometastases in sentinel lymph node, peripheral blood and bone marrow from breast cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 690. [Abstract]  

M. Hauschild, A. Thomas, S. Maza, S. Kuemmel, T. Fischer, P. Mallmann, D. L. Munz, and J. U. Blohmer

Sentinel node biopsy in breast cancer after neoadjuvant therapy
J Clin Oncol (Meeting Abstracts) 2004 22: 691. [Abstract]  

Z. Agur, L. Arakelyan, G. Belilty, N. Dahan, H. Harpak, Y. Kogan, Y. Merbl, A. Rabinovich, M. Shoham, and I. Ziv

Application of the Virtual Cancer Patient Engine (VCPE) for improving oncological treatment desig
J Clin Oncol (Meeting Abstracts) 2004 22: 692. [Abstract]  

P. Lind, U. Blom-Goldman, M. Anderson, B. Wennberg, and G. Svane

Prevention of radiation pneumonitis in breast cancer irradiation through dose-volume constraint
J Clin Oncol (Meeting Abstracts) 2004 22: 693. [Abstract]  

K. Motomura, S. Nagumo, C. Egawa, Y. Komoike, T. Kasugai, Y. Hasegawa, H. Inaji, and H. Koyama

Role of three axillary lymph node sampling for predicting non-sentinel node metastases in patients with breast cancer and positive sentinel node
J Clin Oncol (Meeting Abstracts) 2004 22: 694. [Abstract]  

U. Kraus-Tiefenbacher, A. Scheda, L. Bauer, F. Melchert, and F. Wenz

Intraoperative radiotherapy (IORT) as a boost in patients with early breast cance
J Clin Oncol (Meeting Abstracts) 2004 22: 695. [Abstract]  

K. Haider, G. Kornek, W. Kwasny, D. Depisch, T. Payrits, W. Scheithauer, and F. Lang

Multicenter phase II trial of gemcitabine plus liposomal doxorubicin in chemotherapeutically pretreated patients with advanced breast cancer (ABC
J Clin Oncol (Meeting Abstracts) 2004 22: 696. [Abstract]  

R. Aft, L. Ylagan, S. Sadeghi, T. Eberlein, V. Herrmann, J. Dietz, P. Fracasso, M. Naughton, and K. Weilbaecher

Effect of neoadjuvant chemotherapy on bone marrow micrometastases in women with locally advanced breast cance
J Clin Oncol (Meeting Abstracts) 2004 22: 697. [Abstract]  

H. Iwata, M. Mizutani, K. Kamei, T. Toyama, Y. Ando, D. Ota, N. Kawaguchi, C. Shigemori, and H. Iwase

A phase I/II dose-escalation study of weekly paclitaxel in combination with 5'-deoxy-5-fluorouridine for advanced or recurrent breast cance
J Clin Oncol (Meeting Abstracts) 2004 22: 698. [Abstract]  

F. Gago and D. R. Ciocca

Breast cancer patients co-expressing estrogen receptor alpha and/or progesterone receptors and HER2/neu: Response to adjuvant therap
J Clin Oncol (Meeting Abstracts) 2004 22: 699. [Abstract]  

A. Reyners, H. Hollema, and N. Mulder

Intensive chemotherapy with autologous bone marrow transplantation in patients with locally advanced breast cancer: 12-years follow-u
J Clin Oncol (Meeting Abstracts) 2004 22: 700. [Abstract]  

M. A. Lacombe, W. Al-Najjar, J. McMahon, V. Raghavan, and W. D. Bloomer

Accelerated partial breast irradiation using intensity modulated radiotherapy: Dose-volume histogram comparison with standard breast irradiatio
J Clin Oncol (Meeting Abstracts) 2004 22: 701. [Abstract]  

S. R. Bunker and C. B. Dunleavy

Fusion changes patient management with PET & C
J Clin Oncol (Meeting Abstracts) 2004 22: 702. [Abstract]  

A. Ezzat, M. Rahal, T. Twegieri, S. Akhtar, A. Al Sayed, D. Ajarim, A. Tulbah, O. Al Malik, and M. Al Shabanah

Primary chemotherapy with doxorubicin followed by docetaxel-cisplatin in locally advanced breast cance
J Clin Oncol (Meeting Abstracts) 2004 22: 703. [Abstract]  

F. Fulfaro, M. R. Valerio, G. Badalamenti, C. Arcara, G. Cicero, C. Intrivici, A. Crosta, C. Sciortino, A. Russo, and N. Gebbia

Weekly paclitaxel (T) and pegylated liposomal doxorubicin (PLD) as first line treatment in metastatic breast cancer (MBC) patient
J Clin Oncol (Meeting Abstracts) 2004 22: 704. [Abstract]  

N. Gebbia, F. Fulfaro, G. Badalamenti, C. Arcara, G. Cicero, G. Rinaldi, L. Vizzini, F. Spinnato, A. Russo, and M. R. Valerio

A phase 2 study of oxaliplatin (O) -capecitabine (C) chemotherapy in metastatic breast cancer (MBC) patients pretreated with anthracyclines and taxane
J Clin Oncol (Meeting Abstracts) 2004 22: 705. [Abstract]  

S. Verma, V. Gallant, M. Trudeau, and S. Dahrouge

Trastuzumab (T) and docetaxel (D) for the treatment of HER2 metastatic breast cancer (MBC): A literature based (LB) and individual patient data (IPD) meta-analysis (MA) of phase II trial
J Clin Oncol (Meeting Abstracts) 2004 22: 706. [Abstract]  

H. Zafar, B. Pollock, I.-T. Yeh, and W. Knight

Her-2/Neu over expression in patients with breast cancer and early central nervous system (CNS) relaps
J Clin Oncol (Meeting Abstracts) 2004 22: 707. [Abstract]  

W. Wong, B. Pockaj, M. Halyard, R. Gray, S. Vora, S. Schild, and H. Apsey

Integration of intra-operative electron irradiation (IOERT) in breast conserving treatment for T1/T2N0 breast cancer: Early results of a phase II tria
J Clin Oncol (Meeting Abstracts) 2004 22: 708. [Abstract]  

J. P. Lamont, M. Faynsod, D. Smith, R. Pezner, and J. D. I. Ellenhorn

Evaluation of routine radiation boost following breast conservation therapy in young patient
J Clin Oncol (Meeting Abstracts) 2004 22: 709. [Abstract]  

K.-S. Khoo, M. Zaidi, V. Srimuninnimit, Z. F. Jiang, P. Prem Kumar, A. Bustam, A. H. Villalon, and M. Lehnert

Randomized phase II trial of three gemcitabine (GEM)-taxane combinations in metastatic breast cancer (MBC
J Clin Oncol (Meeting Abstracts) 2004 22: 710. [Abstract]  

M. Martino, F. Morabito, M. C. Zavettieri, M. Nardi, S. Palazzo, G. Filippelli, B. Lazzaro, S. Molica, G. Longo, and P. Iacopino

Long-term results of high-dose chemotherapy with autologous peripheral stem cells support on the outcome of progression free and overall survival in metastatic breast cancer patients classified according to a risk group scor
J Clin Oncol (Meeting Abstracts) 2004 22: 711. [Abstract]  

X. Tchiknavorian, S. Perruchio, P. Agin, A. Lachard, B. Beedassy, J. M. Blanc, and L. Cals

Retrospective analysis of 561 breast magnetic resonance imaging (MRI). The largest study to dat
J Clin Oncol (Meeting Abstracts) 2004 22: 712. [Abstract]  

N. Naqi, M. Ilyas, and R. Hashim

Skeletal related events in breast cancer patients with metastatic bone diseas
J Clin Oncol (Meeting Abstracts) 2004 22: 713. [Abstract]  

C. Wenzel, D. Hussian, R. Bartsch, U. Pluschnig, G. J. Locker, M. Gnant, R. Jakesz, C. C. Zielinski, and G. G. Steger

Feasibility of docetaxel, epirubicin, and capecitabine (TEX) plus pegfilgrastim as neoadjuvant treatment for primary breast cancer: A pilot stud
J Clin Oncol (Meeting Abstracts) 2004 22: 714. [Abstract]  

A. E. Ring, P. A. Ellis, A. Jones, C. Shannon, E. Galani, and I. E. Smith

Chemotherapy for breast cancer given during pregnancy: A case serie
J Clin Oncol (Meeting Abstracts) 2004 22: 715. [Abstract]  

A. Chan, J. Yau, S. Huan, D. Vergidis, M. Anthes, C. Falkson, A. Kirk, and H. Dhaliwal

Adherence to clinical practice guidelines for adjuvant therapy of breast cance
J Clin Oncol (Meeting Abstracts) 2004 22: 716. [Abstract]  

C. D. Cheli, R. P. Thiel, and D. Luftner

Clinical utility of a HER-2/neu assay in monitoring and predicting response to therapies in patients with metastatic breast cance
J Clin Oncol (Meeting Abstracts) 2004 22: 717. [Abstract]  

G. Sanna, A. Balduzzi, L. Franceschelli, L. Corsetto, M. G. Zampino, I. Minchella, C. Catania, K. Lorizzo, A. Rocca, and F. Nolè

An effective chemotherapy regimen for patients with heavily pretreated metastatic breast cancer (MBC) using vinorelbine (V) administered with weekly epirubicin (E) and continuous infusion of 5- fluorouracil (CIFU
J Clin Oncol (Meeting Abstracts) 2004 22: 718. [Abstract]  

L. Cals, P. Nouyrigat, X. Tchiknavorian, C. Veyret, and J. L. Wendling

Neoadjuvant weekly paclitaxel, and epirubicin (PE) in patients with inflammatory and T4 breast cancer (IBC-T4BC): Result of a VAR Cancer Society tria
J Clin Oncol (Meeting Abstracts) 2004 22: 719. [Abstract]  

R. M. Wolfort, B. D. L. Li, R. H. Turnage, M. R. Ramaswamy, F. Ampil, G. Burton, and Q. D. Chu

The role of positron emission tomography in the detection of recurrence in symptomatic patients with stage II and III breast cance
J Clin Oncol (Meeting Abstracts) 2004 22: 720. [Abstract]  

N. Mullai, C. Tong, J. Samuel, and C. Clarke

Breast conservation surgery (BCS) versus modified radical mastectomy (MRM) decision: Role of patient and physicia
J Clin Oncol (Meeting Abstracts) 2004 22: 721. [Abstract]  

M. J. Rabinowitz, A. Mangalik, F.-C. Lee, C. Cathcart, C. Verschraegen, and I. Rabinowitz

Phase I/II study of carboplatin, vinorelbine and capecitabine in metastatic breast cance
J Clin Oncol (Meeting Abstracts) 2004 22: 722. [Abstract]  

J. C. Hu, G. Hallden, C. Shorrock, G. Simpson, R. Coffin, T. Kamalati, and C. Coombes

Combination of a second generation genetically modified herpes simplex virus 1 (HSV1) with paclitaxel in the treatment of breast cancer in vitro
J Clin Oncol (Meeting Abstracts) 2004 22: 723. [Abstract]  

C. Catania, F. Nolè, A. Balduzzi, L. Franceschelli, C. Marenghi, L. Corsetto, G. Sanna, C. Noberasco, M. G. Zampino, and A. Goldhirsch

Caring for heavily pretreated patients with metastatic breast cancer (MBC): Carboplatin (CBDCA) - gemcitabine (GCB) combination is effective and well tolerate
J Clin Oncol (Meeting Abstracts) 2004 22: 724. [Abstract]  

F. Ciardiello, T. Troiani, F. Caputo, M. De Laurentiis, G. Palmieri, A. Marinelli, G. Colantuoni, M. R. Diadema, S. De Placido, and A. R. Bianco

A Phase II study of gefitinib combined with docetaxel as first-line treatment in patients with advanced breast cance
J Clin Oncol (Meeting Abstracts) 2004 22: 725. [Abstract]  

H. J. Stemmler, C. Salat, H. Lindhofer, M. Menzel, H. Sauer, M. Untch, G. Konecny, G. Ledderose, H. J. Kolb, and V. Heinemann

High dose chemotherapy (HDCT) and hematopoietic stem cell transplantation (HPSCT) with subsequent immunotherapy in metastatic breast cancer (MBC): Final results of a phase I stud
J Clin Oncol (Meeting Abstracts) 2004 22: 726. [Abstract]  

B. Overmoyer, P. Silverman, R. Leeming, R. Shenk, J. Lyons, N. Ziats, J. Jesberger, L. Dumadag, S. Remick, and H. Chen

Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cance
J Clin Oncol (Meeting Abstracts) 2004 22: 727. [Abstract]  

A. Polyzos, D. Mavroudis, J. Boukovinas, E. Tsiakopoulos, N. Malamos, G. Milaki, C. Kouroussis, A. Kotsakis, A. Pallis, and V. Georgoulias

A multicenter phase II study of docetaxel, gemcitabine and trastuzumab administration as first-line treatment in patients with advanced breast cancer (ABC) overexpressing HER-
J Clin Oncol (Meeting Abstracts) 2004 22: 728. [Abstract]  

M. Namer

Unilateral versus bilateral breast cancers, synchronous versus non-synchronous bilateral breast cancers: Results of a long survey (25 years) concerning 3632 patient
J Clin Oncol (Meeting Abstracts) 2004 22: 729. [Abstract]  

L. Petruzelka and M. Zimovjanova

Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy -results from a compassionate use progra
J Clin Oncol (Meeting Abstracts) 2004 22: 730. [Abstract]  

G. Bernardo, R. Palumbo, A. Bernardo, G. Villani, M. Melazzini, G. Poggi, M. Frascaroli, and I. Jedrychowska

Final results of a phase II study of weekly trastuzumab and vinorelbine in chemonaive patients with HER2-overexpressing metastatic breast cance
J Clin Oncol (Meeting Abstracts) 2004 22: 731. [Abstract]  

I. J. Diel, D. Tripathy, J.-J. Body, and B. Bergström

Effect of 1-year intravenous ibandronate treatment on time to serum creatinine increase in patients with skeletal metastases from breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 733. [Abstract]  

A. Schneeweiss, C. Rudlowski, H.-P. Sinn, F. Beldermann, D. Von Fournier, and G. Bastert

Dose dense gemcitabine/epirubicin (GE) followed sequentially by dose dense docetaxel (Doc) as primary systemic therapy (PST) of patients (pts) with early breast cancer (BC): First results of a phase I/II trial
J Clin Oncol (Meeting Abstracts) 2004 22: 734. [Abstract]  

J.-J. Body, M. Lichinitser, N. Andreeva, M. Budde, and B. Bergström

Safety of an intravenous (i.v.) dose of ibandronate followed by daily oral dosing in metastatic bone disease: Results of an open-label study
J Clin Oncol (Meeting Abstracts) 2004 22: 735. [Abstract]  

P. Borrega, A. Lorenzo, C. Madroñal, J. J. Sanz, M. Ruiz, M. Centelles, A. Casas, C. González de La Puente, V. Perez, and M. González-Barón

Dose-dense neoadjuvant treatment with biweekly docetaxel (T) plus epirubicin (E) for locally advanced breast cancer (LABC). An ONCOPAZ Cooperative Group Study
J Clin Oncol (Meeting Abstracts) 2004 22: 736. [Abstract]  

S. E. Jones, J. Pippen, and A. Webster

A retrospective analysis of the proportion of patients responding for > 1 year in two phase III studies of fulvestrant vs. anastrozole
J Clin Oncol (Meeting Abstracts) 2004 22: 737. [Abstract]  

K. Eichler, S. Zangos, M. G. Mack, J. O. Balzer, O. Söllner, C. Herzog, K. Engelmann, and T. J. Vogl

Hepatic intra-arterial chemotherapy with gemcitabine: An ongoing phase II study in patients with liver metastases of breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 738. [Abstract]  

K. Jabboury, A. Wong, A. Deutsch, R. Behar, K. King, S. Thomas, C. Reilly, P. Curtis, and O. Mangini

5-year survival with dose intensive L-FAC multimodality therapy of breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 739. [Abstract]  

R. Colomer, J. I. Mayordomo, L. Calvo, J. Hornedo, F. Carabantes, M. Gil, B. Martin, and H. Cortes-Funes

Gemcitabine, paclitaxel plus trastuzumab (GTH) in HER2 ECD-positive metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 740. [Abstract]  

B. Xu, L. Tian, Q. Wu, M. Zhou, H. Wang, Z. Tong, H. Li, L. Li, G. Hu, and J. Shi

Capecitabine (X) combined with vinorelbine (V) in Chinese patients (pts) with metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2004 22: 741. [Abstract]  

T. R. Chaudhuri, Z. Cao, S. Ponnazhagan, A. Stargel, P. L. Simhadri, T. Zhou, A. F. Lobuglio, D. J. Buchsbaum, and K. R. Zinn

Detection of disseminated breast cancer growth and treatment response using non-invasive bioluminescence imaging
J Clin Oncol (Meeting Abstracts) 2004 22: 742. [Abstract]  

E. E. Franco, J. A. Silva, M. Perez, M. Silva, R. Villalobos, S. Labastida, G. Olivares, and A. L. Castruita

Docetaxel as adjuvant therapy on patients with locally advanced breast cancer (LABC), after neoadjuvant chemotherapy with anthracyclines followed by radical surgery +/– radiotherapy
J Clin Oncol (Meeting Abstracts) 2004 22: 743. [Abstract]  

C. R. Meier, H. J. Illiger, M. Steder, M. Braun, H. Deertz, and H. T. Oeney

Weekly vinorelbine (VIN) vs weekly docetaxel (DOC) for metastatic breast cancer failing anthracyclines. Planned interim analysis of a randomized trial
J Clin Oncol (Meeting Abstracts) 2004 22: 744. [Abstract]  

M. Hino, T. Saeki, Y. Sato, and M. Sano

Late phase II study of S-1 in patients with taxane resistant breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 745. [Abstract]  

S.-H. Lee, J. Y. Lee, Y.-H. Im, J. Park, H. Y. Kim, Y. S. Park, J. H. Kim, S. J. Nam, J. H. Yang, and K. Park

Doxorubicin plus docetaxel as neoadjuvant treatment in patients with large (T>5cm), locally advanced carcinoma of the breast
J Clin Oncol (Meeting Abstracts) 2004 22: 746. [Abstract]  

M. Fabbro, S. Thezenas, S. Wandzel, A. Kramar, A. Martinez, and D. Mir

Phase I study of high-dose chemotherapy with peripheral blood stem-cells reinfusion (PBSC) in patients with metastatic or inflammatory breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2004 22: 747. [Abstract]  

L. G. Estevez, N. Batista, P. Sánchez-Rovira, A. Velasco, M. Domine, F. Lobo, J. Oramas, and J. Cruz

Phase II study with the combination of capecitabine (C) and vinorelbine (V) in metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes
J Clin Oncol (Meeting Abstracts) 2004 22: 748. [Abstract]  

C. Couteau, F. Dalenc, G. Ferron, M. Lacroix-Triki, M.-H. Marty, I. Garrido, L. Gladieff, and H. Roché

Neoadjuvant sequential treatment in women with breast cancer: FEC100 then docetaxel: Results in clinical practice
J Clin Oncol (Meeting Abstracts) 2004 22: 749. [Abstract]  

S. Giard, P. Carpentier, C. Bercez, and C. Dedourge

Sentinel node biopsy versus complete axillary clearance in breast cancer: The patients' point of view. Results of a prospective survey
J Clin Oncol (Meeting Abstracts) 2004 22: 750. [Abstract]  

A. Anton, T. Puertolas, M. Ramos, A. Barnadas, J. Florian, R. Grande, N. Ribelles, and M. Lomas

Phase II study of vinorelbine (NVB) and UFT in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes
J Clin Oncol (Meeting Abstracts) 2004 22: 751. [Abstract]  

M. Bellet, M. Muñoz, A. Pelegri, J. Corominas, B. Bellosillo, I. Tusquets, and X. Fabregat

Phase II study of capecitabine (C) in combination with docetaxel (D) as neoadjuvant treatment in patients with locally advanced breast cancer (IIIA and IIIB stage)
J Clin Oncol (Meeting Abstracts) 2004 22: 752. [Abstract]  

A. Nicolini, G. Tartarelli, P. Ferrari, A. Carpi, M. Conte, C. Spinelli, L. Anselmi, R. Spisni, and P. Miccoli

Intensive post-operative follow-up of breast cancer patients with tumour markers: Accuracy of serum MCA-CA15.3 and CEA-TPA-CA15.3 tumour marker panels for early detection of relapse
J Clin Oncol (Meeting Abstracts) 2004 22: 753. [Abstract]  

U. Euler, B. Knopf, and A. H. Tulusan

Breast cancer in young women aged 35 or less
J Clin Oncol (Meeting Abstracts) 2004 22: 754. [Abstract]  

P. Stieber, D. Lässig, M. Untch, D. Nagel, and V. Heinemann

How can CEA and CA15–3 be used for estimation of the clinical status and effectiveness of therapy during metastatic breast cancer?
J Clin Oncol (Meeting Abstracts) 2004 22: 755. [Abstract]  

G. Perez Manga, J. M. Garcia Bueno, H. Palombo, S. Morales, M. Méndez, and B. Esteban

A phase II study of vinorelbine (VNR) and letrozole (LTZ) in aged women with metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2004 22: 756. [Abstract]  

S. V. Labropoulos, G. Fountzilas, S. Papadopoulos, M. Karina, M. Xylouri, A. Doudoulakakis, S. Chalkidou, and E. D. Razis

Study of serum EGFR, HER-2/neu,VEGF in metastatic breast cancer patients treated with taxanes
J Clin Oncol (Meeting Abstracts) 2004 22: 757. [Abstract]  

S. K. Das, A. Baydush, S. Zhou, M. Miften, X. Yu, K. Light, T. Wong, S. Borges-Neto, and L. Marks

Complication models to predict radiation-induced cardiac toxicity in patients with breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 758. [Abstract]  

A. Morabito, G. Carillio, P. Bonginelli, S. Amici, R. Longo, R. Sarmiento, M. Fanelli, S. C. Stani, D. Gattuso, and G. Gasparini

Gemcitabine, vinorelbine and trastuzumab combination (GemVinT) as second-third line therapy for HER-2 overexpressing metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2004 22: 759. [Abstract]  

V. C. Sezgin, U. A. Sanli, B. Karabulut, R. Uslu, G. G. Muezzinoglu, N. Ozdemir, and E. Goker

Capecitabine (X) monotherapy in patients (pts) with pretreated metastatic breast cancer (MBC): Is response correlated to cerbB-2 expression?
J Clin Oncol (Meeting Abstracts) 2004 22: 760. [Abstract]  

S. Barni, M. T. Ionta, R. Labianca, A. Zaniboni, A. Ardizzoia, B. Massidda, C. Tondini, D. Capra, C. Demontis, and M. E. Cazzaniga

Phase II, multicentre study evaluating cisplatin (P), epirubicin (E) and vinorelbine (V) as first line chemotherapy (CHT) in advanced breast cancer (ABC): A new promise
J Clin Oncol (Meeting Abstracts) 2004 22: 761. [Abstract]  

A. Bensalem and K. Bouzid

Gemcitabine (G) and Doxorubicin (DXR) as first-line treatment of metastatic breast cancer (MBC): Preliminary results
J Clin Oncol (Meeting Abstracts) 2004 22: 762. [Abstract]  

J. Bayo, J. I. Mayordomo, P. Sanchez-Rovira, R. Perez-Carrion, J. Illaramendi, E. Gonzalez Flores, J. M. García Bueno, M. Ramos Vazquez, C. Crespo, and A. Garcia Palomo

Trastuzumab and vinorelbine combination in the treatment of Her2 positive metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 763. [Abstract]  

J. E. Trey, J. E. Simon, and A. Khiyami

Treatment of leptomeningeal carcinomatosis from breast cancer with systemically administered chemotherapy
J Clin Oncol (Meeting Abstracts) 2004 22: 764. [Abstract]  

A. Herrero, R. Grandez, T. Puertolas, V. Alonso Orduña, J. Martinez Trufero, R. Pazo Cid, A. Artal, J. Lao, A. Ruiz de Lobera, and A. Anton Torres

High incidence of brain metastases at the time of death in women with metastatic breast cancer treated with trastuzumab
J Clin Oncol (Meeting Abstracts) 2004 22: 765. [Abstract]  

S. Bonardi, A. Bottini, P. Sperone, M. P. Brizzi, G. Allevi, A. Berruti, D. Generali, S. Aguggini, C. Bernardi, and L. Dogliotti

Chemotherapy followed by surgery of residual disease in metastatic breast cancer: A single institution prospective study
J Clin Oncol (Meeting Abstracts) 2004 22: 766. [Abstract]  

R. Coleman

Association between prior chemotherapy and the adverse event (AE) profile of adjuvant anastrozole (A) or tamoxifen (T): A retrospective analysis from the ATAC trial
J Clin Oncol (Meeting Abstracts) 2004 22: 767. [Abstract]  

G. Oster, T. E. Delea, A. Berger, P. Klein, G. Lieberman, V. E. Paton, and A. Chawla

Cost-effectiveness of HER-2 testing strategies to select women with metastatic breast cancer (MBC) for treatment with trastuzumab
J Clin Oncol (Meeting Abstracts) 2004 22: 768. [Abstract]  

A. El Khodary, Y. Gouda, S. Al Noweim, H. Kohail, R. Gaafar, H. Zawahry, A. A. Wareth, O. Mansour, S. Shehata, and T. A. Hamid

Gemcitabine plus cisplatin in patients with locally advanced or metastatic breast cancer (MBC) who failed prior anthracycline therapy +/– taxanes
J Clin Oncol (Meeting Abstracts) 2004 22: 769. [Abstract]  

W. Distler

Impact of age on the gynecologic adverse event (AE) profile of anastrozole (A) or tamoxifen (T) in the ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial
J Clin Oncol (Meeting Abstracts) 2004 22: 770. [Abstract]  

C. E. Collen and V. Vinh-Hung

Long term prognostic value of ER and PR in early stage breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 771. [Abstract]  

J. Lakicevic, D. Lakic, and M. Sorat

The site of first relapse in postmenopausal high-risk node positive operable breast cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 772. [Abstract]  

M. J. Clemons, S. Verma, V. Leung, G. Dranitsaris, I. Shalaby, S. Oldfield, F. Charbonneau, A. Giotis, T. Petrella, and M. Trudeau

Palliative chemotherapy with vinorelbine or capecitabine in women with anthracycline and taxane refractory metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 773. [Abstract]  

D. Ajarim, A. Ezzat, S. Bazarbashi, M. Rahal, M. El Foudeh, C. Pai, and M. Raja

Gemcitabine plus cisplatin combination as second-line treatment in patients with metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2004 22: 774. [Abstract]  

C. Nisticò, E. Bria, A. Carpino, G. Vitelli, F. Cuppone, F. Izzo, F. Tropea, B. Vanni, P. Astorre, and E. Terzoli

Evaluation of weekly epirubicin-paclitaxel (EP) cardiotoxicity with serum troponin-t and myoglobin and echocardiography in advanced breast cancer (ABC)
J Clin Oncol (Meeting Abstracts) 2004 22: 775. [Abstract]  

G. H. Lyman, J. Crawford, D. C. Dale, D. A. Wolff, and E. Culakova

Predicting the risk of neutropenic complications and reduced dose intensity in patients with early-stage breast cancer (ESBC): Results from a prospective nationwide registry
J Clin Oncol (Meeting Abstracts) 2004 22: 776. [Abstract]  

D. Gupta, G. H. Perkins, S. M. Garcia, A. A. Sahin, and L. P. Middleton

Male breast cancer: Clinico-pathological study with evaluation of biologic markers
J Clin Oncol (Meeting Abstracts) 2004 22: 777. [Abstract]  

J. H. Chun, H. G. Lee, E. S. Lee, E. Kim, J. H. Oh, and J. Ro

Frontline docetaxel (T)/ capecitabine (X) combination therapy in patients (pts) with metastatic breast cancer (MBC): A phase II study
J Clin Oncol (Meeting Abstracts) 2004 22: 778. [Abstract]  

D. G. Kirsch, C. J. Ledezma, C. S. Mathews, M. Ancukiewicz, A. K. Bahn, F. H. Hochberg, and J. S. Loeffler

Brain metastases from breast cancer: Survival by HER2 status in the trastuzumab era
J Clin Oncol (Meeting Abstracts) 2004 22: 779. [Abstract]  

A. Alimonti, S. Di Cosimo, G. Ferretti, P. Carlini, P. Papaldo, A. Fabi, A. Gelibter, I. Sperduti, L. Di Lauro, and F. Cognetti

Timing of adjuvant chemotherapy by menstrual cycle phase and risk of secondary amenorrhea in women with early breast cancer: Preliminary results
J Clin Oncol (Meeting Abstracts) 2004 22: 780. [Abstract]  

B. Schauf, N. Schweizer, E. Solomayer, D. Wallwiener, and J. Huober

Direct toxic effect of cytostatic drugs on erythrocytes as possible reason for chemotherapy-induced anemia
J Clin Oncol (Meeting Abstracts) 2004 22: 781. [Abstract]  

R. Lara, J. I. Mayordomo, A. Modolell, M. Burillo, J. Sanz, L. Murillo, J. Janariz, V. Perez, R. Andres, and A. Tres

Feasibility of adjuvant chemotherapy with doxorubicin plus docetaxel followed by sequential capecitabine in patients with node positive breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 782. [Abstract]  

T. Bouillet, P. Saintigny, E. Levy, J.-P. Spano, F. Morin, A. Pommeyrol, B. Brun, M. Bennamoun, J.-L. Breau, and J.-F. Morère

Weekly paclitaxel (P) combined with biweekly vinorelbine (V) in metastatic breast cancer (MBC): Final results of a clinical phase II study
J Clin Oncol (Meeting Abstracts) 2004 22: 783. [Abstract]  

S. McCloskey, L. Botnick, C. Rose, A. Malcolm, M. L. Ozohan, R. Mena, and M. L. Tao

Long-term outcome after breast conservation (BCT) for early stage breast cancer in a community setting
J Clin Oncol (Meeting Abstracts) 2004 22: 784. [Abstract]  

S. S. Mitra, A. Salman, D. Bloomfield, and A. Johri

A retrospective review of wide excision alone for ductal carcinoma in situ (DCIS) of the breast
J Clin Oncol (Meeting Abstracts) 2004 22: 785. [Abstract]  

H. Rudnicka, A. Jagiello-Gruszfeld, S. Jaczewska, I. Glogowska, I. Lemanska, and T. Pienkowski

Noninvasive breast cancer orbital metastases treatment saving the visual and oculomotor nerves
J Clin Oncol (Meeting Abstracts) 2004 22: 786. [Abstract]  

V. Duric, M. R. Stockler, P. Butow, L. Sharpe, J. Beith, A. Sullivan, F. Boyle, H. Dhillon, A. S. Coates, and R. J. Simes

Predictors of the benefits women consider necessary to make adjuvant chemotherapy (ACT) worthwhile for early breast cancer (EBC)
J Clin Oncol (Meeting Abstracts) 2004 22: 787. [Abstract]  

C. Llorca, J. Mayordomo, E. Adrover, I. Alvarez, C. Madroñal, M. Burillo, J. Sanz, A. Lorenzo, H. Palombo, and J. Janariz

Activity and safety of biweekly docetaxel plus capecitabine as first-line treatment for patients with metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 788. [Abstract]  

S. Karmarkar, D. Jones, S. Hatch, F. Klementich, K. Ansari, B. Grube, C. Chao, and C. Townsend

Phase II trial of neoadjuvant docetaxel and carboplatin with filgrastim (G-CSF) support in patients with locally advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 789. [Abstract]  

K. Kai, R. Nishimura, M. Matsuda, and H. Miyayama

Evaluation of cross-resistance among endocrine therapies and predictive factors for response in recurrent or advanced breast cancer treated with 3rd generation aromatase inhibitors
J Clin Oncol (Meeting Abstracts) 2004 22: 790. [Abstract]  

C. M. Schlotter, K. Wassmann, U. Bosse, K. P. Bielawski, and U. Vogt

Synergistic effect of ibandronate (Ib) and zoledronic acid (Zol) in different drug regimens in breast tumor growth inhibition (BTGI) in ATP-cell viability assay (ATP-CVA
J Clin Oncol (Meeting Abstracts) 2004 22: 791. [Abstract]  

P. H. Slee, R. S. De Jong, A. Honkoop, C. Rodenburg, S. Eelkman Rooda, J. Coenen, P. C. De Jong, and J. Douma

Combination chemotherapy with docetaxel and gemcitabine in anthracycline pretreated patients with metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2004 22: 792. [Abstract]  

F. Montemurro, M. Gatti, R. Faggiuolo, A. Durando, G. Choa, R. Piccinno, S. Redana, P. Sismondi, P. Gabriele, and M. Aglietta

Concomitant radiation therapy does not affect adjuvant CMF delivery in patients with operable breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 793. [Abstract]  

A. M. Kallab, R. Dalton, R. Hessler, K. Yeh, T. Wang, P. Schoenlein, A. May, S. McKinnon, and A. Jillella

Immunohistochemical tumor markers do not predict response to neoadjuvant doxorubicin and docetaxel in breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 794. [Abstract]  

A. Galid, A. Witt, and E. Kubista

The influence of preoperative core biopsy on specimen volume in breast conserving therapy for breast cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 795. [Abstract]  

D. E. Heron, K. Gerszten, A. M. Brufsky, and M. Kurman

The effect of chemotherapy (CT) and external beam radiotherapy (RT) on bone marrow (BM) toxicity of radionuclides in the treatment of bone metastases secondary to breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 796. [Abstract]  

L. N. Minea, D. L. Stanculeanu, A. Cringeanu, and R. M. Anghel

Capecitabine monotherapy for elderly patients with metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 797. [Abstract]  

B. C. Pestalozzi, R. Caduff, C. Rageth, D. Fink, and Z. Varga

Predictive factors before and after neoadjuvant chemotherapy for breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 798. [Abstract]  

C. Markopoulos, A. Polychronis, C. Farfarelos, V. Zobolas, J. Papadiamantis, D. Bafaloukos, J. Misitzis, A. Michailidou, and H. Gogas

The effect of exemestane on the lipidemic profile of breast cancer patients: Preliminary results of the TEAM trial Greek sub-study
J Clin Oncol (Meeting Abstracts) 2004 22: 799. [Abstract]  

D. L. Stanculeanu, A. Cringeanu, L. N. Minea, R. M. Anghel, and N. Gutulescu

Treatment of metastatic breast cancer with alternative vinorelbine and gemcitabine
J Clin Oncol (Meeting Abstracts) 2004 22: 800. [Abstract]  

J. A. Wernberg and J. L. Hoehn

Tamoxifen related uterine sarcoma - A retrospective review
J Clin Oncol (Meeting Abstracts) 2004 22: 801. [Abstract]  

S. Molica, C. Battaglia, R. Santoro, R. Mirabelli, R. Squillace, P. Iannaccaro, F. Iuliano, and G. Muleo

Prevalence of inherited and acquired risk factors for venous thromboembolic (VTE) disease among women with breast cancer taking adjuvant tamoxifen (TAM)
J Clin Oncol (Meeting Abstracts) 2004 22: 802. [Abstract]  

S. E. Waintraub

Phase II Trial to study the efficacy and toxicity of combined docetaxel (D), carboplatin (C), +/– trastuzumab (T) administered weekly in patients with HER-2/neu +/– metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2004 22: 803. [Abstract]  

D. Rossner, K. Knobloch, R. Lichtinghagen, A. Lichtenberg, H. Kuehnle, and H. J. Lueck

NT-pro-BNP and CA 125 as potential markers of mortality during long-term immunetherapy with trastuzumab in HER-2-positive metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 804. [Abstract]  

F. Ghani, S. Schildhauer, H. Eggemann, R. Geppert, K. Wernecke, M. Weigand, K. Possinger, D. Elling, and D. Lüftner

Confirmation of C9741 intergroup results in a prospectively randomized trial comparing dose-intense chemotherapy with G-CSF support to 3-weekly chemotherapy for adjuvant therapy of nodal-positive (1–3 LN) breast cancer: Longitudinal CA 27.29 results indicate higher decay of minimal residual disease in the dose-dense arm
J Clin Oncol (Meeting Abstracts) 2004 22: 805. [Abstract]  

J. A. Stewart, L. Fehrenbacher, R. A. Blanchard, G. I. Rodriguez, C. L. Vogel, and P. Anavekar

Phase II trial of trastuzumab and paclitaxel or docetaxel administered every 3 weeks to patients receiving a first treatment for HER2+ metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 806. [Abstract]  

G. Rosti, U. De Giorgi, G. L. Frassineti, G. Ciucci, L. Spinolo, E. Flamini, N. Giovannini, M. Monti, F. Zumaglini, and M. Marangolo

High-dose dense chemotherapy with epirubicin and paclitaxel with peripheral blood progenitor cell support in women with high-risk stage II-IIIA breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 807. [Abstract]  

R. Hui

Axillary soft tissue metastases: A significant prognostic factor in breast carcinoma patients
J Clin Oncol (Meeting Abstracts) 2004 22: 808. [Abstract]  

J. Horiguchi

Low ER level is one factor in the resistance of ER-positive and HER-2-positive tumors to hormone therapy
J Clin Oncol (Meeting Abstracts) 2004 22: 809. [Abstract]  

R. Rouzier, K. Slimane, J.-R. Garbay, R. Arriagada, H. Marsiglia, M.-C. Mathieu, F. Andre, S. Delaloge, and M. Spielmann

Prognostic role of serum Ca 15–3 and circumstances of diagnostic in advanced breast cancer: Data from a prospective randomized trial
J Clin Oncol (Meeting Abstracts) 2004 22: 810. [Abstract]  

J. Wadhwa, G. Kichenadasse, G. S. Chowdhary, T. Seth, V. Raina, S. V. S. Deo, N. K. Shukla, and G. K. Rath

Clinical characteristics and survival outcome in women with metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 811. [Abstract]  

S. Nakamura, S. Ohno, M. Toi, Y. Takatsuka, K. Kuroi, H. Iwata, K. Hisamatsu, K. Yamazaki, N. Masuda, and F. Akiyama

Cyclophosphamide, epirubicin and fluorouracil followed by docetaxel (CEF-DOC) as preoperative chemotherapy in primary operable breast cancer: Evaluation of chemotherapeutic response by breast MRI
J Clin Oncol (Meeting Abstracts) 2004 22: 812. [Abstract]  

A. Fabi, P. Papaldo, M. Ciccarese, N. Salesi, V. Lorusso, G. Ferretti, P. Carlini, I. Sacchi, F. Cecere, and F. Cognetti

Pegylated liposomal doxorubicin (PLD) and gemcitabine (G) in metastatic breast cancer (MBC) patients: A phase II study
J Clin Oncol (Meeting Abstracts) 2004 22: 813. [Abstract]  

A. K. Vaid, S. Gupta, D. Doval, V. Talwar, S. Shrestha, K. Pavithran, J. B. Sharma, and D. Lokanathan

Capecitabine: Single institution experience from North India in metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 815. [Abstract]  

A. Niwinska, M. Tacikowska, Z. Miskiewicz, T. Pienkowski, and J. Meder

Late cardiac and pulmonary complications in breast cancer patients after adjuvant chemo-radiotherapy: 5-years follow-up
J Clin Oncol (Meeting Abstracts) 2004 22: 816. [Abstract]  

M. Ghosn, G. Chahine, J. Kattan, F. Farhat, F. Nasr, W. Moukaddem, E. Tueni, J. Dagher, F. Younes, and J. Gasmi

Phase II study of sequential administration of vinorelbine -capecitabine combination followed by weekly docetaxel as first line chemotherapy for advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 817. [Abstract]  

J.-P. Guastalla, A.-C. Hardy-Bessard, J.-F. Geay, H. Cure, I. Ray-Coquard, D. Paraiso, and E. Pujade-Lauraine

Phase I study of pegylated liposomal doxorubicin (CA) and docetaxel (T) bimonthly in the first-line treatment of metastatic breast cancer (MBC): The CAT regimen
J Clin Oncol (Meeting Abstracts) 2004 22: 818. [Abstract]  

O. Garrone, E. Principe, M. Occelli, B. Favilla, S. Giubergia, P. D. Rattazzi, and M. Merlano

Endometrial effects of tamoxifen (T) and exemestane (E) in early breast cancer patients (EBCP). A randomized phase III trial
J Clin Oncol (Meeting Abstracts) 2004 22: 819. [Abstract]  

R. V. Iaffaioli, R. Formato, A. Tortoriello, A. Pisano, S. Del Prete, S. Cigolari, V. Pisconti, L. Manzione, and F. Giotta

Preliminary data of GOIM 2107 study: Multicenter phase II study of sequential hormonotherapy with anastrozole/exemestane in metastatic breast disease
J Clin Oncol (Meeting Abstracts) 2004 22: 820. [Abstract]  

C. J. Poole, H. C. Howard, L. Hiller, J. A. Dunn, A. M. Wardley, A. Bowman, R. E. Coleman, I. N. Fernando, D. M. Ritchie, and H. M. Earl

A prospective evaluation of pulmonary, cardiac, and hepatic function (fn) in ‘tAnGo’: A randomized phase III trial of gemcitabine (G) in paclitaxel (T)-containing, epirubicin/cyclophosphamide (EC)-based, adjuvant chemotherapy (CT) for early stage breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 821. [Abstract]  

H. S. Coskun, O. Er, M. Ozkan, B. Eser, and M. Altinbas

Adjuvant sequential docetaxel and cyclophosphamide-doxorubicin combination in operable breast cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 822. [Abstract]  

C. Wasemann, A. Ertan, C. Strunck, W. Schmidt, K. Diedrich, and M. Friedrich

Docetaxel versus epirubicin/cyclophosphamide (EC) as first-line therapy in metastatic breast cancer (MBC): Results from the randomized phase II TIPP study
J Clin Oncol (Meeting Abstracts) 2004 22: 823. [Abstract]  

S. Costa, G. Von Minckwitz, C. Jackisch, G. Raab, J.-U. Blohmer, A. Loehr, B. Gerber, H. Eidtmann, J. Hilfrich, and M. Kaufmann

TAC as neoadjuvant chemotherapy in patients with primary breast cancer - interim progress report on 907 cases of the randomized prospective Gepartrio-trial
J Clin Oncol (Meeting Abstracts) 2004 22: 825. [Abstract]  

C. J. Wolf, G. Raab, W. Eiermann, and I. Grammatikakis

An open label, randomized phase II trial of primary systemic therapy with exemestane (EXE 25 mg/d) plus epirubicin (EPI, 20 vs 30 mg/m² q1w x 8–12) in breast cancer: An interim analysis of the German Neoadjuvant Aromasin Initiative (GENARI-3)
J Clin Oncol (Meeting Abstracts) 2004 22: 826. [Abstract]  

S. Aggarwal

Capecitabine: Efficacy in advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 827. [Abstract]  

R. J. Goulet, S. Badve, L. Brannon-Peppas, D. Rouch, C. Huntley, and A. M. Storniolo

Pilot trial assessing the feasibility of intra-ductal delivery of epirubicin (epi)-containing nanoparticles (NP) via InDuct^@ Breast Microcatheter (IDBM)
J Clin Oncol (Meeting Abstracts) 2004 22: 828. [Abstract]  

A. Onyenadum, P. Kosmidis, G. Aravantinos, D. Bafaloukos, H. Gogas, C. Bacoyiannis, E. Razis, C. Markopoulos, T. Makatsoris, and H. P. Kalofonos

Mitoxantrone plus gemcitabine in pretreated patients with advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 829. [Abstract]  

G. G. Cartenì

Final efficacy and safety results of an Italian, multicenter clinical trial in 312 breast cancer patients with newly diagnosed bone metastases treated with zoledronic acid
J Clin Oncol (Meeting Abstracts) 2004 22: 830. [Abstract]  

M. De Wit, N. Harbeck, C. Thomssen, K. Becker, A. Psonka, R. Hoffmann, C. Villena, M. Schutte, and D. K. Hossfeld

Interim results of a prospective, open-label, multicentre phase II trial of the efficacy and safety of vinorelbine (N) and trastuzumab (H) in patients with HER2-positive metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2004 22: 831. [Abstract]  

M. T. Laloni, F. Moura Silva, C. Tosello, A. H. R. Garcia, A. P. A. P. Bertozzi, and J. C. G. S. Góes

A randomized neoadjuvant chemotherapy (NC) study in advanced breast cancer (BC): AC vs FEC 60
J Clin Oncol (Meeting Abstracts) 2004 22: 832. [Abstract]  

A. Shamseddine, M. Seoud, J. Abbas, M. Charafeddine, Z. Salem, F. Geara, K. Bikhazi, M. Khalifeh, M. Sidani, and N. El- Saghir

Clinical characteristics and long-term survival of early breast cancer cases in the American University of Beirut Medical Center, Beirut, Lebanon
J Clin Oncol (Meeting Abstracts) 2004 22: 833. [Abstract]  

M. Venturini, T. Catzeddu, L. Del Mastro, C. Bighin, E. Maggi, M. Clavarezza, G. Lunardi, S. Pastorino, A. Lambiase, and R. Rosso

Erlotinib given sequentially to capecitabine and vinorelbine as first-second line chemotherapy in metastatic breast cancer patients. A dose finding study
J Clin Oncol (Meeting Abstracts) 2004 22: 834. [Abstract]  

F. Moura Silva, M. T. Laloni, C. Tosello, A. P. A. P. Bertozzi, M. P. Carvalho, and J. C. G. S. Góes

FEC 60 adjuvant chemotherapy (ACT) in breast cancer (BC) patients (Pts): 5-year and 10-year follow-up results of a Brazilian single center institution
J Clin Oncol (Meeting Abstracts) 2004 22: 835. [Abstract]  

M. Coplin and M. Naughton

Clinical and pathologic predictors of complete pathologic response to neoadjuvant docetaxel/anthracycline chemotherapy in breast cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 836. [Abstract]  

K. Slimane, S. Delaloge, F. André, A. Dunant, A. Perez, J. Grenier, M. Spielmann, and C. Hill

Risk factors for brain metastases in patients with a metastatic relapse of breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 837. [Abstract]  

R. Giuliani, A. M. Minisini, M. Paesmans, J. Y. Leroy, M. Reginster, J. Demol, J.-P. Kains, A. Di Leo, M. J. Piccart, and L. Biganzoli

Is age a risk factor of congestive heart failure (CHF) in patients receiving trastuzumab (H)? Results from two Belgian compassionate use programs in metastatic breast cancer (MBC) patients (pts)
J Clin Oncol (Meeting Abstracts) 2004 22: 838. [Abstract]  

F. Longo, E. Magnolfi, A. Borgomastro, D. Gemma, M. Salerno, A. Alida Ciorra, D. Traficante, and M. Di Seri

Capecitabine (X) in elderly patients (pts) with hormone-refractory metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2004 22: 839. [Abstract]  

T. Hamaoka, C. M. Costelloe, J. E. Madewell, G. N. Hortobagyi, and N. T. Ueno

Evidence-based tumor response assessment with imaging in bone metastases from breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 840. [Abstract]  

D. W. Chicken, K. S. Johnson, M. R. Falzon, A. C. Lee, G. Briggs, D. Pickard, I. J. Bigio, S. G. Bown, and M. R. S. Keshtgar

Optical biopsy utilising elastic scattering spectroscopy for intra-operative diagnosis of sentinel lymph node metastases
J Clin Oncol (Meeting Abstracts) 2004 22: 841. [Abstract]  

A. Ardavanis, A. Alexopoulos, G. Lainakis, and G. Rigatos

Three-weekly (q3w) trastuzumab (H) plus chemotherapy in HER2-positive recurrent breast cancer (RBC)
J Clin Oncol (Meeting Abstracts) 2004 22: 842. [Abstract]  

E. E. Harris, J. Starzyk, and L. J. Solin

Results of biopsies performed after breast conservation therapy for stage I-II breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 843. [Abstract]  

G. R. Gibson and L. Lai

Metaplastic breast cancer: Clinical traits and outcomes
J Clin Oncol (Meeting Abstracts) 2004 22: 844. [Abstract]  

P. J. Perik, E. G. E. De Vries, D. J. Van Veldhuisen, W. T. A. Van der Graaf, D. T. H. Sleijfer, and J. A. Gietema

Circulating apoptosis-related proteins in long-term disease free breast cancer survivors
J Clin Oncol (Meeting Abstracts) 2004 22: 845. [Abstract]  

I. Makhoul, P. Eslinger, D. Popescu, H. Harvey, K. Parkinson, and A. Lipton

Effect of aromatase inhibitor therapy on cognitive function
J Clin Oncol (Meeting Abstracts) 2004 22: 846. [Abstract]  

P. E. Goss, J. N. Ingle, S. Martino, N. J. Robert, H. B. Muss, M. J. Piccart, M. M. Castiglione, D. Tu, L. E. Shepherd, and J. L. Pater

Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 847. [Abstract]  

T. Palangie, P. Viens, H. Roché, P. Beuzeboc, V. Dieras, T. Dorval, J.-Y. Pierga, V. Mosseri, B. Asselain, and P. Pouillart

Dose-intensified chemotherapy and additional Docetaxel may improve inflammatory breast cancer patients outcome over two decades: Results from Institut Curie protocols 1977–1987 and two consecutive French multicenter trials Pegase 02 (1995–96) and Pegase 05 (1997–99)
J Clin Oncol (Meeting Abstracts) 2004 22: 848. [Abstract]  

S. Rizel, M. Ben-David, H. J. Brenner, and S. M. Stemmer

Doxorubicin 75mg/M² followed by cyclophosphamide, methotrexate, and fluorouracil (A=> CMF) in the adjuvant treatment of node positive breast cancer: Outcome and toxicity in 136 patients
J Clin Oncol (Meeting Abstracts) 2004 22: 849. [Abstract]  

R. Lambert-Falls, M. Ackerman, G. T. Jones, and R. Smith

A phase II study to evaluate the feasibility of bi-weekly docetaxel followed by bi-weekly doxorubicin and cyclophosphamide as adjuvant therapy for operable breast cancer (T-AC)
J Clin Oncol (Meeting Abstracts) 2004 22: 850. [Abstract]  

R. A. Nagourney, J. Link, B. Sommers, W. Lyons, J. Blitzer, S. Hager, and M. Flam

Carboplatin & gemcitabine repeating doublet in recurrent breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 851. [Abstract]  

N. S. El-Saghir, M. Seoud, M. Charafeddine, J. Abbas, Z. Salem, F. Geara, K. Bikhazi, M. Khalifeh, M. Sidani, and A. Shamseddine

Clinical characteristics and long-term survival of advanced breast cancer at the American University of Beirut Medical Center, Beirut, Lebanon
J Clin Oncol (Meeting Abstracts) 2004 22: 852. [Abstract]  

V. Maheshwari, J. Falk, D. Landsittel, T. Seenivasan, R. Johnson, H. Edington, E. Avissar, and V. Vogel

Survival outcomes of breast cancer in pregnancy
J Clin Oncol (Meeting Abstracts) 2004 22: 854. [Abstract]  

T. Puertolas, R. Grandez, A. Ruiz de Lobera, J. Lao, A. Herrero, J. Martinez Trufero, R. Pazo, V. Alonso Orduña, A. Artal Cortes, and A. Anton Torres

Phase II trial of docetaxel plus doxorubicin and cyclophosphamide in locally advanced breast cancer (LABC)
J Clin Oncol (Meeting Abstracts) 2004 22: 855. [Abstract]  

J. W. Zinser, C. Cano, F. Lara, J. Velasco, H. López-Basave, A. Alvaradp, N. Castañeda, and F. Morales

Breast cancer patients (BCP) with liver metastases (LM). Clinical experience at one institution
J Clin Oncol (Meeting Abstracts) 2004 22: 856. [Abstract]  

M. Kaminski, L. Rosen, D. Gordon, M. Zheng, and Y. J. Hei

Zoledronic acid versus pamidronate in patients with breast cancer and multiple myeloma who are at high risk for skeletal complications
J Clin Oncol (Meeting Abstracts) 2004 22: 857. [Abstract]  

S. P. Rajurkar, T. Singh, M. Arora, S. Saha, H. Gayar, N. Talwar, and J. Nettleton

Concurrent weekly taxane (T) and radiation therapy (RT) in the adjuvant treatment of breast cancer (BrCa)
J Clin Oncol (Meeting Abstracts) 2004 22: 858. [Abstract]  

F. Medina, I. Enriquez, A. Alvarado, C. Gamboa, F. Morales, N. Castañeda, and J. W. Zinser

Chemoradiosensitizing (CTRT) versus radiation therapy alone (XRT) after adjuvant chemotherapy in breast cancer women with 4 to 9 positive lymph nodes
J Clin Oncol (Meeting Abstracts) 2004 22: 859. [Abstract]  

S. C. Lymberis, S. M. MacDonald, B. Rosenstein, E. P. Lief, J. K. Dewyngaert, and S. C. Formenti

Preliminary clinical results of accelerated IMRT with concomitant boost after breast conserving therapy (BCT)
J Clin Oncol (Meeting Abstracts) 2004 22: 860. [Abstract]  

H. Akbulut, S. Temizkan, A. Arican, N. Zengin, B. Yalcin, and F. Icli

The prognostic role of serum telomerase activity in advanced breast cancer receiving anthracyclines
J Clin Oncol (Meeting Abstracts) 2004 22: 861. [Abstract]  

A. Di Liberto, W. Schmidt, and M. Friedrich

Prospective Trial for clinical evaluation of TRACP 5b as serum marker of bone resorption and for monitoring an oral clodronat-medication in osteolytic metastases of breast carcinoma
J Clin Oncol (Meeting Abstracts) 2004 22: 862. [Abstract]  

M. A. Perez, J. Ruiz, H. Astudillo, M. Silva, J. Silva, and M. A. Pluma

Predicitve factors for neoadjuvant chemotherapy in locally advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 863. [Abstract]  

D. M. Atieh, M. Modiano, L. Shriberg, L. Brafman, M. Szno, and L. Vahdat

A phase II trial of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP) in patients with metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 864. [Abstract]  

A. Naeim and E. Keeler

Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective?
J Clin Oncol (Meeting Abstracts) 2004 22: 865. [Abstract]  

G. L. Giron, J. Fey, P. I. Borgen, and L. L. Montgomery

Breast pain and subsequent breast cancer diagnosis
J Clin Oncol (Meeting Abstracts) 2004 22: 866. [Abstract]  

W. Chen, R. A. Miller, K. A. Hebbe, and G. K. Guron

Sarcoidosis and breast carcinoma: Three case reports and a review
J Clin Oncol (Meeting Abstracts) 2004 22: 867. [Abstract]  

G. Lopes, L. Negret, G. Fernandez, M. Jorda, J. Hurley, J. Powell, and O. Silva

Breast cancer and neuroendocrine tumor can pose a diagnostic challenge
J Clin Oncol (Meeting Abstracts) 2004 22: 868. [Abstract]  

H. M. Linden, A. Hart, J. C. Jackson, L. Reisch, C. Nakano, M. Harrington, and J. G. Elmore

Culturally appropriate surrogates for vulnerable patients perspectives of participation in randomized clinical trials
J Clin Oncol (Meeting Abstracts) 2004 22: 869. [Abstract]  

S. C. Formenti, J. Goldberg, B. Rosenstein, and K. Dewyngaert

Prone accelerated partial breast irradiation (five fractions) after breast conservation therapy with heart and lung sparing
J Clin Oncol (Meeting Abstracts) 2004 22: 870. [Abstract]  

J. Carpenter, S. Davidson, and L. Talley

Primary systemic therapy for locally advanced breast cancer using sequential dDoxorubicin followed by dose dense paclitaxel and cyclophosphamide
J Clin Oncol (Meeting Abstracts) 2004 22: 871. [Abstract]  

M. L. Gemignani, G. L. Giron, J. Fey, L. L. Montgomery, V. Sachini, L. Sclafani, A. Heerdt, P. I. Borgen, K. Van Zee, and H. Cody

Surgical management of the positive sentinel lymph node in elderly breast cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 872. [Abstract]  

S. R. Martinez, L. J. Foshag, and D. L. Morton

Estrogen receptor, progesterone receptor and Her-2/neu status do not affect survival after hepatic resection of breast cancer metastases
J Clin Oncol (Meeting Abstracts) 2004 22: 873. [Abstract]  

R. Gerson, A. Serrano, F. Flores, and A. Vilallobos

FAC followed by paclitaxel in breast cancer (BC) patients (pts)with high risk for recurrence
J Clin Oncol (Meeting Abstracts) 2004 22: 874. [Abstract]  

M. T. T. Ramirez, M. I. Vazquez Lopez, B. E. Vela, D. Flores, M. D. Uribe, M. I. Vazquez, B. E. Santinelli, and I. Zeichner

Correlation of Ca15–3 elevation with number and site of metastasis in breast cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 875. [Abstract]  

H. A. Zaren, E. Sciupokiene, A. Mackeviciute, X. Gao, K. Ferrer, Y. Wang, S. Zhang, M. Sekosan, and K. A. Dookeran

African-American women with breast cancer treated with preoperative chemotherapy have reduced pathologic complete response rates
J Clin Oncol (Meeting Abstracts) 2004 22: 876. [Abstract]  

J. A. Silva, L. M. Perez Michel, and D. Gallardo Rincon

Gemcitabine plus carboplatin in recurrent and advanced breast cancer: A phase II trial
J Clin Oncol (Meeting Abstracts) 2004 22: 877. [Abstract]  

A. Chan, J. C. Yau, S. Huan, D. Vergidis, K. Cranston, C. Falkson, and H. Dhaliwal

Local accrual pattern of a breast cancer adjuvant chemotherapy clinical trial
J Clin Oncol (Meeting Abstracts) 2004 22: 878. [Abstract]  

K. Crew, A. Tiersten, L. Vahdat, T. Frank, H. Hibshoosh, S. Smith, L. Brafman, E. Schwartzreich, and D. Hershman

Phase II evaluation of bi-weekly docetaxel combined with doxorubicin in patients with locally advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 879. [Abstract]  

K. A. Dookeran, X. Gao, K. Ferrer, E. Sciupokiene, R. De La Torre, L. Diaz de Leon, B. Lukaszczyk, S. Zhang, M. Sekosan, and H. A. Zaren

Tumor biology in African-American women with breast cancer treated with preoperative chemotherapy: Lack of pathologic complete response is related to p53 overexpression
J Clin Oncol (Meeting Abstracts) 2004 22: 880. [Abstract]  

S. Cremers, L. Van Zuylen, H. Gelderblom, C. Seynaeve, H.-J. Guchelaar, H. Pols, P. Vermeij, C. Van der Rijt, and S. Papapoulos

Whole body retention in relation to rate of bone resorption after intravenous bisphosphonate (pamidronate) in patients with breast cancer and bone metastases
J Clin Oncol (Meeting Abstracts) 2004 22: 881. [Abstract]  

Cancer Prevention:

S. Martino, J. A. Cauley, E. Barrett-Connor, T. J. Powles, J. L. Mershon, D. Disch, R. J. Secrest, and S. R. Cummings

Incidence of invasive breast cancer following 8 years of raloxifene therapy in postmenopausal women with osteoporosis: Results from the Continuing Outcomes Relevant to Evista (CORE) trial
J Clin Oncol (Meeting Abstracts) 2004 22: 1000. [Abstract]  

A. Decensi, B. Bonanni, A. Guerrieri-Gonzaga, C. Robertson, M. Cazzaniga, F. Mariette, M. Gulisano, A. Latronico, D. Franchi, and K. Johnson

A randomized 2x2 biomarker trial of low-dose tamoxifen and fenretinide in premenopausal women at-high risk for breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 1001. [Abstract]  

J. Garber, L. Digianni, M. Rue, K. Schneider, K. Shannon, N. Borstelmann, K. Kalkbrenner, and R. Scheib

A randomized trial of two different genetic counseling interventions for BRCA1/2 genetic testing
J Clin Oncol (Meeting Abstracts) 2004 22: 1002. [Abstract]  

L. Esserman, M. Campbell, M. Shoemaker, M. Lobo, C. Marx, and C. Benz

Breast cancer inhibition by statins
J Clin Oncol (Meeting Abstracts) 2004 22: 1003. [Abstract]  

J. Sudbø, S. M. Lippman, J. Lee, S. Sagen, A. Dannenberg, and A. Reith

Long-term use of NSAID reduces the risk of oral cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 1004. [Abstract]  

H.-Y. Lee, J.-Y. Han, Y. S. Chang, H. Tran, J. M. Kurie, R. Lotan, D. D. Liu, J. J. Lee, J. S. Lee, and W. K. Hong

Implication of insulin-like growth factor (IGF)/IGF binding protein-3 and alpha-tocopherol in the chemopreventive activity of 9-cis retinoic acid in lung cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 1005. [Abstract]  

J. G. Izzo, W. N. Hittelman, D. D. Liu, J. J. Lee, X. Wu, W. K. Hong, and V. A. Papadimitrakopoulou

Cyclin D1 polymorphism, biochemoprevention and risk of upper aero-digestive tract cancer development
J Clin Oncol (Meeting Abstracts) 2004 22: 1006. [Abstract]  

A. Liljegren, G. Barker, J. Mathers, A. Lindblom, B. Nilsson, S. Rotstein, J. Burn, and T. Bishop

Prevalence of adenomas and hyperplastic polyps in carriers of HNPCC (LYNCH Syndrome)
J Clin Oncol (Meeting Abstracts) 2004 22: 1007. [Abstract]  

R. T. Chlebowski, Z. Chen, T. Rohan, A. Aragaki, D. Lane, N. Dolan, E. Paskett, R. Patterson, A. Hubbell, and R. Prentice

Ethnicity and breast cancer in the Women's Health Initiative: A unifying concept for unfavorable outcome in African American women
J Clin Oncol (Meeting Abstracts) 2004 22: 1008. [Abstract]  

P. James, M. Harris, R. Doherty, M. Young, E. Niedermayr, A. Hunter, and C. Scott

Optimal selection of individuals for BRCA1 and BRCA2 gene testing
J Clin Oncol (Meeting Abstracts) 2004 22: 1009. [Abstract]  

M. Dorval, L. Digianni, J. E. Garber, and A. F. Patenaude

Communication of BRCA1/2 test results to first-degree relatives (FDRs): Factors predicting who women tell
J Clin Oncol (Meeting Abstracts) 2004 22: 1010. [Abstract]  

S. M. Miller, P. Roussi, M. Rodoletz, M. Daly, K. Sherman, M. Diefenbach, and A. Godwin

Facilitating preventive behaviors among women undergoing BRCA1/2 Testing
J Clin Oncol (Meeting Abstracts) 2004 22: 1011. [Abstract]  

A. R. Bradbury, S. A. Cummings, and O. I. Olopade

Prophylactic oophorectomy in BRCA1/2 carriers
J Clin Oncol (Meeting Abstracts) 2004 22: 1012. [Abstract]  

L. Digianni, M. Rue, K. Emmons, and J. Garber

Comparison of complementary medicine use at genetic testing program enrollment and one-year following results disclosure
J Clin Oncol (Meeting Abstracts) 2004 22: 1013. [Abstract]  

B. E. Ratliff, G. Bean, P. K. Marcom, J. V. Scott, L. Yee, B. F. Kimler, C. J. Fabian, C. M. Zalles, H. Shaw, and V. L. Seewaldt

RARbeta P2 promoter methylation: Potential biomarker for use with breast Random Periareolar Fine Needle Aspiration in breast cancer risk assessment
J Clin Oncol (Meeting Abstracts) 2004 22: 1014. [Abstract]  

C. J. Fabian, B. F. Kimler, J. Anderson, O. W. Tawfik, and M. S. Mayo

Breast cancer chemoprevention Phase IB evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator
J Clin Oncol (Meeting Abstracts) 2004 22: 1015. [Abstract]  

C. Lasset, V. Bonadona, H. Mignotte, C. Bailly, I. Treilleux, V. Becette, J. Anjou, A. Bremond, and F. Chauvin

Tamoxifen therapy for breast cancer and its relation to the prognosis and histopathology in subsequent endometrial cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 1016. [Abstract]  

L. Adams-Campbell, K. Makambi, J. Palmer, and L. Rosenberg

The Gail Model as a diagnostic indicator in African-American women: Truth or consequence
J Clin Oncol (Meeting Abstracts) 2004 22: 1017. [Abstract]  

J. A. Cauley, S. Martino, E. Barrett-Connor, T. J. Powles, J. L. Mershon, D. Disch, R. J. Secrest, and S. R. Cummings

Effect of raloxifene on invasive breast cancer incidence in postmenopausal women stratified by Gail risk assessment: Results of the Continuing Outcomes Relevant to Evista (CORE) trial
J Clin Oncol (Meeting Abstracts) 2004 22: 1018. [Abstract]  

J. P. Janssens, I. Verlinden, N. Güngör, J. Raus, and L. Michiels

Different gene expression in the breast after pregnancy
J Clin Oncol (Meeting Abstracts) 2004 22: 1019. [Abstract]  

S. Sheinfeld Gorin

Effects of academic detailing on recommendations for colonoscopy screening among primary care physicians
J Clin Oncol (Meeting Abstracts) 2004 22: 1020. [Abstract]  

P. T. Silberstein, D. Jones, C. Ternent, and H. Lynch

Regression of colorectal adenomas with intravenous chemotherapy in a patient with familial adenomatous polyposis
J Clin Oncol (Meeting Abstracts) 2004 22: 1021. [Abstract]  

C. P. Theuer, T. Taylor, W. Brewster, and H. Anton-Culver

Should colorectal cancer screening guidelines account for gender and race/ethnicity?
J Clin Oncol (Meeting Abstracts) 2004 22: 1022. [Abstract]  

S. K. Peterson, B. G. Watts, M. Daniels, M. Dinh, P. M. Lynch, and K. H. Lu

Screening for gynecologic cancers among women in HNPCC families
J Clin Oncol (Meeting Abstracts) 2004 22: 1023. [Abstract]  

T. Seth, A. Kotwal, and R. Thakur

Understanding factors which influence tobacco (smoking and smokeless) in secondary school children in Delhi (India)
J Clin Oncol (Meeting Abstracts) 2004 22: 1024. [Abstract]  

D. Lin, D. C. Stahl, D. Iklé, and F. W. Grannis

Employee attitudes and smoking behavior at the City of Hope National Medical Center smoke-free campus
J Clin Oncol (Meeting Abstracts) 2004 22: 1025. [Abstract]  

H. Keup, A. Tagayun, K. Nevarez, and F. W. Grannis

Implementation of AHRQ smoking-cessation guidelines in a thoracic surgical clinic: A pilot study
J Clin Oncol (Meeting Abstracts) 2004 22: 1026. [Abstract]  

Y. I. Garces, K. P. Offord, I. T. Croghan, P. A. Decker, P. D. Brown, M. M. Clark, T. A. Rummans, R. L. Foote, and R. D. Hurt

Tobacco use among radiation oncology outpatients
J Clin Oncol (Meeting Abstracts) 2004 22: 1027. [Abstract]  

S. B. Zeliadt, R. Etzioni, D. F. Penson, and S. D. Ramsey

Cost-effectiveness and lifetime implications of using finasteride to reduce prostate cancer incidence and mortality
J Clin Oncol (Meeting Abstracts) 2004 22: 1028. [Abstract]  

J. F. Forbes and M. A. Seccombe

Prevention and treatment trials need different recruitment strategies: Experience from the IBIS 1 prevention trial in Australia and New Zealand
J Clin Oncol (Meeting Abstracts) 2004 22: 1030. [Abstract]  

C. Chauhan and W. Eppard

Systematic education and utilization of volunteer patient advocates for cancer clinical trial information dissemination at NCCTG community sites
J Clin Oncol (Meeting Abstracts) 2004 22: 1031. [Abstract]  

Y. Zafar, B. Kleykamp, M. Foraida, J. Neu, R. Buncher, R. Shipley, A. R. Jazieh, and J. Howington

Characteristics and motivations of participants in a lung cancer screening study
J Clin Oncol (Meeting Abstracts) 2004 22: 1032. [Abstract]  

J. Spaulding, R. Brekken, L. Robinson, K. Koeneman, B. Mickey, J. Cadeddu, C. Croft, A. Sagalowsky, N. Ahmad, and G. E. Tomlinson

Serum markers of angiogenesis in patients with von Hippel-Lindau Disease
J Clin Oncol (Meeting Abstracts) 2004 22: 1033. [Abstract]  

M. Bower, J. Stebbing, C. Thirlwell, T. Newsom-Davis, A. Waterston, S. Mandalia, and B. Gazzard

Anti-retroviral treatment regimens and immune parameters in the prevention of systemic HIV-related non-Hodgkin's lymphoma
J Clin Oncol (Meeting Abstracts) 2004 22: 1034. [Abstract]  

A.-R. Hartman, M. A. Mills, A. W. Kurian, J. M. Ford, D. N. Smith, and B. L. Daniel

Identification of ductal atypia with MR galactography
J Clin Oncol (Meeting Abstracts) 2004 22: 1035. [Abstract]  

S. Waheed and K. A. Wilson

Incidence of interval cancers of an annually screened population in a community cancer screening program: 17-year experience at Audrain Medical Center
J Clin Oncol (Meeting Abstracts) 2004 22: 1036. [Abstract]  

T. J. Kearney, S. Airapetian, and A. Sarvazyan

Tactile breast imaging to increase the sensitivity of breast examination
J Clin Oncol (Meeting Abstracts) 2004 22: 1037. [Abstract]  

A. S. Glicksman, L. Tisch, and P. Calabresi

Community cancer control task forces in Rhode Island
J Clin Oncol (Meeting Abstracts) 2004 22: 1038. [Abstract]  

S. Ethirajan, B. Adkins, S. Spencer, P. Gerken, N. Washburn, S. Simmons, V. Sommer, M. Rogers, and A. Strauss Tranin

Genetic risk assessment in women with breast cancer in the outpatient setting: Establishing the standard of practice for ambulatory care clinics
J Clin Oncol (Meeting Abstracts) 2004 22: 1039. [Abstract]  

Central Nervous System Tumors:

G. Cairncross, W. Seiferheld, E. Shaw, R. Jenkins, B. Scheithauer, D. Brachman, J. Buckner, K. Fink, L. Souhami, and W. Curran

An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: Initial report of RTOG 94–02
J Clin Oncol (Meeting Abstracts) 2004 22: 1500. [Abstract]  

E. Raymond, A. Brandes, A. Van Oosterom, C. Dittrich, P. Fumoleau, B. Coudert, C. Twelves, C. De Balincourt, D. Lacombe, and M. Van Den Bent

Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: An EORTC: NDDG/BTG Intergroup Study
J Clin Oncol (Meeting Abstracts) 2004 22: 1501. [Abstract]  

J. J. Raizer, L. E. Abrey, P. Wen, T. Cloughesy, I. A. Robins, H. A. Fine, F. Lieberman, V. K. Puduvalli, K. L. Fink, and M. Prados

A phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs
J Clin Oncol (Meeting Abstracts) 2004 22: 1502. [Abstract]  

E. Galanis, J. C. Buckner, M. Maurer, K. Ballman, M. Hidalgo, J. I. Kreisberg, J. Boni, C. D. D. James, R. B. Jenkins, and D. J. Walsh

NCCTG phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM)
J Clin Oncol (Meeting Abstracts) 2004 22: 1503. [Abstract]  

M. Prados, W. Yung, P. Wen, L. Junck, K. Fink, T. Cloughesy, I. Robins, S. Chang, and J. Kuhn

Phase I study of ZD1839 plus temozolomide in patients with malignant glioma. A study of the North American Brain Tumor Consortium
J Clin Oncol (Meeting Abstracts) 2004 22: 1504. [Abstract]  

J. H. Uhm, K. V. Ballman, C. Giannini, J. C. Krauss, J. C. Buckner, D. James, B. W. Scheithauer, J. R. O'Fallon, and K. A. Jaeckle

Phase II study of ZD1839 in patients with newly diagnosed grade 4 astrocytoma
J Clin Oncol (Meeting Abstracts) 2004 22: 1505. [Abstract]  

H. Aoyama, H. Shirato, K. Nakagawa, and M. Tago

Interim report of the JROSG99–1 multi-institutional randomized trial, comparing radiosurgery alone vs. radiosurgery plus whole brain irradiation for 1–4 brain metastases
J Clin Oncol (Meeting Abstracts) 2004 22: 1506. [Abstract]  

R. R. Mañon, A. Oneill, M. Mehta, J. Knisely, M. Werner-Wasik, H. Lazarus, H. Wagner, and M. Gilbert

Phase II trial of radiosurgery (RS) for 1 to 3 newly diagnosed brain metastases from renal cell, melanoma, and sarcoma: An Eastern Cooperative Oncology Group Study (E6397)
J Clin Oncol (Meeting Abstracts) 2004 22: 1507. [Abstract]  

J. C. Buckner, K. D. Aldape, K. Ballman, B. W. Scheithauer, P. C. Burger, C. Giannini, P. L. Schaefer, R. B. Jenkins, and C. D. James

Immunohistochemical detection of EGFRvIII and prognostic significance in patients with malignant glioma enrolled in NCCTG clinical trials
J Clin Oncol (Meeting Abstracts) 2004 22: 1508. [Abstract]  

C. Ford, W. Seiferheld, A. K. Choucair, J. Hansen, B. Dabbas, C. Schultz, A. Schulsinger, M. Mehta, and W. Curran

Evaluation of expression of DNA repair molecules as a prognostic factor for long-term survivors with glioblastoma multiforme (GBM) treated on RTOG protocols with irradiation and nitrosoureas
J Clin Oncol (Meeting Abstracts) 2004 22: 1509. [Abstract]  

F. S. Lieberman, T. Cloughesy, H. Fine, J. Kuhn, K. Lamborn, M. Malkin, H. I. Robbins, W. A. Yung, P. Wen, and M. Prados

NABTC phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas
J Clin Oncol (Meeting Abstracts) 2004 22: 1510. [Abstract]  

H. A. Fine, L. Kim, C. Royce, S. Mitchell, J. P. Duic, P. Albert, L. Musib, and D. Thornton

A phase II trial of LY317615 in patients with recurrent high grade gliomas
J Clin Oncol (Meeting Abstracts) 2004 22: 1511. [Abstract]  

C. Conrad, H. Friedman, D. Reardon, J. Provenzale, E. Jackson, H. Serajuddin, D. Laurent, B. Chen, and W. K. A. Yung

A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM)
J Clin Oncol (Meeting Abstracts) 2004 22: 1512. [Abstract]  

D. Reardon, H. Friedman, W. K. A. Yung, M. Brada, C. Conrad, J. Provenzale, E. Jackson, H. Serajuddin, B. Chen, and D. Laurent

A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM)
J Clin Oncol (Meeting Abstracts) 2004 22: 1513. [Abstract]  

U. Bogdahn, P. Hau, A. Brawanski, J. Schlaier, M. Mehdorn, G. Wurm, J. Pichler, M. Kunst, G. Stauder, and K.-H. Schlingensiepen

Specific therapy for high-grade glioma by convection-enhanced delivery of the TGF-ß2 specific antisense oligonucleotide AP 12009
J Clin Oncol (Meeting Abstracts) 2004 22: 1514. [Abstract]  

A. I. Freeman, J. M. Gomori, E. Linetsky, Z. Zakay-Rones, A. Panet, E. Libson, C. S. Irving, E. Galun, and T. Siegal

Phase I/II trial of intravenous OV001 oncolytic virus in resistant glioblastoma multiforme (GBM)
J Clin Oncol (Meeting Abstracts) 2004 22: 1515. [Abstract]  

A. A. Brandes, A. Tosoni, M. Reni, F. Valduga, U. Basso, S. Lonardi, L. M. Pasetto, V. Blatt, S. Monfardini, and M. Ermani

Second line BCNU plus CPT-11 chemotherapy in recurrent glioblastoma (GBM): Phase II study of GICNO (Italian Neuro-Oncology Group)
J Clin Oncol (Meeting Abstracts) 2004 22: 1516. [Abstract]  

M. W. Kieran, R. Packer, J. Boyett, M. Sugrue, and L. Kun

Phase I trial of the oral farnesyl protein transferase inhibitor lonafarnib (SCH66336): A Pediatric Brain Tumor Consortium (PBTC) study
J Clin Oncol (Meeting Abstracts) 2004 22: 1517. [Abstract]  

F. G. El Kamar, L. M. Deangelis, J. Yahalom, D. D. Correa, B. W. Grant, R. V. Larocca, J. J. Raizer, D. Schiff, and L. E. Abrey

Combined immunochemotherapy with reduced dose whole brain radiotherapy (WBRT) for newly diagnosed patients with primary CNS lymphoma (PCNSL)
J Clin Oncol (Meeting Abstracts) 2004 22: 1518. [Abstract]  

T. Batchelor, S. Grossman, K. Carson, and J. Fisher

Updated results from NABTT CNS consortium studies in primary CNS lymphoma
J Clin Oncol (Meeting Abstracts) 2004 22: 1519. [Abstract]  

E. Thiel, K. Jahnke, T. Wagner, N. E. Bechrakis, S. E. Coupland, A. Schmittel, L. Fischer, M. H. Foerster, and A. Korfel

Ifosfamide for intraocular lymphoma
J Clin Oncol (Meeting Abstracts) 2004 22: 1520. [Abstract]  

H. Schulz, H. Pels, U. Schlegel, U. Zeelen, U. Germing, and A. Engert

Intraventricular application of rituximab as a treatment option in patients with CNS lymphoma and leptomeningeal disease
J Clin Oncol (Meeting Abstracts) 2004 22: 1521. [Abstract]  

A. Korfel, P. Martus, M. Nowrousian, D. Hossfeld, W. Weber, J. Bruecher, W. Berdel, J. Birkmann, C. Peschel, and E. Thiel

Impact of response to chemotherapy and treating institution on survival in primary CNS lymphoma (PCNSL): Long-term results of the multicenter BMPD study
J Clin Oncol (Meeting Abstracts) 2004 22: 1522. [Abstract]  

G. Shah, S. Kesari, R. Xu, J. Henson, T. Batchelor, F. Hochberg, A. Oneill, B. Levy, J. Bradshaw, and P. Y. Wen

Comparison of 1D, 2D, 3D and volumetric parameters in measuring tumor response in high-grade gliomas in adults
J Clin Oncol (Meeting Abstracts) 2004 22: 1523. [Abstract]  

P. D. Brown, K. V. Ballman, T. A. Rummans, M. J. Maurer, J. A. Sloan, B. F. Boeve, R. M. Arusell, M. M. Clark, and J. C. Buckner

Prospective NCCTG quality of life (QOL) study in adult newly diagnosed high-grade gliomas (HGG)
J Clin Oncol (Meeting Abstracts) 2004 22: 1524. [Abstract]  

K. A. Jaeckle, K. Ballman, J. Uhm, J. O'Fallon, P. Schomberg, B. Scheithauer, C. Giannini, P. J. Flynn, and J. Buckner

Comparison of survival endpoints in glioblastoma patients receiving or not receiving enzyme-inducing anticonvulsants in NCCTG Trials
J Clin Oncol (Meeting Abstracts) 2004 22: 1525. [Abstract]  

D. S. Keith, D. T. Blumenthal, and L. A. Cannon-Albright

The familiality of primary brain tumors as studied in the Utah Population Database (UPDB)
J Clin Oncol (Meeting Abstracts) 2004 22: 1526. [Abstract]  

K. D. Weaver, S. Grossman, and J. Herman

Methylated tumor-specific DNA as a plasma biomarker in patients with glioma
J Clin Oncol (Meeting Abstracts) 2004 22: 1527. [Abstract]  

D. R. Gomez, B. T. Missett, W. M. Wara, D. A. Larson, P. K. Sneed, M. D. Prados, S. M. Chang, M. S. Berger, N. Gupta, and D. A. Haas-Kogan

High failure rate in spinal ependymomas with long-term follow-up
J Clin Oncol (Meeting Abstracts) 2004 22: 1528. [Abstract]  

H. I. Robins, M. Won, C. Schultz, A. Choucair, D. Brachman, W. Demas, and M. Mehta

A phase II trial of conventional radiation therapy (XRT) plus high dose tamoxifen (TAM) for the treatment of supratentorial glioblastoma multiforme (GBM): RTOG protocol BR-0021
J Clin Oncol (Meeting Abstracts) 2004 22: 1529. [Abstract]  

S. Brem, S. A. Grossman, K. A. Carson, P. New, S. Phuphanich, J. B. Alavi, T. Mikkelsen, and R. Priet

Phase II trial of copper depletion as angiosuppressive treatment in newly diagnosed Glioblastoma Multiforme: Final report
J Clin Oncol (Meeting Abstracts) 2004 22: 1530. [Abstract]  

S. E. Combs, S. Gutwein, D. Schulz-Ertner, M. Van Kampen, C. Thilmann, M. M. Wannenmacher, and J. Debus

Temozolomide combined with radiation as first-line treatment in primary glioblastoma multiforme: Phase I/II-study
J Clin Oncol (Meeting Abstracts) 2004 22: 1531. [Abstract]  

A. Narayana, J. Yamada, M. Hunt, P. Shah, P. Gutin, and S. A. Leibel

Intensity modulated radiotherapy in high grade gliomas: Clinical and dosimetric results
J Clin Oncol (Meeting Abstracts) 2004 22: 1532. [Abstract]  

P. Z. New, S. Grossman, T. Mikkelsen, T. Batchelor, S. Phuphanich, K. Carson, J. Fisher, M. Craig, and P. Cagnoni

Evaluation of safety and tolerance of escalating doses of RSR13 administered with a fixed dose of BCNU every six weeks in patients with recurrent malignant glioma: Results of the phase I NABTT 9806 clinical trial
J Clin Oncol (Meeting Abstracts) 2004 22: 1533. [Abstract]  

J. Suh, B. Stea, A. Nabid, J. Kresl, A. Fortin, J. P. Mercier, N. Senzer, E. Chang, J. B. Holz, and E. Shaw

Standard whole brain radiation therapy (WBRT) with supplemental oxygen (O₂), with or without RSR13 (efaproxiral)in patients with brain metastases: Results of the randomized REACH (RT-009) study
J Clin Oncol (Meeting Abstracts) 2004 22: 1534. [Abstract]  

W. O. Arafat, D. Rein, D. Buchsbaum, D. Curiel, and Z. Zhu

Survivin as a novel radiation/CIS platinum/tumor specific promoter for conditional oncolytic viral therapy
J Clin Oncol (Meeting Abstracts) 2004 22: 1535. [Abstract]  

W. Wick, J. P. Steinbach, J. Schuth, J. Dichgans, M. Bamberg, and M. Weller

One week on/one week off regimen of temozolomide for recurrent glioblastoma: A phase II study
J Clin Oncol (Meeting Abstracts) 2004 22: 1536. [Abstract]  

A. J. Newman, J. Fiveash, S. Rosenfeld, M. Johnson, R. Diasio, W. Wang, A. Cockrell-Donohue, and L. B. Nabors

A phase I study of capecitabine and concurrent radiotherapy (RT) for patients with newly diagnosed glioblastoma multiforme (GBM)
J Clin Oncol (Meeting Abstracts) 2004 22: 1537. [Abstract]  

A. Pace, A. Pompili, M. Maschio, E. Galie', S. Telera, B. Jandolo, E. Occhipinti, and C. M. Carapella

PCV and/or TMZ chemotherapy in 255 gliomas. Analysis of the clinical experience from a neuro-oncology data-base
J Clin Oncol (Meeting Abstracts) 2004 22: 1538. [Abstract]  

M. T. Carpenter, J. C. Flickinger, M. A. Quader, and C. E. Miles

Improvements in technique for whole-brain irradiation
J Clin Oncol (Meeting Abstracts) 2004 22: 1539. [Abstract]  

J. Ikeda, H. Kobayashi, N. Ishii, Y. Sawamura, H. Aoyama, and H. Shirato

Combination chemotherapy with gemcitabine and docetaxel for recurrent germ cell tumors in the central nervous system
J Clin Oncol (Meeting Abstracts) 2004 22: 1540. [Abstract]  

B. Neyns, E. Everaert, E. Joosens, T. Strauven, F. Branle, and J. Menten

Temozolomide for the treatment of recurrent glioma: Results of a compassionate use program in Belgium
J Clin Oncol (Meeting Abstracts) 2004 22: 1541. [Abstract]  

A. Katz, C. H. Barrios, R. Abramoff, S. D. Simon, J. Tabacof, and R. C. Gansl

Imatinib (STI 571) is active in patients (PTS) with high-grade gliomas progressing on standard therapy
J Clin Oncol (Meeting Abstracts) 2004 22: 1542. [Abstract]  

S. Soyuer, E. L. Chang, U. Selek, M. H. Maor, and F. Demonte

Operable benign meningioma patients appear to have expected survival that is equivalent to a normal United States population
J Clin Oncol (Meeting Abstracts) 2004 22: 1543. [Abstract]  

J. M. Simon, G. Noel, K. Hoang-Xuan, A. F. Carpentier, K. Mokhtari, S. Racadot, F. Baillet, and J. J. Mazeron

Radiotherapy and concomitant weekly carboplatin and daily etoposide for patients with inoperable biopsy proven glioblastoma multiforme
J Clin Oncol (Meeting Abstracts) 2004 22: 1544. [Abstract]  

B. S. Abdulkarim, A. Hasbini, J. Cougnard, L. Djafari, C. Lacroix, F. Parker, C. Haie, C. Cioloca, E. Deutsch, and E. Raymond

Baseline pathological and radiological assessment of tumor angiogenesis predicts survival in patients with oligodendrogliomas
J Clin Oncol (Meeting Abstracts) 2004 22: 1545. [Abstract]  

D. Peereboom, K. Carson, D. Lawson, G. Lesser, J. Supko, and S. Grossman

A phase I/II trial of BMS-247550 for patients with recurrent high-grade gliomas
J Clin Oncol (Meeting Abstracts) 2004 22: 1546. [Abstract]  

P. Hau, T. Jauch, B. Hirschmann, E. Drechsel, O. Grauer, H. Koch, C. Wismeth, A. Steinbrecher, and U. Bogdahn

Adjuvant chemotherapy with temozolomide and pegylated liposomal doxorubicin in the first-line therapy of patients with glioblastoma -a phase-II trial
J Clin Oncol (Meeting Abstracts) 2004 22: 1547. [Abstract]  

D. A. Loblaw, L. Holden, A. Xenocostas, S. Chander, P. Cooper, P. C. Chan, E. X. Chen, and C. S. Wong

Erythropoietin cerebrospinal concentrations and functional outcomes after a single intravenous infusion of epoetin alfa in patients with malignant extradural spinal cord compression
J Clin Oncol (Meeting Abstracts) 2004 22: 1548. [Abstract]  

S. Pannullo, S. Hariharam, J. Serventi, R. Hayes, C. Balmaceda, and J. Burton

Phase I/II trial of a twice-daily regimen of temozolomide and celecoxib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma
J Clin Oncol (Meeting Abstracts) 2004 22: 1549. [Abstract]  

G. Dresemann

Imatinib (STI571) plus hydroxyurea: Safety and efficacy in pre-treated, progressive glioblastoma multiforme (GBM) patients (pts)
J Clin Oncol (Meeting Abstracts) 2004 22: 1550. [Abstract]  

S. M. Kurian and E. B. Crowell

Concordance of FDG-PET scan and MRI- spectroscopy in primary and metastatic intracranial tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 1551. [Abstract]  

C. Nieder, N. Wiedenmann, S. Stark, and A. L. Grosu

Phase II trial of functional imaging-optimized stereotactic fractionated radiotherapy plus temozolomide for recurrent high-grade glioma
J Clin Oncol (Meeting Abstracts) 2004 22: 1552. [Abstract]  

M. A. Spear, A. Mirmiran, and E. McClay

Phase I/II trial of IV topotecan (TOPO) in combination with whole brain radiation therapy (WBXRT)
J Clin Oncol (Meeting Abstracts) 2004 22: 1553. [Abstract]  

A. Desjardins, J. A. Quinn, D. A. Reardon, J. N. Rich, J. J. Vredenburgh, C. Efird, and H. S. Friedman

Phase II study of thalidomide and daily cyclophosphamide for adults with malignant glioma
J Clin Oncol (Meeting Abstracts) 2004 22: 1554. [Abstract]  

A. Yung, J. Vredenburgh, T. Cloughesy, B. J. Klencke, P. S. Mischel, D. D. Bigner, K. Aldape, S. Vanderburg, and M. Prados

Erlotinib HCL for glioblastoma multiforme in first relapse, a phase II trial
J Clin Oncol (Meeting Abstracts) 2004 22: 1555. [Abstract]  

U. K. Bartels, C. Hawkins, J. Ma, A. Ray, P. Dirks, J. Rutka, and E. Bouffet

Microvessel density predicts behavior in pediatric optic pathway/hypothalamic gliomas
J Clin Oncol (Meeting Abstracts) 2004 22: 1556. [Abstract]  

G. M. Videtic, D. J. Adelstein, T. Mekhail, T. W. Rice, G. H. J. Stevens, S.-Y. Lee, and J. H. Suh

Validation of the RTOG recursive partitioning analysis (RPA) classification for small cell lung cancer-only brain metastases: A single institution experience
J Clin Oncol (Meeting Abstracts) 2004 22: 1557. [Abstract]  

M. A. Vogelbaum, D. Peereboom, G. Stevens, G. Barnett, and C. Brewer

Phase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent Glioblastoma Multiforme: Interim results
J Clin Oncol (Meeting Abstracts) 2004 22: 1558. [Abstract]  

L. Kutikova, L. Bowman, S. Chang, and S. Long

How costly is brain cancer? Healthcare services use and costs from across the US
J Clin Oncol (Meeting Abstracts) 2004 22: 1559. [Abstract]  

M. Frenay, A. Ramaioli, D. Fontaine, V. Bourg, F. Vandenbos, and C. Lebrun

Prognostic factors of oligodendrogliomas
J Clin Oncol (Meeting Abstracts) 2004 22: 1560. [Abstract]  

E. Shaw, B. Stea, T. Pinter, Y. Hammoud, P. J. Cagnoni, J. Hackman, A. Boyd, M. Craig, J. Marks, and J. Suh

Pharmacokinetics (PK) of RSR13 (efaproxiral) predict survival in patients with brain metastases randomized to receive whole brain radiation therapy (WBRT) with or without RSR13 (REACH RT-009)
J Clin Oncol (Meeting Abstracts) 2004 22: 1561. [Abstract]  

L. Scopece, G. Cavallo, E. Palmerini, E. Franceschi, A. Paioli, F. Spagnolli, S. Rimondini, R. Conforti, R. Degli Esposti, and L. Crino

Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 1562. [Abstract]  

C. Marosi, M. Hassler, J. A. Hainfellner, M. Van Trotsenburg, M. Preusser, P. Birner, and J. Berger

Microvessel density in progressive meningiomas and its influence on time to tumour recurrence
J Clin Oncol (Meeting Abstracts) 2004 22: 1563. [Abstract]  

M. Holdhoff, K. A. Kreuzer, C. Appelt, R. Scholz, A. Jordan, B. Hildebrandt, C. A. Schmidt, R. A. Van Etten, B. Dörken, and P. Le Coutre

Combined administration of imatinib mesylate and ionizing radiation leads to increased radiosensitivity in the human glioblastoma cell line RuSi RS1
J Clin Oncol (Meeting Abstracts) 2004 22: 1564. [Abstract]  

B. E. Lally, J. M. Colasanto, and J. P. S. Knisely

The prognostic effect of hemoglobin levels on survival for patients with high-grade gliomas
J Clin Oncol (Meeting Abstracts) 2004 22: 1565. [Abstract]  

H. Nakagawa, M. Tamura, Y. Fukushima, and S. Majima

Continuous intrathecal chemotherapy with 5-fluoro-2'-deoxyuridine (FdUrd) in treatment of leptomeningeal carcinomatosis
J Clin Oncol (Meeting Abstracts) 2004 22: 1566. [Abstract]  

A. M. P. Omuro, J. J. Raizer, and L. E. Abrey

A phase I trial of temozolomide and vinorelbine in patients with recurrent brain metastases
J Clin Oncol (Meeting Abstracts) 2004 22: 1567. [Abstract]  

E. Franceschi, G. Cavallo, A. Paioli, L. Scopece, R. Degli Esposti, E. Leonardi, F. Spagnolli, A. M. Cremonini, A. Pession, and L. Crino

Evaluation of 1p and 19q chromosomal alterations in oligodendroglial neoplasms using microdissection and microsatellite analysis technique and correlations with response to chemotherapy
J Clin Oncol (Meeting Abstracts) 2004 22: 1568. [Abstract]  

M. A. Badruddoja, D. A. Reardon, G. Akabani, A. H. Friedman, H. S. Friedman, J. N. Rich, J. A. Quinn, K. Penne, J. J. Vredenburgh, and D. D. Bigner

Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 1569. [Abstract]  

J. Sgouros, S. Upadhyay, M. Braun, M. Holmes, and A. Maraveyas

A phase I study of chemo-radiotherapy using gemcitabine as a radiosensitiser in patients with metastases to the brain
J Clin Oncol (Meeting Abstracts) 2004 22: 1570. [Abstract]  

A. Chakravarti, W. Seiferheld, H. I. Robins, A. Guha, D. Brachman, W. Curran, A. Choucair, and M. Mehta

An update of phase I data from RTOG 0211: A phase I/II clinical study of gefitinib+ radiation for newly-diagnosed glioblastoma (GBM) patients
J Clin Oncol (Meeting Abstracts) 2004 22: 1571. [Abstract]  

H. Kobayashi, N. Ishii, J. Ikeda, Y. Sawamura, and Y. Iwasaki

Methylation profiling of the DNA repair genes in glioblastoma multiforme and its clinical relevance
J Clin Oncol (Meeting Abstracts) 2004 22: 1572. [Abstract]  

P. L. Moots, A. O'Neill, G. R. Barger, M. P. Mehta, and M. R. Gilbert

Toxicities associated with chemotherapy followed by craniospinal radiation for adults with poor-risk medulloblastoma/PNET and disseminated ependymoma; a preliminary report of ECOG 4397
J Clin Oncol (Meeting Abstracts) 2004 22: 1573. [Abstract]  

R. Soffietti, A. Costanza, E. Laguzzi, M. Nobile, and R. Rudà

A phase II study of first-line temozolomide and second-line PCV in recurrent/progressive malignant gliomas
J Clin Oncol (Meeting Abstracts) 2004 22: 1574. [Abstract]  

D. Y. Kim, K. W. Lee, T. Yun, J. H. Kim, D. W. Kim, S. A. Im, T. Y. Kim, D. S. Heo, Y. J. Bang, and N. K. Kim

Efficacy of platinum-based chemotherapy after cranial irradiation in patients with brain metastasis from non-small cell lung cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 1575. [Abstract]  

M. Caraglia, R. Addeo, R. Costanzo, L. Montella, V. Faiola, E. Capasso, and S. Del Prete

Pegylated liposomal doxorubicin plus temozolamide in the salvage treatment of brain metastases: The update
J Clin Oncol (Meeting Abstracts) 2004 22: 1576. [Abstract]  

S. Tafuto, R. Guarrasi, A. Tortoriello, F. Buzzi, P. Muto, R. Formato, P. Comella, P. De Rosa, R. V. Iaffaioli, and S. Quattrin

Temozolomide (TMZ) and lomustine (CCNU) in high grade glioma (HGG) patients: Phase I study
J Clin Oncol (Meeting Abstracts) 2004 22: 1577. [Abstract]  

R. V. Larocca, A. Cervera, J. B. Hargis, S. D. Glisson, G. H. Goldsmith, M. A. M. Laureano, and B. Foreman

High-dose (HD) irinotecan in patients with recurrent unresectable high-grade gliomas on glucoronidation-enhancing anticonvulsants (GEACs): A phase I/II study
J Clin Oncol (Meeting Abstracts) 2004 22: 1578. [Abstract]  

C. Garufi, B. Vanni, C. Francesca, C. Campanella, A. M. Aschelter, E. Bria, C. Nisticò, F. Cuppone, I. Sperduti, and E. Terzoli

Evidence for an aggressive biological behaviour of brain metastases in advanced colorectal cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 1579. [Abstract]  

Developmental Therapeutics: Cytotoxic Chemotherapy:

A. B. Sandler, G. R. Blumenschein, T. Henderson, J. Lee, M. Truong, E. Kim, B. Mass, B. Garcia, D. H. Johnson, and R. S. Herbst

Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 2000. [Abstract]  

M. Dickler, H. Rugo, J. Caravelli, E. Brogi, D. Sachs, K. Panageas, S. Flores, M. Moasser, L. Norton, and C. Hudis

Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients (pts) with metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2004 22: 2001. [Abstract]  

R. Salazar, J. Tabernero, F. Rojo, E. Jimenez, I. Montaner, E. Casado, G. Sala, J. Tillner, R. Malik, and J. Baselga

Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (MAb) EMD 72000 administered every three weeks (q3w). A phase I pharmacokinetic/pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD)
J Clin Oncol (Meeting Abstracts) 2004 22: 2002. [Abstract]  

J. H. Schellens, I. E. Kuppens, R. C. Jewell, S. A. Radema, E. O. Witteveen, E. M. Paul, S. G. Mangum, H. Rosing, J. H. Beijnen, and E. E. Voest

Phase I and pharmacological study of oral topotecan and the BCRP and P-gp inhibitor elacridar
J Clin Oncol (Meeting Abstracts) 2004 22: 2003. [Abstract]  

H. A. Burris, P. Lorusso, S. Jones, T. M. Guthrie, J. B. Orr, D. D. Williams, J. P. Hodge, M. Bush, and J. Sabry

Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV days 1, 8, 15 q 28 days
J Clin Oncol (Meeting Abstracts) 2004 22: 2004. [Abstract]  

C. Lee, K. Appleton, J. Plumb, S. Kaye, C. Cruickshank, C. Twelves, P. Vasey, I. Judson, R. Brown, and H. Mackay

A phase I trial of the DNA-hypomethylating agent 5-Aza-2'-Deoxycytidine in combination with carboplatin both given 4 weekly by intravenous injection in patients with advanced solid tumours
J Clin Oncol (Meeting Abstracts) 2004 22: 2005. [Abstract]  

S. D. Baker, A. J. Ten Tije, M. A. Carducci, H. Gelderblom, F. W. Dawkins, W. P. McGuire, and J. Verweij

Evaluation of CYP3A activity as a predictive covariate for docetaxel clearance
J Clin Oncol (Meeting Abstracts) 2004 22: 2006. [Abstract]  

F. A. De Jong, R. H. J. Mathijssen, E. R. Lepper, R. H. Van Schaik, L. Friberg, P. De Bruijn, W. J. Graveland, W. D. Figg, J. Verweij, and A. Sparreboom

Role of CYP3A4 phenotyping by midazolam clearance in predicting irinotecan pharmacokinetics
J Clin Oncol (Meeting Abstracts) 2004 22: 2007. [Abstract]  

S. C. Glasgow, J. Yu, D. C. Linehan, M. A. Watson, and H. L. McLeod

Modeling the response of colorectal cancer (CRC) to common chemotherapy using multivariate gene expression
J Clin Oncol (Meeting Abstracts) 2004 22: 2008. [Abstract]  

C. Kitagawa, M. Ando, Y. Ando, Y. Sekido, M. Usui, K. Takahashi, K. Shimokata, and Y. Hasegawa

Genetic polymorphisms of the multidrug resistance-associated protein 2 gene (ABCC2) and Irinotecan toxicity
J Clin Oncol (Meeting Abstracts) 2004 22: 2009. [Abstract]  

F. Innocenti, S. D. Undevia, P. X. Chen, S. Das, J. Ramirez, M. E. Dolan, M. V. Relling, D. L. Kroetz, and M. J. Ratain

Pharmacogenetic analysis of interindividual irinotecan (CPT-11) pharmacokinetic (PK) variability: Evidence for a functional variant of ABCC2
J Clin Oncol (Meeting Abstracts) 2004 22: 2010. [Abstract]  

L. C. Iacono, W. L. Furman, K. R. Crews, J. C. Panetta, B. B. Freeman, N. C. Daw, and C. F. Stewart

Effect of gefitinib on the systemic disposition of intravenous irinotecan (IRN) in pediatric patients with refractory solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 2011. [Abstract]  

K. R. Crews, W. L. Furman, J. C. Panetta, B. B. Freeman, L. C. Iacono, P. J. Houghton, and C. F. Stewart

Effect of gefitinib on the bioavailability of oral irinotecan in children with refractory solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 2012. [Abstract]  

R. Sharma, J. Hoskins, P. Beale, K. Li, and S. Clarke

Genotyping to predict for response and toxicity to capecitabine in advanced colorectal cancer patients (pts)
J Clin Oncol (Meeting Abstracts) 2004 22: 2013. [Abstract]  

R. Suk, S. Gurubhagavatula, S. Park, W. Zhou, L. Su, T. J. Lynch, J. C. Wain, D. Neuberg, G. Liu, and D. C. Christiani

The ERCC1 C8092A polymorphism and grade III/IV gastrointestinal (GI) toxicity in non-small cell lung cancer (NSCLC) patients treated with chemoradiation
J Clin Oncol (Meeting Abstracts) 2004 22: 2014. [Abstract]  

H. Gelderblom, W. J. Loos, T. M. Sissung, H. Burger, K. Nooter, O. Soepenberg, J. W. R. Nortier, J. Verweij, W. D. Figg, and A. Sparreboom

Effect of ABCG2 genotype and mRNA expression on the bioavailability of topotecan
J Clin Oncol (Meeting Abstracts) 2004 22: 2015. [Abstract]  

J. M. Kolesar, A. Breunig, J. Miller, P. Stephenson, H. McLeod, S. Marsh, S. Keller, D. Johnson, and J. H. Schiller

CYP3A5*3 and CYP3A4*1B polymorphisms are associated and more frequent in NSCLC tumors than in normal volunteers
J Clin Oncol (Meeting Abstracts) 2004 22: 2016. [Abstract]  

C. H. Takimoto, M. W. Saif, P. M. Lorusso, C. Sweeney, M. P. Ducharme, S.-C. Q. Chu, G. H. Schwartz, M. Danna, R. L. De Jager, and E. K. Rowinsky

A pharmacokinetic (PK) dose escalation study of DX-8951f (DX) in adult cancer patients with hepatic dysfunction: A comparison of the NCI hepatic dysfunction criteria and the Child-Pugh classification
J Clin Oncol (Meeting Abstracts) 2004 22: 2017. [Abstract]  

S. Remick, C. Sweeney, C. Takimoto, D. Douer, and A. Bernareggi

Pharmacokinetics (PK) of arsenic trioxide in cancer patients (pts) with renal dysfunction: Preliminary results
J Clin Oncol (Meeting Abstracts) 2004 22: 2018. [Abstract]  

J. W. Fisher, J. A. Florian, R. S. Parker, A. P. Venook, M. J. Ratain, and M. J. Egorin

Evaluation of potentially excessive plasma gemcitabine (dFdC) concentrations produced by 30-minute dFdC infusions
J Clin Oncol (Meeting Abstracts) 2004 22: 2019. [Abstract]  

A. M. Alousi, R. Parchment, R. Boinpally, S. Gadgeel, R. Weigand, J. McCormick, and P. Lorusso

Phase I clinical trial of XK469 in patients with chemo-refractory solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 2020. [Abstract]  

E. Sprague, S. D. Undevia, F. Innocenti, J. Ramirez, L. K. House, H. L. Kindler, D. A. Singh, A. A. Desai, R. L. Schilsky, and M. J. Ratain

A dose-escalation study of the quinoxaline antitumor agent R(+)XK469 (XK) in patients with refractory solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 2021. [Abstract]  

C. W. Taylor, P. Walker, D. Tang-Liu, T. Joshi, C. Gebremarian, S. Jordan, Z. Yu, D. Von Hoff, and L. Garland

A phase I and pharmacokinetic clinical trial of the orally administered retinoic acid receptor- Agonist, AGN 195183
J Clin Oncol (Meeting Abstracts) 2004 22: 2022. [Abstract]  

J. G. Kuhn, S. Jones, D. Hein, N. Willcutt, F. A. Greco, E. Raefsky, D. Thompson, A. Meluch, D. Brown, and H. Burris

A phase I pharmacokinetic, pharmacogenomic trial of weekly amonafide in patients (pts) with solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 2023. [Abstract]  

K. D. Holen, S. Syed, A. L. Hannah, K. Binger, L. Wood, Y. Zhou, G. F. Cropp, R. G. Johnson, E. Rowinsky, and G. Wilding

Phase I study using continuous intravenous (CI) KOS-862 (Epothilone D) in patients with solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 2024. [Abstract]  

A. Mita, A. C. Lockhart, T.-L. Chen, K. Bochinski, J. Curtright, W. Cooper, L. Hammond, M. Rothenberg, E. Rowinsky, and S. Sharma

A phase I pharmacokinetic (PK) trial of XAA296A (Discodermolide) administered every 3 wks to adult patients with advanced solid malignancies
J Clin Oncol (Meeting Abstracts) 2004 22: 2025. [Abstract]  

P. P. Bapsy, D. Raghunadharao, A. Majumdar, S. Ganguly, A. Roy, G. Uppal, R. Mukherjee, A. Burman, and N. Saha

DO/NDR/02 a novel polymeric nanoparticle paclitaxel: Results of a phase I dose escalation study
J Clin Oncol (Meeting Abstracts) 2004 22: 2026. [Abstract]  

D. W. Nyman, K. J. Campbell, E. Hersh, K. Richardson, K. Patrick, V. Trieu, N. Desai, and D. D. Von Hoff

A phase I trial of ABI-007, nanoparticle paclitaxel, administered to patients with advanced non-hematologic malignancies
J Clin Oncol (Meeting Abstracts) 2004 22: 2027. [Abstract]  

S. K. Syed, M. Beeram, C. H. Takimoto, J. Jakubowitz, M. Kimura, M. Ducharme, S. Gadgeel, R. De Jager, E. Rowinsky, and P. Lorusso

Phase I and Pharmacokinetics (PK) of DJ-927, an oral taxane, in patients (Pts) with advanced cancers
J Clin Oncol (Meeting Abstracts) 2004 22: 2028. [Abstract]  

L. E. Broker, F. Y. De Vos, H. Gall, J. A. Gietema, M. Voi, M. B. Cohen, E. G. De Vries, and G. Giaccone

A phase I trial of the novel oral taxane BMS-275183 in patients with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 2029. [Abstract]  

Y. Yamada, N. Yamamoto, T. Shimoyama, A. Horiike, Y. Fujisaka, K. Takayama, T. Sakamoto, Y. Nishioka, S. Yasuda, and T. Tamura

A phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days
J Clin Oncol (Meeting Abstracts) 2004 22: 2030. [Abstract]  

S. Letrent, F. Callegari, T. Wong, H. Burris, R. Cohen, P. Lorusso, V. Papadimitrakopoulou, G. Shapiro, T. Griffin, and A. Decillis

Evaluation of a novel RNA biomarker of CDK2 inhibition in phase 1 clinical trials with BMS-387032
J Clin Oncol (Meeting Abstracts) 2004 22: 2031. [Abstract]  

A. Fischman, S. Letrent, A. Bonab, E. Livni, E. Carter, R. Rubin, D. Mauro, C. Tarby, S. Galbraith, and T. Griffin

PET as a biomarker of the antitumor effects of the CDK2 inhibitor BMS-387032
J Clin Oncol (Meeting Abstracts) 2004 22: 2032. [Abstract]  

R. S. McDermott, N. J. Meropol, L. M. Weiner, G. Yeslow, and G. R. Hudes

Phase I clinical and pharmacokinetic study of the farnesyl transferase inhibitor BMS-214662 administered intravenously for five consecutive days in patients with advanced malignancies
J Clin Oncol (Meeting Abstracts) 2004 22: 2033. [Abstract]  

M. Michael, P. Mitchell, R. Hicks, A. Scott, A. Ellis, M. Thompson, J. Hoskins, S. Bates, N. Tebbutt, and J. R. Zalcberg

The utility of in-vivo functional and genetic parameters of drug elimination for the estimation of irinotecan (Ir) clearance (CL)
J Clin Oncol (Meeting Abstracts) 2004 22: 2034. [Abstract]  

M. L. Veronese, K. T. Flaherty, R. Townsend, A. Mosenkis, R. Zimmer, M. Rosen, M. Gallagher, and P. J. O'Dwyer

Pharmacodynamic study of the raf kinase inhibitor BAY 43–9006: Mechanisms of hypertension
J Clin Oncol (Meeting Abstracts) 2004 22: 2035. [Abstract]  

J. H. Beumer, G. Lappin, M. Cohen, S. Galbraith, R. C. Garner, J. H. Beijnen, T. Griffin, and J. H. Schellens

Mass balance study with ixabepilone using Accelerator Mass Spectrometry
J Clin Oncol (Meeting Abstracts) 2004 22: 2036. [Abstract]  

Y. Miyagi, K. Fujiwara, J. Kigawa, H. Itamochi, S. Nagao, E. Aotani, N. Terakawa, and I. Kohno

Development of a mathematical model of intraperitoneal/intravenous infusion of carboplatin. A Sankai Gynecology Study Group study
J Clin Oncol (Meeting Abstracts) 2004 22: 2037. [Abstract]  

A. Y. Bedikian, A. Vardeleon, and T. Smith

Pharmacokinetics (PK) study of sphingosomal vincristine (SV) in patients with metastatic melanoma (MM)
J Clin Oncol (Meeting Abstracts) 2004 22: 2038. [Abstract]  

J. G. Supko, L. Alderson, P. Wen, K. Cassidy, S. Pace, M. Obrocea, and F. Hochberg

Pharmacokinetics of gimatecan, and orally administered camptothecin analogue, in patients with malignant gliomas
J Clin Oncol (Meeting Abstracts) 2004 22: 2039. [Abstract]  

A. X. Zhu, R. Bukowski, A. C. Lockhart, K. K. Wang, W. Cooper, J. Grover, M. Cohen, L. Appleman, M. Shapiro, and M. L. Rothenberg

Phase 1 trial of oral MAC-321 in subjects with advanced malignant solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 2040. [Abstract]  

M. G. Jannuzzo, E. Di Salle, R. Spinelli, N. Pirotta, G. Massimini, and P. Buchan

Estrogen suppression of 8-week treatment with exemestane combined with triptorelin versus triptorelin alone in healthy premenopausal women
J Clin Oncol (Meeting Abstracts) 2004 22: 2041. [Abstract]  

A. I. B. Benson, E. Rubin, S. Beers, P. Mucci-Lorusso, W. Vermuelen, L. Denis, L. Compton, D. Pavlov, and M. L. Rothenberg

Phase I dose escalation and safety study of a semi-solid matrix (SSM) formulation of oral irinotecan and capecitabine tablets in patients with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 2042. [Abstract]  

L. D. Lewis, G. L. Rosner, A. A. Miller, M. J. Egorin, M. V. Relling, H. Kastrissios, R. Bies, and M. J. Ratain

The pharmacokinetics and pharmacodynamics of docetaxel (DCTX) in Caucasian and African American patients with solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 2043. [Abstract]  

W. S. Lakhai, J. H. Beijnen, S. S. Den Boer, A. M. Westermann, M. Versola, K. Koch, P. Ho, L. Pandite, D. J. Richel, and J. Schellens

Phase I trial to determine the safety and tolerability of GW572016 in combination with oxaliplatin (OX)/5-fluorouracil (5-FU)/leucovorin (LV) [FOLFOX4] in patients with solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 2044. [Abstract]  

T. Lesimple, J. Egreteau, P. Fumoleau, M. Campone, A. Lortholary, P. Soulié, C. Peraire, P. Principe, B. Le Mosquet, and C. Granger

Oral absorption of diflomotecan, a new E-ring modified camptothecin analogue, administered as soft-gel capsule
J Clin Oncol (Meeting Abstracts) 2004 22: 2045. [Abstract]  

P. Principe, I. F. Troconiz, C. Segura, M. J. Garrido, J. M. Cendros, C. Peraire, and R. Obach

Population PK/PD model for diflomotecan, a new E-ring modified camptothecin analogue, in patients of a phase I study
J Clin Oncol (Meeting Abstracts) 2004 22: 2046. [Abstract]  

G. S. Chatta, M. Fakih, S. Ramalingam, C. P. Belani, R. K. Ramanathan, W. Zamboni, D. Friedland, D. Lis, S. Tutchko, and M. Egorin

Phase I pharmacokinetic (PK) study of daily imatinib in combination with docetaxel for patients with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 2047. [Abstract]  

A. J. Olszanski, L. D. Lewis, C. Mita, R. C. Walovitch, R. P. Perez, D. P. Tuck, and E. K. Rowinsky

Phase 1 and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system (HDDS) for paclitaxel
J Clin Oncol (Meeting Abstracts) 2004 22: 2048. [Abstract]  

S. Aamdal, S. Dueland, M. J. Lind, H. Thomas, C. R. Franks, M. L. Sandvold, and W. Rasch

Phase I trial of a nucleoside analog CP-4055 given daily for 5 days every 3 weeks in patients (pts) with advanced solid tumors - preliminary results
J Clin Oncol (Meeting Abstracts) 2004 22: 2049. [Abstract]  

H. T. Tran, R. Zinner, G. R. Blumenschein, Y. W. Oh, V. A. Papadimitrakopoulou, E. S. Kim, C. Lu, M. Malik, B. Lum, and R. S. Herbst

Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC)
J Clin Oncol (Meeting Abstracts) 2004 22: 2050. [Abstract]  

S. J. Faivre, C. Delbaldo, P. Pautier, V. Boige, S. Henriet, J. P. Armand, B. Grau, F. Namouni, R. Peck, and E. Raymond

Phase I study of ixabepilone given every other week in combination with irinotecan in patients with advanced malignancies
J Clin Oncol (Meeting Abstracts) 2004 22: 2051. [Abstract]  

G. Bocci, C. Barbara, F. Vannozzi, A. Di Paolo, A. Melosi, M. Battistoni, G. Barsanti, G. Allegrini, A. Falcone, and M. Del Tacca

A pharmacokinetic-based test to predict the risk of life-threatening 5-fluorouracil toxicities in cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 2052. [Abstract]  

A. Awada, R. Clark, H. Dumez, T. Gil, A. Hanauske, M. Piccart, A. Suri, and A. Van Oosterom

Phase I trial of pemetrexed plus paclitaxel administered every 21 days in patients with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 2053. [Abstract]  

E. Chatelut, W. J. Loos, F. Léger, P. Canal, R. Bugat, J. Verweij, and A. Sparreboom

Pharmacokinetic-pharmacodynamic models for topotecan-induced neutropenia
J Clin Oncol (Meeting Abstracts) 2004 22: 2054. [Abstract]  

G. Friberg, P. Schumm, M. J. Ratain, R. L. Schilsky, and G. F. Fleming

Circadian variations in plasma 5-fluorouracil (5-FU) levels during 24-hour infusions
J Clin Oncol (Meeting Abstracts) 2004 22: 2055. [Abstract]  

A. Wu and M. R. Scheffler

Multiple-dose pharmacokinetics and safety of CC-5013 in 15 multiple myeloma patients
J Clin Oncol (Meeting Abstracts) 2004 22: 2056. [Abstract]  

S. Iqbal, S. Cole, D. Yang, P. N. Lara, P. H. Gumerlock, S. Shibata, T. Synold, J. H. Doroshow, D. Gandara, and H. J. Lenz

Phase I study of PS-341 (bortezomib) with 5-fluorouracil/leucovorin (5-FU/LV) in advanced solid tumors: A California Cancer Consortium study
J Clin Oncol (Meeting Abstracts) 2004 22: 2057. [Abstract]  

W. P. Yong, B. C. Goh, L. Z. Wang, N. Norita, F. Lu, R. Lim, L. K. Soo, S. C. Lee, and H. S. Lee

Docetaxel clearance is non linear and not predicted by CYP3A phenotyping when administered with ketoconazole
J Clin Oncol (Meeting Abstracts) 2004 22: 2058. [Abstract]  

M. Airoldi, L. Cattel, R. Passera, C. Micari, E. Ferrarato, and C. Zanon

Clinical and pharmacokinetic study of gemcitabine (GEM) - oxaliplatin (OXA) association in metastatic or locally advanced pancreatic adenocarcinoma
J Clin Oncol (Meeting Abstracts) 2004 22: 2059. [Abstract]  

J. Murren, S. Gerson, S. Kummar, M. Davies, S. Remick, E. Chu, V. Karsten, and M. Sznol

A Phase I trial of the sulfonylhydrazine alkylator, VNP40101M (101M), administered weekly in patients (pts) with metastatic cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 2060. [Abstract]  

A. G. Gaba, Z. Yuan, Y. H. Ling, A. Bennett, and T. K. Weber

Cytosine B-D Arabino-Furanoside (Ara-C) and CPT-11 inhibit cell proliferation in human colorectal cancer with microsatellite instability
J Clin Oncol (Meeting Abstracts) 2004 22: 2061. [Abstract]  

R. Largillier, J. L. Formento, A. Ginot, M. C. Etienne, M. Francoual, N. Renée, J. M. Ferrero, C. Foa, M. Namer, and G. Milano

Thymidylate synthase (TS) and methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms: Relationships with capecitabine (X) pharmacodynamics in advanced breast cancer (ABC) patients (pts)
J Clin Oncol (Meeting Abstracts) 2004 22: 2062. [Abstract]  

C. Balram, E. H. Tan, Q. Zhou, Y. B. Cheung, C. Kibat, and S. S. Leong

Pharmacogenetics of ABC transporters and drug metabolising enzymes and their influence on Irinotecan (CPT-11) elimination pathways in Asian cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 2063. [Abstract]  

C. Massacesi, S. Terrazzino, F. Marcucci, M. B. L. Rocchi, C. Cappelletti, L. Giustini, M. Lombardo, L. Rinaldi, R. Mattioli, and M. Bonsignori

Role of UGT1A1, MTHFR AND TS gene polymorphisms in the prediction of irinotecan (CPT11) and raltitrexed (TOM) gastrointestinal toxicity in pre-treated patients (pts) with metastatic colorectal cancer (CRC)
J Clin Oncol (Meeting Abstracts) 2004 22: 2064. [Abstract]  

A. Jenabian, N. Goasgen, J. P. Flinois, S. Gad, P. Beaune, and P. Laurent-Puig

Genetic polymorphisms of CES2 and their functional consequences
J Clin Oncol (Meeting Abstracts) 2004 22: 2065. [Abstract]  

H. C. Chung, S. Y. Rha, H. Jeung, Y. Choi, K. Park, J. Sohn, C. Kim, G. E. Kim, J. H. Yoo, and Y. S. Kim

Gemcitabine pathway genotype analysis to predict toxicity in phase II gemcitabine monotherapy in heavily pre-treated metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 2066. [Abstract]  

K. Mulder, A. G. Scarfe, S. Koski, H. J. Au, C. Butts, A. Fields, H. Razavy, K. Graham, C. E. Cass, and M. B. Sawyer

A prospective pharmacogenetic study of 5FU/LV in high-risk stage II and III colon cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 2067. [Abstract]  

Y. Rustum, S. Cao, F. Durrani, and M. Fakih

Se-(methyl)selenocysteine (MSC) potentiates the antitumor activity of irinotecan against human tumor xenografts and protects against drug induced toxicity
J Clin Oncol (Meeting Abstracts) 2004 22: 2068. [Abstract]  

C. J. Sweeney, M. W. Saif, P. M. Lorusso, M. P. Ducharme, R. Demnati, M. Danna, E. Rowinsky, M. Mita, R. Dejager, and C. Takimoto

A phase I study of DX 8951f (exatecan mesylate for injection) in patients with renal dysfunction
J Clin Oncol (Meeting Abstracts) 2004 22: 2069. [Abstract]  

C. Delbaldo, E. Chatelut, M. Ré, A. Deroussent, A. Jambu, A. Mackrodt, A. Lecesne, and G. Vassal

Inflammatory response affects the pharmacokinetics (PK) and pharmacodynamics (PD) of imatinib and CGP 74588 in patients with advanced gastro-intestinal-sarcoma (GIST)
J Clin Oncol (Meeting Abstracts) 2004 22: 2070. [Abstract]  

M. Hidalgo, C. Lee, K. Carducci, J. Jolivet, and S. Baker

Phase I evaluation of troxacitabine administered by continuous infusion in patients with refractory solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 2071. [Abstract]  

A. Singh, L. Paoluzzi, D. Price, R. Danesi, R. H. Mathijssen, J. Verweij, W. D. Figg, and A. Sparreboom

Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38
J Clin Oncol (Meeting Abstracts) 2004 22: 2072. [Abstract]  

M. V. McNamara, J. H. Doroshow, J. Dupont, D. Spriggs, E. Eastham, S. Pezzulli, S. Syed, A. Bernareggi, and C. Takimoto

Preliminary pharmacokinetics of CT-2106 (polyglutamate camptothecin) in patients with advanced malignancies
J Clin Oncol (Meeting Abstracts) 2004 22: 2073. [Abstract]  

A. C. Lockhart, C. M. Rudin, J. D. Berlin, B. J. Roth, K. R. Hande, R. R. Martin, T. M. Sullivan, J. M. Grindel, R. Zhang, and M. L. Rothenberg

A phase I trial of an anti-pka oligonucleotide (GEM231) administered with weekly CPT-11
J Clin Oncol (Meeting Abstracts) 2004 22: 2074. [Abstract]  

J. L. Grem, M. Wright, G. Morrison, P.-X. Lin, G. Leonard, D. Nguyen, X.-D. Guo, and E. Szabo

Phase I pharmacokinetic (PK) & pharmacogenetic study of sequential infusional irinotecan (IR) and fluorouracil (FU)
J Clin Oncol (Meeting Abstracts) 2004 22: 2075. [Abstract]  

J. H. Beijnen, J. M. Rademaker-Lakhai, S. Horenblas, W. Meinhardt, E. Stokvis, T. M. De Rijke, J. M. Jimeno, L. Lopez Lazaro, J. A. Lopez Martin, and J. Schellens

Phase I and pharmacokinetic study of Kahalalide F in patients with advanced androgen refractory prostate cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 2076. [Abstract]  

M. Katz, M. Bouvet, S. Takimoto, D. Spivack, A. Moossa, and R. M. Hoffman

Survival efficacy of adjuvant cytosine-analog CS-682 in a fluorescent orthotopic model of human pancreatic cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 2077. [Abstract]  

Q. S. Chu, K. D. Holen, E. K. Rowinsky, G. Wilding, J. L. Volkman, J. B. Orr, D. D. Williams, J. P. Hodge, and J. Sabry

Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV Q 21 days
J Clin Oncol (Meeting Abstracts) 2004 22: 2078. [Abstract]  

H. Kobayashi, K. R. Hande, J. D. Berlin, B. J. Roth, J. A. Sosman, A. C. Lockhart, A. Hagey, K. Meek, A. Coates, and M. L. Rothenberg

Phase I results of ABT-751, a novel microtubulin inhibitor, administered daily x 7 every 3 weeks
J Clin Oncol (Meeting Abstracts) 2004 22: 2079. [Abstract]  

S. Y. Cho, P. C. Adamson, A. E. Hagey, B. C. Widemann, J. M. Maris, E. Fox, D. Medina, Y. Cui, G. B. Gordon, and F. M. Balis

Phase I trial and pharmacokinetic (PK) study of ABT-751, an orally bioavailable tubulin binding agent, in pediatric patients with refractory solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 2080. [Abstract]  

P. L. Abrams, M. J. Egorin, R. K. Ramanathan, R. A. Parise, T. F. Lagattuta, M. Hayes, B. Peng, S. P. Ivy, A. Murgo, and S. Remick

Intrapatient consistency of imatinib pharmacokinetics (PK) in patients (pts) with advanced cancers
J Clin Oncol (Meeting Abstracts) 2004 22: 2081. [Abstract]  

P. Bonate, S. Ebbinghaus, J. P. Eder, A. Mita, E. Rubin, C. C. Cunningham, E. K. Rowinsky, E. Hersh, A. R. Craig, and L. A. Hammond

Pharmacokinetics of synthadotin (ILX651), a novel tubulin polymerization inhibitor, in patients with solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 2082. [Abstract]  

S. F. Jones, J. D. Hainsworth, D. R. Spigel, N. W. Peacock, N. T. Willcutt, L. N. Pandite, M. J. Versola, K. M. Koch, F. Greco, and H. A. Burris

A phase I study of the dual kinase inhibitor GW572016 in combination with paclitaxel (EGF10009)
J Clin Oncol (Meeting Abstracts) 2004 22: 2083. [Abstract]  

T. G. Roberts, B. H. L. Goulart, S. C. Stallings, L. Squitieri, B. A. Chabner, S. N. Finkelstein, and J. W. Clark

Analysis of over 2,400 modern phase I cancer trials: Composition, outcomes, and use of surrogate endpoints
J Clin Oncol (Meeting Abstracts) 2004 22: 2084. [Abstract]  

W. Liu, F. Innocenti, P. X. Chen, A. Desai, C. Grimsley, A. Di Rienzo, S. Das, and M. Ratain

Haplotype analysis of UGT1A1 and UGT1A9 gene polymorphisms related to the glucuronidation of SN-38, the active metabolite of irinotecan
J Clin Oncol (Meeting Abstracts) 2004 22: 2085. [Abstract]  

M. S. Ewer, M. T. Vooletich, and R. S. Benjamin

A mathematical model for doxorubicin cardiotoxicity: Added evidence for the concept of sequential stress
J Clin Oncol (Meeting Abstracts) 2004 22: 2086. [Abstract]  

G. N. John, J. Giannios, E. Michailakis, S. Konstandinidou, G. Xepapadakis, N. Alexandropoulos, and T. Kononas

Combined administration of hydrophilic antimitotic desoxyepothilone B and vinorelbine induce PUMA, suppression of microtubule dynamics, development of hypodiploidy and multinucleation, cell cycle perturbation at G2/M and apoptosis in advanced breast carcinoma (ABC) characterised by MDR-1 (Pgp),bcl-2 and mutant b-tubulin
J Clin Oncol (Meeting Abstracts) 2004 22: 2087. [Abstract]  

E. Michailakis and J. N. Giannios

Immunochemoconjugate of anti-DNMT1/HDAC2 bispecific F(ab)2-bsAb linked with cleavable disulfide to vinorelbine induces apoptosis in chemoresistant infiltrating ductal carcinoma (IDC) characterised by HDAC2 overexpression and 5'CpG island hypermethylation of the FHIT, RAR-ß2, BRCA-1, APC, p16(CDKN2A), RASSF1A, CDH1(E-cadherin), 14–3-3- (stratifin), HIC1 and MDG1 tumor suppressor genes
J Clin Oncol (Meeting Abstracts) 2004 22: 2088. [Abstract]  

S. S. Shord and J. R. Camp

Paclitaxel (PAC) alters the metabolism of gemcitabine (GEM) to its active metabolite difluorodeoxycytidine triphosphate (dFdCTP)
J Clin Oncol (Meeting Abstracts) 2004 22: 2089. [Abstract]  

D. A. Rinaldi, N. A. Lormand, J. M. Rainey, J. E. Brierre, J. L. Cole, and K. B. Roden

A phase I trial of weekly gemcitabine (GEM), administered as a constant dose-rate infusion, and docetaxel (DOC) in patients with advanced solid tumors (LOA-8)
J Clin Oncol (Meeting Abstracts) 2004 22: 2090. [Abstract]  

A. Benghiat, W. P. Steward, P. M. Loadman, M. Middleton, D. Talbot, L. H. Patterson, S. Ford, and A. Turner

Phase 1 dose escalation study of AQ4N, a selective hypoxic cell cytotoxin, with fractionated radiotherapy (RT): First report
J Clin Oncol (Meeting Abstracts) 2004 22: 2091. [Abstract]  

M. G. Fakih, W. C. Zamboni, N. Ramnath, M. M. Javle, J. K. Schwarz, R. A. French, L. L. Regal, R. K. Gorenflo, and P. J. Creaven

A phase I and pharmacokinetic (PK) study of weekly docetaxel (D), cisplatin (P), and daily capecitabine (C) (DPC) in patients with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 2092. [Abstract]  

H. Dumez, A. T. Van Oosterom, J. D. Rothermel, R. Mull, and A. H. Calvert

Phase Ib/II dose-escalation trial evaluating the safety and tolerability of EPO906 plus capecitabine in patients with advanced cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 2093. [Abstract]  

K. Hande, P. Nygren, M. Fedgchin, K. Vandyck, A. Majumdar, D. Panebianco, K. Petty, M. Sjolund, V. Cocquyt, and S. Vanbelle

An open-label, balanced, 2-period crossover study to investigate the influence of aprepitant on docetaxel pharmacokinetics
J Clin Oncol (Meeting Abstracts) 2004 22: 2094. [Abstract]  

A. Gurpide, A. Aldaz, J. L. Perez-Gracia, J. M. Lopez-Picazo, L. Zufia, F. Pardo, J. Espinos, L. Arbea, A. Viudez, and S. Martin-Algarra

Pharmacokinetics of paclitaxel and carboplatin after orthotopic liver transplantation
J Clin Oncol (Meeting Abstracts) 2004 22: 2095. [Abstract]  

D. S. Martin, A. Alfieri, J. Koutcher, V. Fantin, D. Spriggs, and L. Norton

Efficacy of a mitochondrial toxin, F16, in a multi-ATP-depleting regimen + chemotherapy on human breast cancer (MDA-MB-468) xenografts
J Clin Oncol (Meeting Abstracts) 2004 22: 2096. [Abstract]  

I. Kariv, J. Nieva, P. McNeeley, K. Nguyen, M. Nerenberg, J. Diver, K. Bethel, and A. Saven

Use of a moving optical gradient to determine ex vivo chemosensitivity of B- cell chronic lymphocytic leukemias (B-CLL)
J Clin Oncol (Meeting Abstracts) 2004 22: 2097. [Abstract]  

S. Anderson, D. Dizon, P. Sabbatini, J. Dupont, S. Pezzulli, A. Massey, and C. Aghajanian

Phase I trial of BMS-247550 and gemcitabine in patients with advanced solid tumor malignancies
J Clin Oncol (Meeting Abstracts) 2004 22: 2098. [Abstract]  

E. Calvo, E. K. Rowinsky, A. W. Tolcher, Q. S. Chu, M. Beeram, L. Forero, K. L. Mettinger, E. Eastham, A. D. Goetz, and A. Patnaik

A phase I and pharmacokinetic study of rubitecan, an orally administered topoisomerase I (topo-I) inhibitor, combined with gemcitabine in patients with advanced cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 2099. [Abstract]  

M. Cooper, E. Rankin, D. Bissett, M. Nicolson, H. Thomas, J. Steiner, G. Mellows, G. Allen, D. Norris, and J. Waterfall

Initial phase I study of XR5944, a novel DNA and RNA targeting agent
J Clin Oncol (Meeting Abstracts) 2004 22: 2100. [Abstract]  

M. E. Scheulen, B. Kynast, U. Jaehde, R. A. Hilger, E. Scheuch, V. Arion, P. Kupsch, M. M. Henke, C. Dittrich, and B. K. Keppler

A phase I dose-escalation trial with the new redox activated compound sodium trans-[tetrachlorobis(1 H-indazole)ruthenate(III)]/indazolhydrochloride (1:1.1) (FFC14A) in patients with solid tumors - a CESAR study
J Clin Oncol (Meeting Abstracts) 2004 22: 2101. [Abstract]  

B. I. Nilsson

Usability of evaluations of the relationship between efficacy and toxicity in the development of anticancer drugs
J Clin Oncol (Meeting Abstracts) 2004 22: 2102. [Abstract]  

T. Graefe, C. Lubbing, C. Bolling, S. Muller-Hagen, B. Leisner, J. Fleet, F. E. Ludtke, J. Blatter, A. Suri, and A.-R. Hanauske

Phase I study of pemetrexed plus paclitaxel in patients with solid tumor
J Clin Oncol (Meeting Abstracts) 2004 22: 2103. [Abstract]  

R. D. Petty, G. I. Murray, K. Kerr, M. C. Nicolson, D. Bissett, and E. Collie-Duguid

Molecular profiling of response to platinum based therapy in non-small cell lung cancer (NSCLC) patients
J Clin Oncol (Meeting Abstracts) 2004 22: 2104. [Abstract]  

K. Charles, L. P. Rivory, M. Stockler, P. Beale, J. Beith, M. Boyer, and S. Clarke

Predictors of clinical outcomes of weekly docetaxel in patients with advanced cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 2105. [Abstract]  

S. Goel, S. Mani, T. Iqbal, K. Desai, R. A. Parise, R. Afroze, M. J. Egorin, and W. C. Zamboni

The effect of food on the oral absorption of 9-nitrocamptothecin (9NC) in patients with relapsed solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 2106. [Abstract]  

V. Berger, S. Dupuis, M. Boisdron-Celle, E. Gamelin, and P. Ritz

Total Body Water predicts 5-FU plasma concentration after the first cure of chemotherapy
J Clin Oncol (Meeting Abstracts) 2004 22: 2107. [Abstract]  

M. Gil-Delgado, G. Bastian, B. Paule, S. Urien, J.-P. Spano, G. Deguetz, K. Chouania, P. Saintini, J.-L. Breau, and D. Khayat

Pharmacokinetic study of oxaliplatin (lohp) and capecitabine combination in advanced colorectal cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 2108. [Abstract]  

L. Pusztai, B. W. Gregory, K. A. Baggerly, F. J. Esteva, C. Laronga, H. N. Gabriel, O. J. Semmes, G. L. Wright, D. R. Richard, and A. Vlahou

Pharmacoproteomic analysis of pre-and post-chemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 2109. [Abstract]  

M. N. Fishman, Y. Elsayed, N. Damjanov, J. L. Steinberg, J. J. Mahany, J. A. Nieves, S. P. Wanaski, J. L. Dul, and J. W. Sherman

Phase I study of liposome entrapped paclitaxel (LEP-ETU) in patients with advanced cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 2110. [Abstract]  

S. S. Krishnamurthi, J. M. Brell, K. M. Coviello, A. Dowlati, M. J. Egorin, C. L. Hoppel, S. T. Ingalls, S. P. Ivy, X. Li, and S. C. Remick

Phase I study of oxaliplatin (Ox), irinotecan (Irino), and capecitabine (Cape) in patients with solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 2111. [Abstract]  

T. Ryan, H. Hochster, J. Escalon, and F. M. Muggia

Results of a phase I study of fixed dose rate gemcitabine /irinotecan (FIGI)
J Clin Oncol (Meeting Abstracts) 2004 22: 2112. [Abstract]  

D. T. Friedman, S. Goel, K. Desai, D. Verdier-Pinard, A. Kaubisch, A. Bulgaru, F. Camacho, G. Goldberg, and S. Mani

A phase I clinical trial with weekly irinotecan (IRI) and capecitabine (CAP) in patients with advanced gastrointestinal and other solid malignancies
J Clin Oncol (Meeting Abstracts) 2004 22: 2113. [Abstract]  

C. F. Verschraegen, F. C. Lee, I. Rabinowitz, A. Mangalik, C. Jennings, A. Maestas, and Z. Shen

Phase I and translational study of capecitabine, cisplatin, and irinotecan in patients with solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 2114. [Abstract]  

T. Chen, A. Molina, S. Moore, S. Goel, K. Desai, A. Hamilton, T. Griffin, A. D. Colevas, S. Mani, and F. Muggia

Epothilone B analog (BMS-247550) at the recommended phase II dose (RPTD) in patients (pts) with gynecologic (gyn) and breast cancers
J Clin Oncol (Meeting Abstracts) 2004 22: 2115. [Abstract]  

K. Schimmel, R. Bennink, A. Van Kuilenburg, N. Steinmetz, M. Van Den Hoff, M. Pfaffendorf, A. Verschuur, and H.-J. Guchelaar

Cardiotoxicity of the experimental cytotoxic drug cyclopentenyl cytosine (CPEC) in rats
J Clin Oncol (Meeting Abstracts) 2004 22: 2116. [Abstract]  

A. Segura, C. Fernández-Martos, J. Aparicio, J. M. Campos, J. Vicent, I. Busquier, C. Molins, and V. Guillem

Phase I trial of cisplatin, infusional 5-FU and irinotecan in advanced gastric cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 2117. [Abstract]  

S. Radulovic and S. Bjelogrlic

Cardioprotective activities of dexrazoxane (D), amifostine (A) and D,L-alpha-tocopherol (E) against cardiotoxicity of doxorubicin (Dx) alone and in combination with cyclophosphamide (C)
J Clin Oncol (Meeting Abstracts) 2004 22: 2118. [Abstract]  

J. Porter, D. Murry, S. Dropcho, D. Seitz, P. Helft, C. Yoder, K. Fife, and C. J. Sweeney

A dose escalation and pharmacokinetic (PK) trial of weekly docetaxel combined with daily erlotinib in adult cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 2119. [Abstract]  

J. G. Maring, B. N. Oonk, E. G. E. De Vries, and G. A. P. Hospers

Plasma pharmacokinetics of uracil after an oral uracil challenge dose for dihydropyrimidine dehydrogenase (DPD) phenotyping
J Clin Oncol (Meeting Abstracts) 2004 22: 2120. [Abstract]  

M. Bibas, G. Zampa, and M. Moscato

Feasibility of twice-weekly schedule of paclitaxel and carboplatin for solid tumors: A 119 patients study
J Clin Oncol (Meeting Abstracts) 2004 22: 2121. [Abstract]  

K. H. Jung, D. H. Lee, H. K. Kim, J. Y. Han, I. J. Jang, Y. S. Park, S. Y. Joo, J. Ro, and J. S. Lee

Phase I clinical study of heptaplatin (H) and paclitaxel (P) in previously treated patients with advanced solid tumor
J Clin Oncol (Meeting Abstracts) 2004 22: 2122. [Abstract]  

Y. H. Park, B.-Y. Ryoo, S.-J. Choi, and H. T. Kim

Paclitaxel plus cisplatin in cancer of unknown primary site (CUP)
J Clin Oncol (Meeting Abstracts) 2004 22: 2123. [Abstract]  

F. Zustovich, G. Cartei, A. Trestin, G. Palù, M. Palumbo, L. Barzon, E. Franchin, M. Mattiazzi, S. Binato, and S. Zovato

Analysis of topoisomerase (TOP) expression in peripheral blood mononuclear cell (PBMCs) from patients (PTS) undergoing chemotherapy (CHT) for solid tumors( ST)
J Clin Oncol (Meeting Abstracts) 2004 22: 2124. [Abstract]  

J. Drevs, K. Mross, F. Kratz, M. Medinger, and C. Unger

Phase I dose-escalation and pharmacokinetic (PK) study of a(6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH) in patients with advanced cancers
J Clin Oncol (Meeting Abstracts) 2004 22: 2125. [Abstract]  

M. Nakagawa, F. Tanaka, K. Takenaka, and H. Wada

Efficacy of intrapleural administration of amrubicin, a novel anthracycline derivative, for disseminated pleural tumor model
J Clin Oncol (Meeting Abstracts) 2004 22: 2126. [Abstract]  

R. Goel, S. Gertler, D. J. Stewart, S. Laurie, G. Goss, N. Reaume, C. Cripps, D. Bedard, A. Rodgers, and D. Cutler

Phase I study of temozolomide in conjunction with gemcitabine
J Clin Oncol (Meeting Abstracts) 2004 22: 2127. [Abstract]  

L. A. White, N. N. Sjak-Shie, C. Kimminau, A. M. Schmidt, A. O. Greco, and J. R. Eckardt

Early results of a phase I study of weekly topotecan (T) in combination with weekly platinum compounds
J Clin Oncol (Meeting Abstracts) 2004 22: 2128. [Abstract]  

M. O' Leary, R. O' Connor, S. Roy, J. Ballot, W. Ooi, D. Fennelly, L. Sheehan, C. Collins, M. Clynes, and J. Crown

Phase I trial of the multi-drug resistance (MDR) Protein-1 (MRP-1) modulating agent sulindac (S) plus epirubicin (E) in patients (pts) with advanced cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 2129. [Abstract]  

L. K. Mattison, M. R. Johnson, W. Saif, A. S. Modak, Y. Hirao, T. Koga, T. Shimizu, and R. B. Diasio

Validation of a novel [2-¹³C]-uracil breath test (UraBT) to detect dihydropyrimidine dehydrogenase (DPD) deficiency by LC-MS-MS analysis of [2-¹³C]-uracil (URA) and [2-¹³C]-dihydrouracil (DHU) plasma levels
J Clin Oncol (Meeting Abstracts) 2004 22: 2130. [Abstract]  

S. J. Vukelja, W. E. Samlowski, S. P. Anthony, J. C. Arseneau, J. J. Nemunaitis, C. C. Cunningham, B. S. Berman, K. D. Fowers, and K. S. Callahan

A dose-escalation, Phase I study of a depot formulation of paclitaxel administered intralesionally in end-stage cancer patients with solid malignant tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 2131. [Abstract]  

A. Chiappori, G. R. Simon, L. Kvols, L. Tetteh, J. J. Mahany, R. Lush, and D. M. Sullivan

Phase I trial of carboplatin, irinotecan and etoposide in advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 2132. [Abstract]  

M. C. Boruban, M. O. Babaoglu, O. Sencan, A. Bozkurt, and U. Yasar

Tamoxifen inhibits cytochrome P450 2C9 activity: A possible mechanism for tamoxifen-warfarin interaction
J Clin Oncol (Meeting Abstracts) 2004 22: 2133. [Abstract]  

A. G. Floares, C. Floares, M. Cucu, M. Marian, and L. Lazar

Optimal drug dosage regimens in cancer chemotherapy with neural networks
J Clin Oncol (Meeting Abstracts) 2004 22: 2134. [Abstract]  

D. Shrayer, D. Essis, S. Mehta, and H. Wanebo

Ceramide, a mediator of apoptosis, synergizes with paclitaxel to induce regression of the L3.6 human pancreatic carcinoma implanted in SCID mice
J Clin Oncol (Meeting Abstracts) 2004 22: 2135. [Abstract]  

D. Bottke, T. Wiegel, A. M. Asemissen, K. Heufelder, W. Hinkelbein, and U. Keilholz

Induction of multidrug resistance on mRNA and on protein level by fractionated irradiation
J Clin Oncol (Meeting Abstracts) 2004 22: 2136. [Abstract]  

E. Kim, H. Hochster, Y. Novik, A. Chachoua, J. Speyer, and F. Muggia

A phase I study of carboplatin plus oral topotecan in advanced malignancies
J Clin Oncol (Meeting Abstracts) 2004 22: 2137. [Abstract]  

S. Tam, P. Gumerlock, I. Galvin, T. Kimura, R. Livingston, T. Thompson, and J. Gralow

Beta-tubulin III isotype expression and response to anti-tubulin therapy in metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2004 22: 2138. [Abstract]  

E. Barrajon, G. Esquerdo, A. Lopez, and C. Llorca

Schedule dependency of 5-fluorouracil (5FU) chemotherapy in patients with advanced colorectal cancer: A systematic review
J Clin Oncol (Meeting Abstracts) 2004 22: 2139. [Abstract]  

J. S. Kortmansky, N. Sauter, E. O'Reilly, M. Shah, G. K. Abou-Alfa, J. Winkelmann, S. Yi, M. Gonen, D. P. Kelsen, and G. K. Schwartz

Management of hyperglycemia in patients with metastatic pancreatic cancer receiving UCN-01 and fluorouracil
J Clin Oncol (Meeting Abstracts) 2004 22: 2140. [Abstract]  

A. Dudek, T. Larson, C. E. Mellskog, L. P. Bloss, and C. Obasaju

A phase I clinical study of biweekly pemetrexed and gemcitabine in patients with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 2141. [Abstract]  

Developmental Therapeutics: Immunotherapy:

U. Ricardi, S. Regazzoni, P. Ghio, D. Giachino, M. De Marchi, S. Novello, G. Selvaggi, and G. V. Scagliotti

The K751Q polymorphism of XPD gene in lung cancer patients receiving platinum-based chemotherapy
J Clin Oncol (Meeting Abstracts) 2004 22: 2500. [Abstract]  

E. H. Kraut, M. N. Fishman, P. M. Lorusso, J. L. Steinberg, J. A. Nieves, G. J. Fetterly, I. M. Darling, S. P. Wanaski, J. L. Dul, and J. W. Sherman

Pharmacogenomic and pharmacokinetic assessment of liposome encapsulated SN-38 (LE-SN38) in advanced cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 2501. [Abstract]  

A. C. Gowda, F. J. Hernandez-Ilizaliturri, G. Connolly, and M. S. Czuczman

Structural changes in the internal domain of the CD20 antigen is associated with the development of rituximab resistance: Effects on signaling and redistribution of CD20 into lipid raft domains in rituximab-resistant cell lines (RRCL)
J Clin Oncol (Meeting Abstracts) 2004 22: 2502. [Abstract]  

H. S. Rugo, R. S. Herbst, G. Liu, J. W. Park, M. S. Kies, Y. K. Pithavala, T. M. McShane, H. M. Steinfeldt, S. D. Reich, and G. Wilding

Clinical and dynamic imaging results of the first phase I study of AG–013736, an oral anti-angiogenesis agent, in patients (pts) with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 2503. [Abstract]  

M. Jaeger, M. A. Stroehlein, A. Schoberth, A. Burges, M. M. Heiss, and H. Lindhofer

Immunotherapy with the trifunctional antibody removab leads to significant elimination of tumor cells from malignant ascites in ovarian cancer: Results of a phase I/II study
J Clin Oncol (Meeting Abstracts) 2004 22: 2504. [Abstract]  

L. H. Camacho, A. Ribas, J. A. Glaspy, G. Lopez-Berestein, J. M. Reuben, C. Parker, E. Seja, B. Comin-Anduix, C. Bulanhagui, and J. Gomez-Navarro

Phase 1 clinical trial of anti-CTLA4 human monoclonal antibody CP-675,206 in patients (pts) with advanced solid malignancies
J Clin Oncol (Meeting Abstracts) 2004 22: 2505. [Abstract]  

J. Vieweg, Z. Su, and J. Dannull

Enhancement of antitumor immunity following depletion of CD4⁺CD25⁺ regulatory T cells
J Clin Oncol (Meeting Abstracts) 2004 22: 2506. [Abstract]  

Z. Su, J. W. Vieweg, J. Dannull, and P. Dahm

Vaccination of metastatic prostate cancer patients using mature dendritic cells transfected with mRNA encoding hTERT or an MHC class II targeted hTERT/LAMP fusion protein: Results from a phase I clinical trial
J Clin Oncol (Meeting Abstracts) 2004 22: 2507. [Abstract]  

M. Morse, T. Clay, A. Hobeika, T. Osada, D. Panicali, and H. K. Lyerly

Phase I study of immunization with dendritic cells (DC) modified with recombinant fowlpox encoding carcinoembryonic antigen (CEA) and the triad of costimulatory molecules CD54, CD58, and CD80 (rF-CEA(6D)-TRICOM) in patients with advanced malignancies
J Clin Oncol (Meeting Abstracts) 2004 22: 2508. [Abstract]  

W. Song and R. Levy

Therapeutic antitumor immunity induced by combined intratumoral injection of dendritic cells (DCs) and systemic chemotherapy in murine lymphoma
J Clin Oncol (Meeting Abstracts) 2004 22: 2509. [Abstract]  

Y. Soen, D. S. Chen, T. B. Stuge, J. S. Weber, P. P. Lee, P. O. Brown, and M. M. Davis

A novel cellular microarray identifies functional deficiencies in tumor-specific T cell responses
J Clin Oncol (Meeting Abstracts) 2004 22: 2510. [Abstract]  

A. D. Gilliam, E. G. Topuzov, A. M. Garin, I. Pulay, P. Broome, S. A. Watson, B. Rowlands, A. Takhar, and I. Beckingham

Randomised, double blind, placebo-controlled, multi-centre, group-sequential trial of G17DT for patients with advanced pancreatic cancer unsuitable or unwilling to take chemotherapy
J Clin Oncol (Meeting Abstracts) 2004 22: 2511. [Abstract]  

C. L. Bennett, S. Luminari, A. R. Nissenson, S. A. Klinge, N. McWilliams, J. McKoy, D. W. Raisch, B. Kim, N. Casadevall, and M. S. Tallman

Re-importation of pharmaceuticals may be unsafe: Lessons learned from the RADAR assessment of erythropoietin (EPO)-associated pure red cell aplasia (PRCA)
J Clin Oncol (Meeting Abstracts) 2004 22: 2512. [Abstract]  

H. L. Kaufman, R. Dipaola, M. Von Mehren, J. Marshall, H. K. Lyerly, H. Streicher, J. Schlom, D. Panicali, and T. Schuetz

Safety profile of therapeutic pox virus-based vaccines for cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 2513. [Abstract]  

T. Crombet, E. Neninger, M. Osorio, M. Catala, A. Torre, I. Leonard, B. Garcia, G. Gonzalez, R. Perez, and A. Lage

Vaccination with epidermal growth factor (EGF) for non small cell lung cancer (NSCLC) therapy: Preliminary results from a randomized phase II clinical trial
J Clin Oncol (Meeting Abstracts) 2004 22: 2514. [Abstract]  

Z. Li, Y. Qiao, B. Liu, and P. Srivastava

Heat shock protein 70-based vaccine stimulates both innate and adaptive immunity against chronic myeloid leukemia
J Clin Oncol (Meeting Abstracts) 2004 22: 2515. [Abstract]  

G. J. Ullenhag, J.-E. Frödin, M. Jeddi-Tehrani, K. Strigård, E. Eriksson, A. Samanci, B. Nilsson, E. D. Rossmann, S. Mosolits, and H. Mellstedt

Long lasting CEA specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and GM-CSF. The antibody response correlated significantly to survival
J Clin Oncol (Meeting Abstracts) 2004 22: 2516. [Abstract]  

E. Abruzzese, M. Bocchia, M. Trawinska, L. Morino, F. Iuliano, G. Orlandi, P. Panetta, G. Del Poeta, F. Lauria, and S. Amadori

Peptide-vaccine treatment associated with imatinib in patients with residual CML disease is able to induce both immunologic response and molecular remission
J Clin Oncol (Meeting Abstracts) 2004 22: 2517. [Abstract]  

J. S. Cebon, I. D. Davis, C. Barrow, H. Jackson, W. Hopkins, L. Miloradovic, P. Parente, S. Green, E. Hoffman, and W. Chen

Quantitation of immune responses against the cancer testis antigen NY-ESO-1 following vaccination with protein with and without ISCOMATRIX adjuvant
J Clin Oncol (Meeting Abstracts) 2004 22: 2518. [Abstract]  

F. E. Millard, M. Gerloni, D. Darrah, P. Farness, and M. Zanetti

Phase I study of transgenic B lymphocyte immunization (TLI) against telomerase in androgen-independent prostate cancer (PC)
J Clin Oncol (Meeting Abstracts) 2004 22: 2519. [Abstract]  

O. N. Koc, C. Redfern, P. Wiernik, F. Rosenfelt, J. Winter, T. Guthrie, L. Kaplan, P. Holman, J. Densmore, and J. Hainsworth

Successful anti-Id T-cell responses to Id-KLH immunotherapy in B-cell depleted patients with follicular lymphoma (FL) may prolong TTP after rituximab: Phase II trial of FavId
J Clin Oncol (Meeting Abstracts) 2004 22: 2520. [Abstract]  

R. A. Ibrahim, M. S. Achtar, V. E. Herrin, B. Gause, S. A. Bernstein, T. B. Brent-Steel, C. M. Maruffi, J. A. Berzofsky, and S. N. Khleif

Mutant P53 vaccination of patients with advanced cancers generates specific immunological responses
J Clin Oncol (Meeting Abstracts) 2004 22: 2521. [Abstract]  

P. M. Arlen, J. Gulley, W. Dahut, L. Skarupa, S. Morin, M. Pazdur, N. Todd, D. Panicali, K. Y. Tsang, and J. Schlom

A phase I study of sequential vaccinations with recombinant Fowlpox-PSA (L155)-TRICOM (rF)alone, or in combination with recombinant vaccinia-PSA (L155)-TRICOM (rV), and the role of GM-CSF, in patients (Pts) with prostate cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 2522. [Abstract]  

S. A. North, C. Yeung, K. Graham, D. Bodnar, and P. Venner

Phase II study of liposomal MUC1 vaccine in PSA failures post-radical prostatectomy (RP)
J Clin Oncol (Meeting Abstracts) 2004 22: 2523. [Abstract]  

H. M. Zarour, S. Land, C. Sander, R. Mascari, W. J. Storkus, J. Shipe-Spotloe, L. Stover, R. B. Herberman, S. S. Agarwala, and J. M. Kirkwood

Phase I-II vaccine trial with MHC class II and MHC class I epitopes from Melan-A/MART-1 for patients with metastatic melanoma
J Clin Oncol (Meeting Abstracts) 2004 22: 2524. [Abstract]  

G. Y. Ishioka, M. L. Disis, M. A. Morse, C. C. Cunningham, H.-J. Lenz, R. A. Figlin, R. W. Chesnut, and J. Fikes

A phase I trial of a multi-epitope cancer vaccine (EP-2101) in non-small cell lung (NSCLC) and colon cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 2525. [Abstract]  

D. E. Avigan, D. J. George, P. W. Kantoff, R. A. Figlin, D. W. Kufe, T. E. Olencki, M. J. Vasconcelles, B. S. Vasir, Y. Xu, and R. M. Bukowski

Interim safety and efficacy results from a phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma
J Clin Oncol (Meeting Abstracts) 2004 22: 2526. [Abstract]  

R. Porta, M. M. Dikov, J. M. Amann, and D. P. Carbone

Receptor selective retinoids promote monocyte (Mo) differentiation to mature dentritic cells (DC) in peripheral blood of cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 2527. [Abstract]  

P. Peethambaram, S. Alberts, K. Rinn, and L. A. Jones

Antigen presenting cell based immunotherapy targeting HER2/Neu positive solid tumors: Results of a phase 1 study of APC8024
J Clin Oncol (Meeting Abstracts) 2004 22: 2528. [Abstract]  

A. M. Al-Katib, A. Aboukameel, F. Beck, and R. Mohammad

Synergistic interaction between rituximab and 2-chlorodeoxyadenosine (2-CdA) against Waldenstrom's Macroglobulinemia preclinical model
J Clin Oncol (Meeting Abstracts) 2004 22: 2529. [Abstract]  

A. Casaco, G. López, R. Fernandez, L. Diaz, A. Perera, J. Batista, R. Leyva, Y. Peña, J. A. Rodriguez, and I. Garcia

Loco-regional radioimmunotherapy of high grade malignant gliomas using the humanized monoclonal antibody, h-R3, labeled with 188-Re
J Clin Oncol (Meeting Abstracts) 2004 22: 2530. [Abstract]  

S.-E. Al-Batran, A. Neumann, A. Atmaca, M. Ruppert, J. Karbach, G. Ritter, E. Hoffman, L. Old, A. Knuth, and E. Jaeger

LUD01–014: Phase 1/2 study of chimeric monoclonal antibody cG250 in combination with vinblastine in patients with advanced renal cell carcinoma (ARCC)
J Clin Oncol (Meeting Abstracts) 2004 22: 2531. [Abstract]  

M. Stroehlein, M. Jaeger, H. Lindhofer, C. Peschel, K. W. Jauch, and M. M. Heiss

Intraperitoneal immunotherapy of peritoneal carcinomatosis from solid tumors by trifunctional antibodies
J Clin Oncol (Meeting Abstracts) 2004 22: 2532. [Abstract]  

L. H. Le, H. W. Hirte, S. J. Hotte, M. Maclean, A. Iacobucci, A. Corey, N. L. Fox, and A. M. Oza

Phase I study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 4 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkin's lymphoma (NHL)
J Clin Oncol (Meeting Abstracts) 2004 22: 2533. [Abstract]  

C. F. Eisenbeis, J. Leonard, J. Rosenblatt, K. D. Khan, P. Porcu, S. Milan, S. E. Wilson, D. Hurst, M. A. Caligiuri, and L. Piro

Conversion of antibody-resistant cancer patients to antibody-sensitive: Investigation of Fc receptor polymorphisms and response to IL-2 and rituximab treatment in rituximab-refractory NHL patients
J Clin Oncol (Meeting Abstracts) 2004 22: 2534. [Abstract]  

A. H. Zea, M. B. Atkins, D. McDermont, A. O'Neil, M. Regan, C. Hernandez, A. Youmans, J. Desalvo, and A. Ochoa

Role of CD3 expression and arginase activity in predicting response and survival in metastatic renal cell carcinoma (mRCC) patients receiving IL-2
J Clin Oncol (Meeting Abstracts) 2004 22: 2535. [Abstract]  

F. S. Hodi, M. Seiden, M. Butler, F. G. Haluska, I. Lowy, E. Vincent-Brunick, D. Lautz, M. Mihm, and G. Dranoff

Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody blockade in patients previously vaccinated with irradiated, autologous tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor (GM-CSF)
J Clin Oncol (Meeting Abstracts) 2004 22: 2536. [Abstract]  

C. M. Kurbacher, E.-M. Cramer, K. Rhiem, P. K. Mallmann, and I. A. Cree

A pilot trial of chronic low-dosegranulocyte-macrophage colony-stimulating factor therapy in patients with intensively pretreated breast or female genital tract cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 2537. [Abstract]  

R. Kurzrock, I. Khouri, C. Bueso-Ramos, F. Giles, S. Pilat, D. A. Thomas, J. Cortes, and A. M. Tsimberidou

Low-dose interleukin-11 has activity in patients with bone marrow failure
J Clin Oncol (Meeting Abstracts) 2004 22: 2538. [Abstract]  

K. Muta, T. Ito, Y. Abe, K. Nagafuji, E. Baba, T. Matsushima, K. Mitsuki, S. Nakano, H. Nawata, and M. Harada

Nonmyeloablative allogeneic stem cell transplantation as immunotherapy for pancreatic cancer and other solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 2539. [Abstract]  

I. M. Borrello, R. Vij, R. A. Vescio, T. G. Martin, D. Siegel, J. R. Berenson, F. Janmohamed, M. Bonyhadi, R. J. Berenson, and M. W. Frohlich

A phase I/II study of Xcellerated T Cells after autologous peripheral blood stem cell transplantation in patients with multiple myeloma
J Clin Oncol (Meeting Abstracts) 2004 22: 2540. [Abstract]  

U. Toh, H. Yamana, T. Fujii, T. Sasatomi, S. Takamori, Y. Araki, E. Ogo, and K. Shirozou

Repeated immune cell transfer therapy combined with non myeloablative chemotherapy in patients with refractory recurrent gastrointestinal and lung cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 2541. [Abstract]  

E. Y. Chen, O. W. Press, and M. C. Jensen

CD8 immunomagnetic selection and interleukin-15 (IL-15) facilitate the isolation of human CD8⁺ cytotoxic T-lymphocytes (CTL) genetically engineered to express an anti-CD20 chimeric T-cell receptor (cTCR)
J Clin Oncol (Meeting Abstracts) 2004 22: 2542. [Abstract]  

D. L. Morton, R. Essner, E. C. Hsueh, L. A. Wanek, L. J. Foshag, S. J. O'Day, R. K. Gupta, D. S. Hoon, and G. Gammon

Active specific immunotherapy with a polyvalent cancer vaccine prolongs survival in AJCC stage IV melanoma
J Clin Oncol (Meeting Abstracts) 2004 22: 2543. [Abstract]  

P. Squiban, T. Velu, B. Mennecier, M. Pless, V. Morel, E. Levy, V. Richard, T. Maciejewska, N. Bizouarne, and E. Quoix

MVA-MUC1-IL2 vaccine immunotherapy for advanced non small cell lung cancer (NSCLC): Interim phase II data
J Clin Oncol (Meeting Abstracts) 2004 22: 2544. [Abstract]  

J.-F. Chatal, J.-L. Harousseau, F. Griesinger, J. Meller, C. Renner, C. M. Kirsch, R. Naumann, J. Kropp, W. A. Wegener, and D. M. Goldenberg

Radioimmunotherapy in non-Hodgkin's lymphoma (NHL) using a fractionated schedule of DOTA-conjugated, ⁹⁰Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab
J Clin Oncol (Meeting Abstracts) 2004 22: 2545. [Abstract]  

D. Ma, J. P. Gardner, C. E. Hopf, M. A. Cohen, G. P. Donovan, N. Schuelke, W. F. Goeckeler, and W. C. Olson

Fully human monoclonal antibodies to PSMA selectively target cytotoxins, radiotoxins and host immunity to prostate cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 2546. [Abstract]  

N. K. Ibrahim, J. Murray, J. Parker, L. Finke, and D. Miles

Humoral immune-response to naturally occurring STn in metastatic breast cancer patients (MBC pts) treated with STn-KLH vaccine
J Clin Oncol (Meeting Abstracts) 2004 22: 2547. [Abstract]  

G. Gonzalez, C. Viada, E. Neninger, T. Crombet, I. Leonard, B. Garcia, and A. Lage

Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: Analysis of pooled data from three clinical trials
J Clin Oncol (Meeting Abstracts) 2004 22: 2548. [Abstract]  

M. L. Glode, A. Pantuck, C. S. Higano, J. Meyer, L. Hami, S. Craig, R. J. Berenson, and M. W. Frohlich

A phase I/II trial of CD3/CD28 activated T cells (Xcellerated T Cells) in patients with hormone refractory prostate cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 2549. [Abstract]  

P. Masci, L. Rybicki, K. Tong, T. Olencki, B. Jacobs, L. Wood, and E. Borden

A Phase I evaluation of IFN -1b in solid tumors, lymphoma or myeloma
J Clin Oncol (Meeting Abstracts) 2004 22: 2550. [Abstract]  

D. Blaise, J. O. Bay, C. Faucher, M. Michallet, J. M. Boiron, J. Y. Cahn, M. Mohty, D. Maraninchi, and P. Viens

Reduced intensity conditioning regimen (RIC) followed by allogeneic stem cell transplantation (ASCT): Low related transplant mortality and high survival probability in patients with advanced solid tumors in a multicenter trial
J Clin Oncol (Meeting Abstracts) 2004 22: 2551. [Abstract]  

M. S. Zand, J. J. Ifthikharuddin, C. Abboud, and J. L. Liesveld

Induction of myeloma cell apoptosis by polyclonal rabbit anti-thymocyte globulin (rATG)
J Clin Oncol (Meeting Abstracts) 2004 22: 2552. [Abstract]  

M. J. Robertson, J. Mier, T. Logan, H. Koon, J. Weisenbach, S. Roberts, C. Oei, L. Kirby, S. Kathman, and L. Pandite

Tolerability and anti-tumor activity of recombinant human IL-18 (rhIL-18) administered as five daily intravenous infusions in patients with solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 2553. [Abstract]  

C. M. Richman, S. J. Denardo, R. T. O'Donnell, A. Yuan, A. Natarajan, T. Wun, J. M. Tuscano, H. L. Chew, P. N. Lara, and G. L. Denardo

Combined modality radioimmunotherapy (RIT) in metastatic prostate (PC) and breast cancer (BC) using paclitaxel (PT) and a MUC-1 monoclonal antibody, m170, linked to yttrium-90 (Y-90): A phase I trial
J Clin Oncol (Meeting Abstracts) 2004 22: 2554. [Abstract]  

R. Blumenthal, M. Rodriguez, C. Damoci, L. Osorio, H. J. Hansen, and D. M. Goldenberg

Therapeutic effects of anti-CEA (CEACAM5) and anti-NCA90 (CEACAM6) antibody monovalent fragments in vitro and in vivo
J Clin Oncol (Meeting Abstracts) 2004 22: 2555. [Abstract]  

N. M. Reddy, F. J. Hernandez-Ilizaliturri, and M. S. Czuczman

The role of natural killer (NK) cell expansion and activation on the in vivo anti-tumor activity of immunomodulatory drug (IMiD) CC4047 plus rituximab in a severe combined immunodeficiency (SCID) lymphoma mouse model
J Clin Oncol (Meeting Abstracts) 2004 22: 2556. [Abstract]  

D. A. Law, D. Afar, V. Bhaskar, E. Ibsen, R. Powers, D. Breinberg, M. Wong, R. Dubridge, V. Ramakrishnan, and R. Murray

Identification and validation of anti-TMEFF2-Auristatin E conjugated antibodies in the treatment of prostate cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 2557. [Abstract]  

I. D. Davis, Z. Liu, W. Saunders, F. T. Lee, V. Spirkoska, W. Hopkins, F. Smyth, E. W. Hoffman, L. J. Old, and A. M. Scott

A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients (pts) with advanced renal cell carcinoma (RCC)
J Clin Oncol (Meeting Abstracts) 2004 22: 2558. [Abstract]  

D. Morgensztern, J. D. Rosenblatt, D. G. Pham, K. Yi, S. Shah, K. A. Tolba, and H. Nechushtan

HSV amplicon mediated augmentation of antitumor effects induced by tumor-specific T cells in the lymphopenic host
J Clin Oncol (Meeting Abstracts) 2004 22: 2559. [Abstract]  

U. Prabhakar, H. Jang, Q. Jiao, J. Ford, B. E. Miller, M. A. Graham, and H. M. Davis

Correlation of serum CNTO 328-Anti IL-6 monoclonal antibody (MAb) concentrations and biomarker expression in renal cell carcinoma (RCC) patients
J Clin Oncol (Meeting Abstracts) 2004 22: 2560. [Abstract]  

A. Pachnio, S. Dietrich, W. Klapper, C. Schulte, M. Kneba, and C. Beck

A novel, selective, proliferation based procedure to eliminate alloreactive T-cells induces mixed chimerism and reduces GvHD in sublethally irradiated mice receiving allogeneic bone marrow transplantation
J Clin Oncol (Meeting Abstracts) 2004 22: 2561. [Abstract]  

R. Ridolfi, A. Riccobon, M. Petrini, L. Ridolfi, L. Fiammenghi, M. Stefanelli, M. Selva, and D. Amadori

Comparison between immature and mature dendritic cells in a vaccination trial
J Clin Oncol (Meeting Abstracts) 2004 22: 2562. [Abstract]  

D. Berd, T. Sato, J. Kuchar, T. Riley, and M. J. Mastrangelo

Phase I-II trial of a novel mixed haptenized autologous melanoma vaccine
J Clin Oncol (Meeting Abstracts) 2004 22: 2563. [Abstract]  

T. Schuetz, J. Marshall, H. L. Kaufman, H. Safran, and D. Panicali

Two phase I studies of prime-boost vaccinations with vaccinia-fowlpox vaccines expressing CEA, MUC-1, and TRICOM costimulatory molecules (B7.1/ICAM-1/LFA-3) in patients with advanced pancreatic cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 2564. [Abstract]  

M. B. Faries, E. C. Hsueh, S. Shu, E. Famatiga, and D. L. Morton

Post-vaccination CTLA-4 expression correlates inversely with survival in patients vaccinated with allogeneic melanoma cell vaccine
J Clin Oncol (Meeting Abstracts) 2004 22: 2565. [Abstract]  

W. G. Wierda, T. J. Kipps, J. Castro, M. J. Keating, J. Bole, B. Anderson, J. Meyer, K. Anderson, R. J. Berenson, and M. W. Frohlich

A Phase I/II trial of CD3/CD28 activated T cells in patients with chronic lymphocytic leukemia (CLL)
J Clin Oncol (Meeting Abstracts) 2004 22: 2566. [Abstract]  

A. M. Scott, N. Tebbutt, F.-T. Lee, T. Cavicchiolo, Z. Liu, A. Poon, M. W. Brechbiel, E. Stockert, E. W. Hoffman, and L. J. Old

Phase I trial of hu3S193 in patients with advanced epithelial cancers which express the Lewis-y antigen
J Clin Oncol (Meeting Abstracts) 2004 22: 2567. [Abstract]  

D. M. Wall, L. R. Mileshkin, H. M. Prince, B. E. Loveland, M. Thompson, J. Coverdale, J. Wong, P. X. Xing, R. Taylor, and R. J. Hicks

In vivo tracking of dendritic cell therapy in patients with multiple myeloma
J Clin Oncol (Meeting Abstracts) 2004 22: 2568. [Abstract]  

T. Nesselhut, R. Y. Chang, C. Matthes, D. Marx, D. R. Lorenzen, N. Cillien, M. Martin, R. Gorter, and J. H. Peters

Cancer therapy with unloaded monocyte-derived dendritic cells in patients with inoperable pancreatic and gall bladder cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 2569. [Abstract]  

G. A. Daniels and R. G. Vile

Sequential plasmid vaccinations targeting normal melanocytes protects against challenge with melanoma in a syngenic murine model
J Clin Oncol (Meeting Abstracts) 2004 22: 2570. [Abstract]  

M. Hokland, M. S. Petersen, C. C. Fleischer, S. B. Hansen, H. Stüdkilde-Jürgensen, U. Skands, J. Marqversen, T. Blankenstein, H. J. Gundersen, and R. Agger

Monitoring in vivo T cell traficking to tumors by positron emission tomography and magnetic resonance imaging
J Clin Oncol (Meeting Abstracts) 2004 22: 2571. [Abstract]  

J. J. Nemunaitis, C. C. Cunningham, N. N. Senzer, E. Haltom, B. Jones, S. J. Vukelja, D. A. Richards, and M. J. Uprichard

A phase 1 trial of PT-100 in patients receiving myelosuppressive chemotherapy
J Clin Oncol (Meeting Abstracts) 2004 22: 2572. [Abstract]  

J. T. Reynolds, D. Reinke, and S. Weiler

Irradiated haploidetical donor lymphocytes: A different approach to the immunotherapy of advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 2573. [Abstract]  

M. N. Brackin, L. A. Miller, N. K. Hutson, S. W. Morris, and G. H. MacDonald

Alphavirus immunotherapy of NPM/ALK+ anaplastic large cell lymphoma in a mouse model
J Clin Oncol (Meeting Abstracts) 2004 22: 2574. [Abstract]  

D. Jaeger, E. Saller, A. Zippelius, C. Frei, M. Gerlinger, T. Bartnick, E. Jaeger, and A. Knuth

The breast differentiation antigen NY-BR-1: A novel target antigen for active immunotherapy in breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 2575. [Abstract]  

R. Or, A. Ackerstein, S. Morecki, Y. Gelfand, S. Samuel, and S. Slavin

Treatment of patients with metastatic solid tumors with intentionally mismatched lymphocytes activated with rIL-2 in the outpatient setting
J Clin Oncol (Meeting Abstracts) 2004 22: 2576. [Abstract]  

T. R. Geldart, M. Harvey, N. Carr, M. Glennie, and P. Johnson

Cancer immunotherapy with a chimeric anti-CD40 monoclonal antibody: Evidence of preclinical efficacy
J Clin Oncol (Meeting Abstracts) 2004 22: 2577. [Abstract]  

O. J. Finn, T. Whiteside, J. McKolanis, A. J. Moser, H. Zeh, K. Lee, D. Bartlett, A. Schmotzer, and R. K. Ramanathan

A phase 1B study of a MUC1 pulsed autologous dendritic cell (DC) vaccine as adjuvant therapy in patients (Pts) with resected pancreatic or biliary tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 2578. [Abstract]  

A. B. Deisseroth, Y. Tang, L. Zhang, H. Akbulut, and P.-J. Linton

Vector vaccine overcomes anergy
J Clin Oncol (Meeting Abstracts) 2004 22: 2579. [Abstract]  

N. Singh, E. S. Yolcu, R. W. Miller, H. Shirwan, R. M. Huseby, O. Kilinc, D. Taylor, M. Oechsli, and R. Larocca

Primary tumor cells from cancer patients "decorated" with a novel form of CD80 protein effectively induce autologous T-cell responses ex-vivo
J Clin Oncol (Meeting Abstracts) 2004 22: 2580. [Abstract]  

W. Kindsvogel, S. Hughes, K. Bannink, M. Heipel, B. Johnson, R. Holly, P. Sivakumar, C. Clegg, E. L. Sievers, and D. Foster

IL-21 enhances rituximab-mediated killing of B-lymphoma cell lines in vitro and in vivo
J Clin Oncol (Meeting Abstracts) 2004 22: 2581. [Abstract]  

A. L. Yu, A. Batova, R. Gribi, M. Diccianni, L. Bridgeman, D. Geske, W. London, A. Gilman, and F. Ozkaynak

Antibody-dependent cellular cytotoxicity (ADCC) in COG ANBL0032: A phase III randomized trial of chimeric anti-GD2 and GM-CSF/IL2 in high risk neuroblastoma following myeloablative therapy and autologous stem cell transplant (ASCT)
J Clin Oncol (Meeting Abstracts) 2004 22: 2582. [Abstract]  

S. Ferrari, B. Rovati, E. Collovà, D. Grasso, P. Sagrada, C. Porta, A. Riccardi, and M. Danova

Impact of chemotherapy (CT) on ex-vivo generation of dendritic cells (DCs) in advanced breast cancer (ABC) patients (pts)
J Clin Oncol (Meeting Abstracts) 2004 22: 2583. [Abstract]  

J. P. Gardner, S. F. Slovin, D. M. Morrissey, G. P. Donovan, K. G. Surowitz, W. C. Olson, H. I. Scher, and R. J. Israel

Recombinant soluble prostate-specific membrane antigen (rsPSMA) vaccine: Preliminary findings of a Phase I safety/immunogenicity trial
J Clin Oncol (Meeting Abstracts) 2004 22: 2584. [Abstract]  

K. Shimizu, K. Tanigawa, N. Takeshita, A. Aruga, J. J. Mulé, and K. Takasaki

A phase I trial of combination therapy of tumor lysate-pulsed dendritic cells and adoptive transfer of anti-CD3 activated T cells (TP-DC/CAT) in patients with advanced gastrointestinal (GI) cancers
J Clin Oncol (Meeting Abstracts) 2004 22: 2585. [Abstract]  

S. G. Thakkar, P. Heeger, B. Wacker, M. Roddy, G. Waxenecker, G. Himmler, H. Loibner, P. Elson, and R. Bukowski

A phase Ib trial of an anti-idiotypic vaccine for Lewis Y (IGN 301) administered subcutaneously in patients with refractory solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 2586. [Abstract]  

L. Duval, H. Schmidt, J. J. Jensen, S. M. Soerensen, and H. Von der Maase

A phase I study of adoptive immunotherapy in melanoma using allogeneic cytotoxic T-lymphocytes transfected with a MART-1 receptor-encoding gene
J Clin Oncol (Meeting Abstracts) 2004 22: 2587. [Abstract]  

M. Bueter, M. Gasser, D. Meyer, N. Schramm, A. Mueller, A. M. Gassel, A. Trumpfheller, S. Mueller, A. Thiede, and A. M. Waaga-Gasser

Investigation of a possible escape mechanism in colorectal cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 2588. [Abstract]  

M. S. Achtar, R. A. Ibrahim, V. E. Herrin, B. Gause, S. A. Bernstein, T. B. Brent-Steel, C. M. Maruffi, J. A. Berzofsky, and S. N. Khleif

Vaccine therapy with tumor specific mutated VHL peptides in adult cancer patients with renal cell carcinoma
J Clin Oncol (Meeting Abstracts) 2004 22: 2589. [Abstract]  

L. Fong, B. Rini, B. Kavanaugh, and E. Small

CTLA-4 blockade-based immunotherapy for prostate cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 2590. [Abstract]  

N. Lewis, J. Gollob, R. Cohen, M. Thoreson, C. Oei, L. Kirby, K. Koch, L. Thurmond, M. Dar, and W. Bell

Phase I dose escalation study to assess tolerability and pharmacokinetics of recombinant human IL-18 (rhIL-18) administered as fourteen daily subcutaneous injections in patients with solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 2591. [Abstract]  

T. Radosevich, S. Kisselev, and C. Link

NK-92 cells transduced with retroviral vectors encoding marker genes and class I MHC suppression genes for improved use in adoptive cellular immunotherapy
J Clin Oncol (Meeting Abstracts) 2004 22: 2592. [Abstract]  

E. Lasalvia-Prisco, S. Cucchi, J. Vazquez, E. Lasalvia-Galante, W. Golomar, F. Cotto, and R. Otero

Colorectal cancer: Autologous immunogenicity in chemotherapy (5FU) pre-treated patients
J Clin Oncol (Meeting Abstracts) 2004 22: 2593. [Abstract]  

E. Garcia-Giralt, E. Lasalvia-Prisco, S. Cucchi, and J. Vazquez

Breast cancer: Updated vaccination with an autologous hemoderivative in changing tumor antigen library
J Clin Oncol (Meeting Abstracts) 2004 22: 2594. [Abstract]  

H. M. Prince, L. R. Mileshkin, D. Wall, M. Thompson, J. Wong, D. Rischin, E. Lau, P. Eu, F. Auzelle, and R. Hicks

F-18 Fluorodeoxyglucose (FDG) PET and Indium-111 SPECT scans to track the biodistribution of macrophage-activated killer (MAK) cells linked with MDX-H210 in patients with epithelial ovarian cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 2595. [Abstract]  

K. Hsu, J. F. Head, X. Jiang, and R. L. Elliott

Whole cell preparations of MCF-7 breast carcinoma cells are more active than lysed cell preparations in lymphocyte blastogenesis assays (LBAs) of breast cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 2596. [Abstract]  

J. B. Haanen, A. Bins, A. Jorritsma, A. De Lang, M. Smits, and T. Schumacher

A rapid and strong DNA vaccine optimized by in vivo analysis of antigen expression
J Clin Oncol (Meeting Abstracts) 2004 22: 2597. [Abstract]  

S. Hughes, L. Chin, K. Waggie, P. V. Sivakumar, C. Everson, and C. Clegg

Interleukin 21 efficacy in a mouse model of metastatic renal cell carcinoma
J Clin Oncol (Meeting Abstracts) 2004 22: 2598. [Abstract]  

M. Shibata, M. Suzuki, H. Kanou, H. Abe, and T. Kimura

Enhanced paradoxical type 2 responses generated by interleukin-12 in patients with gastric and colorectal cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 2599. [Abstract]  

M. Peters, A. Dasilva, D. Weckermann, R. Oberneder, B. Ebner, P. Kirchinger, A. Fetter, R. Köhne-Volland, P. Baeuerle, and P. Gjorstrup

Phase I study of the novel fully human monoclonal antibody MT201, directed against epithelial cellular adhesion molecule (Ep-CAM), in patients with hormone-refractory prostate cancer (HRPC)
J Clin Oncol (Meeting Abstracts) 2004 22: 2600. [Abstract]  

R. S. Coffin, B. Liu, Z. Han, G. Simpson, J. Hu, and C. Coombes

OncoVEX: A family of oncolytic herpes simplex viruses optimised for therapeutic use
J Clin Oncol (Meeting Abstracts) 2004 22: 2601. [Abstract]  

P. A. Reay, M. Yi-Sun, B. Liu, Y. McGrath, M. Wakeling, J. John, E. Turnbull, S. Thomas, and R. Coffin

ImmunoVEX ex vivo: A herpes simplex virus-based, dendritic cell-mediated anti-cancer vaccine platform
J Clin Oncol (Meeting Abstracts) 2004 22: 2602. [Abstract]  

J. Mayordomo, A. Tres, D. Miles, L. Finke, and H. Jenkins

Long-term follow-up of patients concomitantly treated with hormone therapy in a prospective controlled randomized multicenter clinical study comparing STn-KLH vaccine with KLH control in stage IV breast cancer following first-line chemotherapy
J Clin Oncol (Meeting Abstracts) 2004 22: 2603. [Abstract]  

E. Talor, J. Timar, G. Repassy, G. Szabo, E. Remenar, Z. Balatoni, and B. Zemplen

Leukocyte interleukin, injection (LI) treatment in advanced primary squamous cell carcinoma of the head & neck a phase II multi-center trial and pathology study
J Clin Oncol (Meeting Abstracts) 2004 22: 2605. [Abstract]  

J.-F. Baurain, N. Van Baren, C. Uyttenhove, V. Brichard, J.-P. Machiels, C. Gerard, T. Boon, and P. G. Coulie

Immunization of melanoma patients with a MAGE-3 peptide combined with IFNa
J Clin Oncol (Meeting Abstracts) 2004 22: 2606. [Abstract]  

J. F. Head, K. Hsu, X. Jiang, and R. L. Elliott

Multiple antigens in a breast cancer vaccine result in a higher immune response rate in breast cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 2607. [Abstract]  

H. Jang, U. Prabhakar, Q. Jiao, J. Ford, B. E. Miller, H. M. Davis, and M. A. Graham

Pharmacokinetic/pharmacodynamic (PK/PD) modeling and trial simulations to guide dose selection with CNTO 328, a chimeric anti-IL-6 monoclonal antibody (MAb), in patients with renal cell carcinoma (RCC)
J Clin Oncol (Meeting Abstracts) 2004 22: 2608. [Abstract]  

H. M. Davis, U. Prabhakar, H. Jang, Q. Jiao, M. Trikha, J. Ford, C. Joel, A. Fasanmade, and M. A. Graham

A rational approach for a phase I clinical study design to evaluate CNTO 95, a novel, fully human anti-a_vmonoclonal antibody (MAb), in patients with solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 2609. [Abstract]  

E. Neninger, G. Gonzalez, T. Crombet, G. Fleites, I. Leonard, M. Gonzalez, T. Badia, and A. Lage

Optimized phase I-II trial design for vaccination with epidermal growth factor (EGF): Effect on immunogenicity and safety
J Clin Oncol (Meeting Abstracts) 2004 22: 2610. [Abstract]  

J. L. Zapas, J. H. Hasskamp, S. L. Beam, S. D. Brown, K. A. Jablonski, and E. G. Elias

The effects of systemic granulocyte-macrophage colony stimulating factor (GM-CSF) and Interleukin-2 (IL-2) on peripheral blood dendritic cell (DC) counts in patients with stage IIB-IV melanoma
J Clin Oncol (Meeting Abstracts) 2004 22: 2611. [Abstract]  

F. Schuetz, K. Ehlert, G. Bastert, A. Schneeweiss, V. Schirrmacher, I. Diel, S. Costa, and P. Beckhove

Cellular immunotherapy in late stage breast cancer patients with reactivated autologous Memory T-cells (MTC) derived from bone marrow (BM)
J Clin Oncol (Meeting Abstracts) 2004 22: 2612. [Abstract]  

R. E. Jimenez, V. Monterroso, F. Brenes, I. Quesada, A. Purcell, and J. Arosemena

HER-2/neu overexpression in breast carcinoma: an immunohistochemical study in 1426 patients from Central America and the Caribbean
J Clin Oncol (Meeting Abstracts) 2004 22: 2613. [Abstract]  

Z. Zhao

The clinical observation of G-CSF used in supplementary chemotherapy of cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 2614. [Abstract]  

K. Okinaga, H. Iinuma, T. Ogiwara, and F. Ogawa

A phase I study of immunotherapy with tumor cell-dendritic cell fusion vaccine in patients with advanced or recurrent gastrointestinal cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 2615. [Abstract]  

X. S. Wang, S. Giralt, C. L. Warneke, T. R. Mendoza, M. Albitar, J. O. Brown, K. O. Anderson, and C. S. Cleeland

Longitudinal assessment of IL-6 and symptom severity in multiple myeloma patients during first 30 days of autologous BMT
J Clin Oncol (Meeting Abstracts) 2004 22: 2616. [Abstract]  

C. Doehn, N. Esser, H.-G. Pauels, D. Jocham, and J. Drevs

A renal cancer cell (RENCA) vaccine successfully inhibits tumor induction and progression in a murine renal cancer model
J Clin Oncol (Meeting Abstracts) 2004 22: 2617. [Abstract]  

C. G. Wood, B. Escudier, S. Gorelov, K. Krajka, L. Lacombe, S. Fossa, A. Hoos, R. Flanigan, R. Figlin, and P. Srivastava

A multicenter randomized study of adjuvant heat-shock protein peptide-complex 96 (HSPPC-96) vaccine in patients with high-risk of recurrence after nephrectomy for renal cell carcinoma (RCC)-a preliminary report
J Clin Oncol (Meeting Abstracts) 2004 22: 2618. [Abstract]  

H. Loibner, H. Eckert, N. Eller, F. Groiss, G. Himmler, F. Rosenkaimer, M. Salzberg, H. Samonigg, M. Schuster, and A. Settaf

A randomized placebo-controlled phase II study with the cancer vaccine IGN101 in patients with epithelial solid organ tumors (IGN101/2–01)
J Clin Oncol (Meeting Abstracts) 2004 22: 2619. [Abstract]  

G. R. Rossi, R. C. Unfer, M. R. Ackermann, T. Seregina, and C. J. Link

Treatment of pre-established subcutaneous tumor and pulmonary melanoma metastasis with a novel vaccine expressing (1,3)Galactosyl Xenoepitopes
J Clin Oncol (Meeting Abstracts) 2004 22: 2620. [Abstract]  

W. Peng, X. Zhang, G. Inghirami, K. Takeshita, A. Pecora, L. Nardone, L. Casey, and G. Spitalny

An anti-C3b/iC3b monoclonal antibody (Mab) as an adjuvant to rituximab killing of non-Hodgkin's lymphoma (NHL) and chronical lymphocytic leukemia (CLL) cells
J Clin Oncol (Meeting Abstracts) 2004 22: 2621. [Abstract]  

D. S. Young, D. Sayegh, J. Desousa-Hitzler, and S. E. Hahn

ARH460–16-2: a therapeutic monoclonal antibody targeting CD44 in Her2/neu negative breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 2622. [Abstract]  

T. S. Crocenzi, C. G. Tretter, J. Fisher, N. Crosby, D. Truman, and M. S. Ernstoff

Induction of T cell precursors in advanced melanoma treated with autologous tumor lysate loaded dendritic cells
J Clin Oncol (Meeting Abstracts) 2004 22: 2623. [Abstract]  

D. V. Oruzio, C. Aulmann, N. Eller, G. Mudde, O. Obwaller, G. Waxenecker, O. Scheiber, S. Stranner, and G. Schlimok

Results from a phase I clinical trial with IGN311, a fully humanized IgG1 antibody against Lewis Y in patients with solid tumors expressing Lewis Y antigen
J Clin Oncol (Meeting Abstracts) 2004 22: 2624. [Abstract]  

S. W. Heeger, G. Moldenhauer, J. M. Flynn, G. Egerer, T. Nikula, C. Apostolidis, M. Brechbiel, U. Haberkorn, A. D. Ho, and R. Haas

Radioimmunotherapy of B-lineage non-Hodgkin's lymphoma using anti-CD19 and anti-CD20 conjugates
J Clin Oncol (Meeting Abstracts) 2004 22: 2625. [Abstract]  

Developmental Therapeutics: Molecular Therapeutics:

M. L. Rothenberg, B. Lafleur, M. K. Washington, D. E. Levy, S. L. Morgan-Meadows, R. K. Ramanathan, J. D. Berlin, A. I. B. Benson, and R. J. Coffey

Changes in epidermal growth factor receptor signaling in serum and tumor biopsies obtained from patients with progressive metastatic colorectal cancer (MCRC) treated with gefitinib (ZD1839): an Eastern Cooperative Oncology Group study
J Clin Oncol (Meeting Abstracts) 2004 22: 3000. [Abstract]  

G. D. Demetri, J. Desai, J. A. Fletcher, J. A. Morgan, C. D. M. Fletcher, A. Kazanovicz, A. Van Den Abbeele, C. Baum, R. Maki, and M. C. Heinrich

SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST)
J Clin Oncol (Meeting Abstracts) 2004 22: 3001. [Abstract]  

A. T. Van Oosterom, H. Dumez, J. Desai, S. Stroobants, A. D. Van Den Abbeele, P. Clement, N. Shand, J. Kovarik, A. Tsyrlova, and G. D. Demetri

Combination signal transduction inhibition: a phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM
J Clin Oncol (Meeting Abstracts) 2004 22: 3002. [Abstract]  

N. Spector, W. Xia, H. A. Burris, H. Hurwitz, C. Dees, A. Dowlati, C. McKay, K. Koch, J. Harris, and S. Bacus

Modulation of tumor growth and survival pathways in cancer patients treated with GW572016
J Clin Oncol (Meeting Abstracts) 2004 22: 3003. [Abstract]  

F. Cappuzzo, E. Magrini, S. Bartolini, G. Ceresoli, V. Ludovini, V. Gregorc, C. Ligorio, L. Lombardo, and L. Crinò

Improved efficacy of gefitinib therapy in phospho-Akt positive patients with advanced non-small cell lung cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 3004. [Abstract]  

S. Perea, D. Oppenheimer, M. Amador, G. Cusati, S. Baker, C. Takimoto, A. Maitra, C. Iacobuzio-Donahue, and M. Hidalgo

Genotypic bases of EGFR inhibitors pharmacological actions
J Clin Oncol (Meeting Abstracts) 2004 22: 3005. [Abstract]  

K. L. Blackwell, E. H. Kaplan, S. X. Franco, P. K. Marcom, J. E. Maleski, M. J. Sorensen, and M. S. Berger

A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 3006. [Abstract]  

L. Garland, C. Rankin, K. Scott, R. Nagle, M. Lobell, D. Gandara, S. Rivkin, W. Samlowski, J. Atkins, and E. Borden

Molecular correlates of the EGFR signaling pathway in association with SWOG S0218: a phase II study of oral EGFR tyrosine kinase inhibitor OSI-774 (NSC-718781) in patients with malignant pleural mesothelioma (MPM)
J Clin Oncol (Meeting Abstracts) 2004 22: 3007. [Abstract]  

A. M. Levine, D. I. Quinn, G. Gorospe, H. J. Lenz, and A. Tulpule

Phase I trial of anti-sense oligonucleotide vascular endothelial growth factor (VEGF-AS, Veglin) in patients with relapsed and refractory malignancies
J Clin Oncol (Meeting Abstracts) 2004 22: 3008. [Abstract]  

J. Dupont, L. Schwartz, J. Koutcher, D. Spriggs, M. Gordon, D. Mendelson, J. Murren, A. Lucarelli, and J. Cedarbaum

Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies
J Clin Oncol (Meeting Abstracts) 2004 22: 3009. [Abstract]  

J. Desai, S. Shankar, M. C. Heinrich, J. A. Fletcher, C. D. M. Fletcher, K. Tuncali, S. G. Silverman, A. D. Van Den Abbeele, E. Vansonnenberg, and G. D. Demetri

Clonal evolution of resistance to imatinib (IM) in patients (pts) with gastrointestinal stromal tumor (GIST): molecular and radiologic evaluation of new lesions
J Clin Oncol (Meeting Abstracts) 2004 22: 3010. [Abstract]  

C. H. Holdsworth, J. Manola, R. D. Badawi, D. A. Israel, C. Blanke, M. Von Mehren, H. T. Joensuu, S. Dimitrijevic, G. D. Demetri, and A. D. Van Den Abbeele

Use of computerized tomography (CT) as an early prognostic indicator of response to imatinib mesylate (IM) in patients with gastrointestinal stromal tumors (GIST)
J Clin Oncol (Meeting Abstracts) 2004 22: 3011. [Abstract]  

A. D. Van Den Abbeele, R. D. Badawi, J. Manola, J. A. Morgan, J. Desai, A. Kazanovicz, M. St. Armand, C. Baum, and G. D. Demetri

Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning
J Clin Oncol (Meeting Abstracts) 2004 22: 3012. [Abstract]  

J. C. Yao, C. Charnsangavej, S. C. Faria, J. Szklaruk, H. Chen, P. Hoff, A. Phan, S.-C. J. Yeung, J. L. Abbruzzese, and J. A. Ajani

Rapid decrease in blood flow (BF), blood volume (BV), and vascular permeability (PS) in carcinoid patients treated with bevacizumab
J Clin Oncol (Meeting Abstracts) 2004 22: 3013. [Abstract]  

R. B. Cohen, G. Simon, C. J. Langer, J. R. Schol, J. McHale, P. Eisenberg, J. D. Hainsworth, K. F. Liau, and D. Healey

Phase I trial of oral CP-547,632 (VEGFR2) in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC)
J Clin Oncol (Meeting Abstracts) 2004 22: 3014. [Abstract]  

L. Orlando, M. Colleoni, F. Bertolini, R. Ghisini, G. Sanna, V. Formica, F. Nolè, G. Viale, L. Franceschelli, and A. Goldhirsch

Metronomic oral chemotherapy (CT) versus the same regimen in association with Thalidomide (TLM): results of a randomized trial in patients (pts) with advanced breast cancer (ABC)
J Clin Oncol (Meeting Abstracts) 2004 22: 3015. [Abstract]  

R. Buckstein, M. Crump, Y. Shaked, C. Foden, R. Nayar, D. Taylor, F. Bertolini, S. Baruchel, S. Man, and R. Kerbel

Palliation of relapsed aggressive histology NHL with high-dose celecoxib and 'metronomic' low-dose cyclophosphamide
J Clin Oncol (Meeting Abstracts) 2004 22: 3016. [Abstract]  

B. J. Giantonio, H. X. Chen, P. J. Catalano, N. J. Meropol, P. J. O'Dwyer, and A. I. B. Benson

Bowel perforation and fistula formation in colorectal cancer patients treated on Eastern Cooperative Oncology Group (ECOG) studies E2200 and E3200
J Clin Oncol (Meeting Abstracts) 2004 22: 3017. [Abstract]  

T. Trarbach, T. Beyer, N. Schleucher, J. Stattaus, S. P. Mueller, D. Appel, J. Tillner, K. W. Schmid, S. Seeber, and U. Vanhoefer

A randomized phase I study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in subjects with advanced gastrointestinal cancers
J Clin Oncol (Meeting Abstracts) 2004 22: 3018. [Abstract]  

Q. Zhou, C. Kibat, Y. B. Cheung, E. H. Tan, P. Ang, and C. Balram

Pharmacogenetics of the epidermal growth factor receptor (EGFR) gene in Chinese, Malay and Indian populations
J Clin Oncol (Meeting Abstracts) 2004 22: 3019. [Abstract]  

M. Isomura, M. Fukuoka, S. Sone, M. Matsuura, T. Noda, T. Muto, and Y. Miki

Identification of single nucleotide polymorphisms (SNPs) associated with adverse effects of gefinitib
J Clin Oncol (Meeting Abstracts) 2004 22: 3020. [Abstract]  

L. Wojnowski, G. Schlueter, S. Vonhof, B. Kulle, H. Bickeboeller, M. Loeffler, M. Pfreundschuh, J. Brockmoeller, G. Hasenfuss, and L. Trumper

Nad(p)h oxidase and MRP genetic polymorphisms associate with doxorubicin-induced cardiotoxicity
J Clin Oncol (Meeting Abstracts) 2004 22: 3021. [Abstract]  

E. K. Rowinsky, S. Pacey, A. Patnaik, A. O'Donnell, M. M. Mita, P. Atadja, B. Peng, M. Dugan, J. W. Scott, and J. S. De Bono

A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 3022. [Abstract]  

R. S. Kristeleit, D. Tandy, P. Atadja, A. Patnaik, J. Scott, J. S. De Bono, I. Judson, S. B. Kaye, P. Workman, and W. Aherne

Effects of the histone deacetylase inhibitor (HDACI) LAQ824 on histone acetylation, Hsp70 and c-Raf in peripheral blood lymphocytes from patients with advanced solid tumours enrolled in a phase I clinical trial
J Clin Oncol (Meeting Abstracts) 2004 22: 3023. [Abstract]  

O. G. Ottmann, D. J. Deangelo, R. M. Stone, H. Pfeifer, B. Lowenberg, P. Atadja, B. Peng, J. W. Scott, M. Dugan, and P. Sonneveld

A Phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase inhibitor LAQ824 in patients with hematologic malignancies
J Clin Oncol (Meeting Abstracts) 2004 22: 3024. [Abstract]  

J. Beck, T. Fischer, E. Rowinsky, C. Huber, M. Mita, P. Atadja, B. Peng, C. Kwong, M. Dugan, and A. Patnaik

Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of LBH589A: A novel histone deacetylase inhibitor
J Clin Oncol (Meeting Abstracts) 2004 22: 3025. [Abstract]  

L. Gore, S. N. Holden, M. Basche, S. K. S. Raj, I. Arnold, C. O'Bryant, S. Witta, B. Rohde, C. McCoy, and S. G. Eckhardt

Updated results from a phase I trial of the histone deacetylase (HDAC) inhibitor MS-275 in patients with refractory solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 3026. [Abstract]  

G. Garcia-Manero, J.-P. Issa, J. Cortes, C. Koller, S. O'brien, E. Estey, A. A. Canalli, J. Chiao, V. Richon, and H. Kantarjian

Phase I study of oral suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, in patients (pts) with advanced leukemias or myelodysplastic syndromes (MDS)
J Clin Oncol (Meeting Abstracts) 2004 22: 3027. [Abstract]  

R. Piekarz, R. Frye, M. Turner, J. Wright, J. Leonard, S. Allen, and S. Bates

Update on the phase II trial and correlative studies of depsipeptide in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma
J Clin Oncol (Meeting Abstracts) 2004 22: 3028. [Abstract]  

P. Chinnaiyan, S. Varambally, S. A. Tomlins, S. Huang, A. M. Chinnaiyan, and P. M. Harari

Enhancing the anti-tumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition
J Clin Oncol (Meeting Abstracts) 2004 22: 3029. [Abstract]  

C. Erlichman, D. Toft, J. Reid, M. Goetz, M. Ames, S. Mandrekar, A. Ajei, A. McCollum, and P. Ivy

A phase I trial of 17-allylamino-geldanamycin (17AAG) in patients with advanced cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 3030. [Abstract]  

R. K. Ramanathan, D. L. Trump, J. L. Eiseman, C. P. Belani, S. S. Agarwala, E. G. Zuhowski, J. Lan, P. Ivy, S. Tutchko, and M. E. Egorin

A phase I pharmacokinetic (PK) and pharmacodynamic (PD) trial of weekly 17-allylamino-17 demethoxygeldanamycin (17AAG, NSC-704057) in patients with advanced tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 3031. [Abstract]  

D. B. Solit, M. Egorin, G. Valentin, A. Delacruz, Q. Ye, L. Schwartz, S. Larson, N. Rosen, and H. I. Scher

Phase 1 pharmacokinetic and pharmacodynamic trial of docetaxel and 17AAG (17-allylamino-17-demethoxygeldanamycin)
J Clin Oncol (Meeting Abstracts) 2004 22: 3032. [Abstract]  

K. N. Chi, E. Eisenhauer, L. Fazli, E. C. Jones, J. Powers, D. Ayers, S. L. Goldenberg, and M. E. Gleave

A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of OGX-011, a 2'methoxyethyl phosphorothioate antisense to clusterin, in patients with prostate cancer prior to radical prostatectomy
J Clin Oncol (Meeting Abstracts) 2004 22: 3033. [Abstract]  

D. D. Von Hoff, C. Taylor, S. Rubin, J. Cohen, and L. Garland

A Phase I and pharmacokinetic study of HMN-214, a novel oral polo-like kinase inhibitor, in patients with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 3034. [Abstract]  

R. Hassan, S. Bullock, R. J. Kreitman, H. L. Kindler, and I. Pastan

Targeted therapy of mesothelin expressing mesotheliomas (MM), ovarian cancer (OC) and pancreatic cancer (PC): Results of phase I study of SS1(dsFv)PE38 (SS1P)
J Clin Oncol (Meeting Abstracts) 2004 22: 3035. [Abstract]  

G. Wilding, M. Carducci, D. C. Yu, J. Burke, F. Borellini, J. Aimi, P. Working, D. Ando, D. Kirn, and E. Small

A Phase 1/11 trial of IV CG7870, a replication-selective, PSA-targeted oncolytic adenovirus (OAV), for the treatment of hormone-refractory, metastatic prostate cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 3036. [Abstract]  

S. J. Hotte, P. P. Major, H. W. Hirte, S. Polawski, M. K. Bamat, N. Rheaume, W. S. Groene, M. S. Roberts, J. A. Miller, and R. M. Lorence

Slow intravenous infusion of PV701, an oncolytic virus: Final results of a phase I study
J Clin Oncol (Meeting Abstracts) 2004 22: 3037. [Abstract]  

N. Senzer, T. Chung, J. R. Hecht, J. Neumuniatis, M. Javle, T. Reid, J. Macko, M. Posner, K. J. Chang, and N. Hanna

Safety and efficacy of TNFerade in unresectable, locally advanced pancreatic cancer (LAPC): Results of the first three cohorts of a dose-escalating study
J Clin Oncol (Meeting Abstracts) 2004 22: 3038. [Abstract]  

M. Urosevic, P. Bleuzen, B. Acres, V. Bataille, P. Slos, G. Burg, P. Squiban, and R. Dummer

Phase I/II study of adenovirus-interferon- (TG1042) in primary cutaneous lymphomas (CL)
J Clin Oncol (Meeting Abstracts) 2004 22: 3039. [Abstract]  

S. Gurubhagavatula, W. Zhou, S. Park, D. S. Neuberg, T. J. Lynch, J. C. Wain, L. Su, G. Liu, and D. C. Christiani

Nucleotide excision repair (NER) gene haplotypes and advanced non-small cell lung cancer (NSCLC) prognosis
J Clin Oncol (Meeting Abstracts) 2004 22: 3040. [Abstract]  

J. Gaudreault, R. Bruno, F. Kabbinavar, A. Sing, D. H. Johnson, and J. Lu

Clinical pharmacokinetics of bevacizumab following every 2- or every 3-week dosing
J Clin Oncol (Meeting Abstracts) 2004 22: 3041. [Abstract]  

J. D. White, J. Cassidy, C. Twelves, C. Benson, S. Pacey, I. Judson, H. McGrath, F. Rose, and L. Frenz

A phase I trial of the oral cyclin dependent kinase inhibitor CYC202 in patients with advanced malignancy
J Clin Oncol (Meeting Abstracts) 2004 22: 3042. [Abstract]  

J. Hoffend, A. Mohammed, M. Eisenhut, F. Bosch, A. Dietz, O. Rosen, A. Kovar, D. Weber, J. Tillner, and U. Haberkorn

Uptake of the anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 in tumors of subjects with head and neck squamous cell carcinoma (HNSCC)
J Clin Oncol (Meeting Abstracts) 2004 22: 3043. [Abstract]  

V. Knezevic, K. K. Iwata, G. Baibakova, J. Wolf, G. Biesecker, and F. Richardson

Development of a HER1 assay using individual human hair follicles
J Clin Oncol (Meeting Abstracts) 2004 22: 3044. [Abstract]  

C. D. Britten, M. Pegram, P. Rosen, R. S. Finn, A. Wax, L. Bosserman, L. Gordon, L. S. Lin, R. Mass, and D. J. Slamon

Targeting ErbB receptor interactions: A phase I trial of trastuzumab and erlotinib in metastatic HER2+ Breast Cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 3045. [Abstract]  

R. Valkema, L. K. Kvols, S. Pauwels, F. Jamar, R. Barone, J. Lasher, and E. P. Krenning

Peptide receptor radiotherapy (PRRT) with [Y-90-DOTA,Tyr3]octreotide: Toxicity and efficacy of 4-cycle and single-cycle regimens
J Clin Oncol (Meeting Abstracts) 2004 22: 3046. [Abstract]  

M. Versola, H. A. Burris, S. Jones, G. Wilding, C. Taylor, L. Pandite, D. A. Smith, A. Stead, and N. L. Spector

Clinical activity of GW572016 in EGF10003 in patients with solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 3047. [Abstract]  

H. Minami, K. Nakagawa, K. Kawada, H. Mukai, M. Tahara, T. Kurata, H. Uejima, T. Nogami, Y. Sasaki, and M. Fukuoka

A phase I study of GW572016 in patients with solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 3048. [Abstract]  

H. Richly, P. Kupsch, K. Passarge, M. Grubert, R. A. Hilger, C. G. Haase, B. Schwartz, M. E. Scheulen, S. Seeber, and D. Strumberg

Results of a phase I trial of BAY 43–9006 in combination with doxorubicin in patients with refractory solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 3049. [Abstract]  

M. Beeram, E. K. Rowinsky, G. R. Weiss, S. Syed, A. Mita, A. Patnaik, M. Mita, M. Goldston, J. S. De Bono, and A. W. Tolcher

Durable disease stabilization and antitumor activity with OSI-774 in renal cell carcinoma: A phase II, pharmacokinetic (PK) and biological correlative study with FDG-PET imaging
J Clin Oncol (Meeting Abstracts) 2004 22: 3050. [Abstract]  

J. V. Heymach, R.-P. Dong, I. Dimery, C. Wheeler, P. Fidias, C. Lu, B. Johnson, and R. Herbst

ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: Results of the run-in phase of a two-part, randomized phase II study
J Clin Oncol (Meeting Abstracts) 2004 22: 3051. [Abstract]  

W. A. Messersmith, S. D. Baker, K. Dinh, L. K. Lassiter, R. A. Akdamar, J. J. Wright, R. C. Donehower, M. A. Carducci, and D. K. Armstrong

Phase I trial of bortezomib (PS-341) in combination with docetaxel in patients with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 3052. [Abstract]  

R. D. Rao, J. M. Reid, M. P. Goetz, A. F. Furth, S. J. Mandrekar, A. A. Adjei, M. M. Ames, S. L. Safgren, C. Erlichman, and H. C. Pitot

Phase I trial of OSI-774 and CPT-11 in patients with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 3053. [Abstract]  

A. B. Suttle, H. Hurwitz, A. Dowlati, N. Fernando, S. Savage, K. Coviello, M. Dar, P. Ertel, B. Whitehead, and L. Pandite

Pharmacokinetics (PK) and tolerability of GW786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 3054. [Abstract]  

M. Medinger, K. Mross, U. Zirrgiebel, R. Strecker, C. Wheeler, G. Clack, J. Lewis, T. A. Puchalski, C. Unger, and J. Drevs

Phase I dose-escalation study of the highly potent VEGF receptor kinase inhibitor, AZD2171, in patients with advanced cancers with liver metastases
J Clin Oncol (Meeting Abstracts) 2004 22: 3055. [Abstract]  

P. Kupsch, K. Passarge, H. Richly, K. Wiesemann, R. A. Hilger, C. G. Haase, B. Schwartz, M. E. Scheulen, S. Seeber, and D. Strumberg

Results of a phase I trial of BAY 43–9006 in combination with oxaliplatin in patients with refractory solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 3056. [Abstract]  

G. R. Simon, S. Olson, C. R. Garrett, I. Eiseman, M. Langevin, J. J. Mahany, D. M. Sullivan, M. G. Schlicht, R. Lush, and P. Lanehan

Phase I pharmacokinetic (PK) and safety study of intravenous (IV) CI-1033 in patients with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 3057. [Abstract]  

P. Haluska, D. O. Toft, S. M. Steinmetz, A. Furth, S. Mandrekar, B. A. Stensgard, A. K. McCollum, L. J. Hanson, A. A. Adjei, and C. Erlichman

A phase I trial of gemcitabine (Gem), 17-allylaminogeldanamycin (17-AAG) and cisplatin (CDDP) in solid tumor patients
J Clin Oncol (Meeting Abstracts) 2004 22: 3058. [Abstract]  

L. L. Siu, C. H. Takimoto, A. Awada, M. J. Moore, M. Piccart, M. Poulin-Costello, C. Lathia, and O. Petrenciuc

A phase I/II trial of BAY 43–9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 3059. [Abstract]  

A. W. Tolcher, M. Mita, A. Patnaik, E. K. Rowinsky, A. Corey, M. Fleming, N. L. Fox, L. M. Weiner, N. J. Meropol, and R. Cohen

A phase I and pharmacokinetic study of HGS-ETR1(TRM-1), a human monoclonal agonist-antibody to TRAIL R1, in patients with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 3060. [Abstract]  

U. Graeven, I. Vogel, B. Killing, S. Hinz, W. Von Bernstorff, J. Baselga, F. Rojo, J. Tillner, P. Gropp, and W. Schmiegel

Phase I study of humanized IgG1 anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 plus gemcitabine (Gem) in advanced pancreatic cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 3061. [Abstract]  

I. Laux, A. Jain, C. A. Tindell, and D. B. Agus

Epidermal growth factor receptor dimerization status determines response to HER-kinase targeted therapies in keratinocytes
J Clin Oncol (Meeting Abstracts) 2004 22: 3062. [Abstract]  

M. N. Lub-De Hooge, P. J. Perik, J. A. Gietema, P. L. Jager, S. Jonkman, J. G. W. Kosterink, D.-J. J. Van Veldhuisen, W. T. A. Van der Graaf, D. T. H. Sleijfer, and E. G. E. De Vries

Biodistribution and pharmacokinetics of radiolabeled trastuzumab in HER2-positive metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 3063. [Abstract]  

M. Verheij, S. R. Vink, J. H. M. Schellens, J. H. Beijnen, H. Sindermann, J. Engel, R. Dubbelman, G. Moppi, M. J. X. Hillebrand, and H. Bartelink

Phase I study of combined treatment with the oral alkyl-lysophospholipid (ALP) Perifosine and radiation in patients with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 3064. [Abstract]  

R. Oliver, C. Wheeler, P. Langmuir, I. Melezinek, and A. Stone

Evaluation of the role of body-surface-area dose adjustment of ZD6126, a novel vascular-targeting agent
J Clin Oncol (Meeting Abstracts) 2004 22: 3065. [Abstract]  

G. K. Dy, L. M. Bruzek, G. A. Croghan, S. Mandrekar, P. Peethambaram, L. J. Hanson, C. Erlichman, and S. Cheng

A phase I trial of the farnesyltransferase (FT) inhibitor, BMS-214662 (B) in combination with paclitaxel (P) and carboplatin (C) in patients with advanced cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 3066. [Abstract]  

D. Sze, S. Freeman, and T. R. Reid

Arterial infusion of Onyx-015: Response rate and survival among patients with metastatic colorectal cancer refractory to 5-fu
J Clin Oncol (Meeting Abstracts) 2004 22: 3067. [Abstract]  

L. A. Hammond, F. Ruvuna, C. C. Cunningham, S. Ebbinghaus, E. Rubin, A. Mita, E. Hersh, J. P. Eder, J. Weiss, and E. K. Rowinsky

Phase (Ph) I evaluation of the dolastatin analogue synthadotin (SYN-D; ILX651): Pooled data analysis of three alternate schedules in patients (pts) with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 3068. [Abstract]  

A. N. Tse, D. Solit, N. Rosen, and G. Schwartz

17-Allylamino-17-Demethoxygeldanamycin (17-AAG) abrogates the G₂/M cell cycle checkpoint by down-regulating chk1 and selectively sensitizes tumor cells with defective p53 to topoisomerase I poison
J Clin Oncol (Meeting Abstracts) 2004 22: 3069. [Abstract]  

G. Schwartz, Q. S.-C. Chu, L. A. Hammond, M. Mita, J. Curtright, M. J. Versola, K. Koch, L. N. Pandite, P. T. C. Ho, and E. K. Rowinsky

Phase I clinical, biology & pharmacokinetic study of the combination of GW 572016 and capecitabine in patients with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 3070. [Abstract]  

D. A. Smith, C. Bowen, J. M. Herendeen, A. Stead, K. M. Koch, and B. P. Andrew

An open-label, randomized, two-way crossover study to evaluate the potential inhibition of GW572016 metabolism by ketoconazole
J Clin Oncol (Meeting Abstracts) 2004 22: 3071. [Abstract]  

D. Rathkopf, M. Fornier, M. Shah, J. Kortmansky, E. O'Reilly, A. King, J. Winkelmann, D. P. Kelsen, S. Olsen, and G. K. Schwartz

A phase I dose finding study of weekly, sequential docetaxel (Doc) followed by flavopiridol (F) in patients with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 3072. [Abstract]  

G. R. Weiss, A. Mita, M. Garrison, S.-C. Q. Chu, S. Syed, O. Haider, P. Bonate, L. A. Hammond, and E. K. Rowinsky

Phase I, pharmacokinetic (PK) study of synthadotin (SYN-D; ILX651), a next generation antitubulin, administered iv weekly x 3 weeks every 4 weeks (wx3q4w)
J Clin Oncol (Meeting Abstracts) 2004 22: 3073. [Abstract]  

S. Di Cosimo, P. Matar, F. Rojo, M. Guzman, S. Rodriguez, J. Jimenez, J. Arribas, F. Cognetti, H. Lane, and J. Baselga

Schedule-dependent effects of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus (RAD001)
J Clin Oncol (Meeting Abstracts) 2004 22: 3074. [Abstract]  

F. Robert, C. Garrett, W. R. Dinwoodie, D. M. Sullivan, M. Bishop, M. Amantea, M. Zhang, and S. D. Reich

Results of 2 phase I studies of intravenous (iv) pelitrexol (AG2037), a glycinamide ribonucleotide formyltransferase (GARFT) inhibitor, in patients (pts) with solid tumors
J Clin Oncol (Meeting Abstracts) 2004 22: 3075. [Abstract]  

M. M. Mita, E. K. Rowinsky, M. L. Goldston, A. C. Mita, Q. Chu, S. Syed, H. L. Knowles, V. M. Rivera, C. L. Bedrosian, and A. W. Tolcher

Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of AP23573, an mTOR Inhibitor, administered IV daily X 5 every other week in patients (pts) with refractory or advanced malignancies
J Clin Oncol (Meeting Abstracts) 2004 22: 3076. [Abstract]  

F. Y. De Vos, R. Hoekstra, F. A. L. M. Eskens, E. G. De Vries, A. Van der Gaast, H. J. M. Groen, R. Knight, R. A. Humerickhouse, J. A. Gietema, and J. Verweij

Dose-finding and pharmacokinetic study of ABT-510 with gemcitabine and cisplatin in patients with advanced cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 3077. [Abstract]  

D. J. Jonker, L. Avruch, D. J. Stewart, R. Goel, G. Goss, S. Dent, M. N. Reaume, T. A. Spencer, and W. P. Peters

A phase I safety and PK study of the novel vascular targeting agent (VTA), Exherin, in patients with refractory solid tumors stratified according to N-cadherin expression
J Clin Oncol (Meeting Abstracts) 2004 22: 3078. [Abstract]  

K. Bartelheim, N. A. Ognerubov, V. F. Semiglazov, O. M. Vtoraya, C. Kaletta, I. Reichenberger, U. Michaelis, K. Naujoks, and M. Clemens

Phase Ib study of the anti-neovascular agent MBT-0206 to evaluate safety and efficacy in patients with metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 3079. [Abstract]  

C. S. Karyekar, R. A. Carr, A. Andre, Q. Wang, I. Facey, K. Marsh, D. Daszkowski, and R. Humerickhouse

Pharmacokinetics (PK) of the angiogenesis inhibitor ABT-510 in healthy subjects
J Clin Oncol (Meeting Abstracts) 2004 22: 3080. [Abstract]  

J. M. Herendeen, D. A. Smith, A. Stead, C. Bowen, K. M. Koch, and A. P. Beelen

An open-label, fixed sequence, two period study to evaluate the potential induction of GW572016 metabolism by carbamazepine
J Clin Oncol (Meeting Abstracts) 2004 22: 3081. [Abstract]  

P. N. Munster, M. Mita, C. Britten, S. Minton, S. Moulder, D. Noe, B. Roedig, L. Denis, D. Slamon, and A. Tolcher

Phase I and pharmacokinetic (PK) Study of CP-724,714, an oral human epidermal growth factor receptor-2 (HER-2) selective tyrosine kinase inhibitor
J Clin Oncol (Meeting Abstracts) 2004 22: 3082. [Abstract]